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Neural tube closure defects (NTDs) are common developmental anomalies that 
result from failure of the embryonic neural tube to bend and fuse during development, 
resulting in herniation and deterioration of nervous system tissue.  Low folate status is 
an important environmental determinant of NTD risk, and maternal folate 
supplementation can prevent the occurrence of NTDs by 50-70%, but the mechanisms 
remain unknown.  Folates function to carry and activate methyl groups for a set of 
anabolic reactions collectively known as one-carbon metabolism (OCM).  OCM is 
required for the de novo biosynthesis of purines and thymylate, and for the 
remethylation of homocysteine to methionine.  Methionine can be adenosylated to 
form S-adenosylmethionine, which is the universal methyl donor for cellular 
methylation reactions, including chromatin methylation.  Impairments in OCM result 
in elevated homocysteine, reduced proliferation, genomic instability, and chromatin 
hypomethylation. 
  Evidence from human genetic studies indicates that NTDs are complex traits 
that arise from deleterious gene-nutrient interactions, although human gene candidates 
that account for population-wide risk have not yet been identified.  In these studies, we 
explore NTDs in response to disruption of two folate-dependent genes, cytoplasmic 
serine hydroxymethyltransferase (Shmt1) and the gene encoding the trifunctional  
enzyme MTHFD1 (Mthfd1).  SHMT1 regulates the partitioning of one-carbons by 
prioritizing thymidylate biosynthesis at the expense of cellular methylation.  MTHFD1 
catalyzes the synthesis of 10-formylTHF, which is required for de novo purine 
biosynthesis.  Disruption of Shmt1 resulted in NTDs in mice that mimicked folate-
responsive NTDs in humans.  This is first gene within folate metabolism that when 
disrupted causes NTDs in mice.  Shmt1 disruption in the splotch mutant, a folate-
responsive NTD model with impaired thymidylate biosynthesis, exacerbated and 
increased the frequency of NTDs, further implicating impaired thymidylate 
biosynthesis in NTD pathogenesis.  Similarly, disruption of MTHFD1 resulted in 
developmental anomalies associated with the maternal, not fetal, genotype, as 
observed in humans.  Supplementation of Mthfd1-deficient dams with hypoxanthine 
also revealed NTDs in Mthfd1-deficient embryos.  These data implicate impaired 
nucleotide biosynthesis in NTD pathogenesis and highlight two new mouse models to 
study mechanisms underlying folate-responsive developmental anomalies. 
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CHAPTER 1 
 
FOLATE MEDIATED ONE CARBON METABOLISM AND NEURAL TUBE 
DEFECTS – BALANCING GENOME SYNTHESIS AND GENE EXPRESSION 
 
 
Abstract 
  
Neural tube defects (NTDs) refer to a cluster of neurodevelopmental conditions 
associated with failure of neural tube closure during embryonic development.  
Worldwide prevalence of NTDs ranges from approximately 0.5 to 60 per 10,000 
births, with regional and population-specific variation in prevalence.  Numerous 
environmental and genetic influences contribute to NTD etiology; accumulating 
evidence from population-based studies has demonstrated that folate status is a 
significant determinant of NTD risk. Folate-mediated one-carbon metabolism is 
essential for de novo nucleotide biosynthesis, methionine biosynthesis, and cellular 
methylation reactions.  Periconceptional maternal supplementation with folic acid can 
prevent occurrence of NTDs in the general population by up to 70%; currently several 
countries fortify their food supply with folic acid for the prevention of NTDs.  Despite 
the unambiguous impact of folate status on NTD risk, the mechanism by which folic 
acid protects against NTDs remains unknown.  Identification of the mechanism by 
which folate status affects neural tube closure will assist in developing more 
efficacious and better targeted preventative measures.  In this review, we summarize 
current research on the relationship between folate status and NTDs, with an emphasis 
on linking genetic variation, folate nutriture, and specific metabolic and/or genomic 
pathways that intersect to determine NTD outcomes.   
 1 
Introduction 
  Failure of the embryonic neural tube to close completely during development 
results in neural tube closure defects (NTDs).  NTDs are among the most common 
congenital birth defects, with worldwide prevalence ranging from 0.5 to 60 per 10,000 
births (1). The most common and most severe NTDs include spina bifida, caused by 
failure of posterior neural tube closure resulting in exposure and/or herniation of the 
spinal chord, and anencephaly, characterized by the absence of the cranial vault and 
brain as the result of failure of anterior neural tube closure. Maternal supplementation 
with folic acid is the most effective measure known to prevent NTDs; it has been 
estimated that up to 70% of NTDs can be prevented by folate supplementation (2).  
Despite the unambiguous impact of folate status on NTD risk, however, the 
mechanism by which folic acid exerts this protective effect remains elusive.   
This review summarizes current research on the relationships among genetic 
variation, folate nutriture, folate-mediated one-carbon metabolism and NTDs, with a 
specific focus on the metabolic and/or genomic pathways that intersect to enable 
proper neural tube closure (Figure 1.1).  
 
Folate and NTDs: Historical and Current Perspectives 
The association of folate status and/or impaired folate metabolism with NTDs was 
originally indicated by the observation that women with recurring NTD-affected 
pregnancies exhibited impairments in folate metabolism and/or status.   In the 1960’s, 
Hibbard and colleagues determined that mothers of infants born with CNS 
malformations excreted more formiminoglutamic acid (FIGLU) in urine, a biomarker 
of impaired folate metabolism, than matched control mothers (3). It was further 
demonstrated that mothers of affected infants had significantly lower erythrocyte 
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Figure 1.1.  Linking alterations in folate status with NTDs.  Alterations 
in folate status affect neural tube closure, but the mechanism(s) remains 
unknown.  Disruption of folate metabolism can result in homocysteine 
accumulation, impaired nucleotide biosynthesis, and impaired cellular 
methylation.  These metabolic impairments evoke genomic responses such 
as alterations in gene expression, genomic instability, reduced mitotic rates, 
and impaired DNA repair. Impairments in metabolism and/or genomic 
responses may influence cellular responses critical to proper neural tube 
closure, including cell proliferation, survival, differentiation, and migration.  
Single nucleotide polymorphisms (SNPs) in folate-related genes can 
influence both maternal and infant folate status, or alternatively SNPs can 
also directly disrupt metabolism. In addition, SNPs in folate-related genes 
may also modify genomic and/or cellular responses directly via another, 
unidentified mechanism. 
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folate levels than control mothers (4,5).   These findings motivated subsequent studies 
to determine the preventative effect of folate nutrition on pregnancy outcomes.  A 
flurry of small observational studies in the 1980’s provided preliminary support for a 
protective effect of periconceptional folate supplementation on NTD recurrence (6-
11); however, in the majority of these studies women were consuming multivitamin  
supplements containing folic acid, and therefore an exclusive role for folic acid in the 
prevention of NTDs remained unproven.   
Two landmark studies in the early 1990’s provided unequivocal evidence that 
maternal supplementation with folic acid during pregnancy prevented both NTD 
recurrence (12) and occurrence (2).  In 1991, the British Medical Research Council 
(MRC) conducted the largest multi-center randomized trial to date to determine the 
effectiveness of folic acid supplementation alone in preventing recurrence of NTDs as 
compared to multivitamin supplements.  Women with a previous NTD-affected 
pregnancy were assigned to one of four groups: 1) 4 mgs/day folic acid alone, 2) 4 
mgs/day folic acid plus multivitamin, 3) multivitamin only, or 4) no vitamin treatment.  
Supplementation with folic acid resulted in a 72% reduction in NTDs; vitamin 
supplements lacking folic acid did not significantly reduce NTD recurrence.  The 
protective effect of supplementation with folic acid was so convincing that the study 
was prematurely terminated due to ethical considerations, i.e. withholding folic acid 
from women in the other treatment groups.  Within the same year, Cziesel and Dudas 
(2) conducted a randomized control trial to determine whether periconceptional 
vitamin supplementation could prevent the first occurrence of NTDs.  Women without 
a history of previous NTD-affected pregnancy were randomly assigned to 
multivitamin supplement including 800 µg of folic acid, or a trace-element control 
supplement without folic acid at least three months prior to conception.  No NTDs 
were observed among 2104 pregnancies in the vitamin supplemented group, as 
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compared to 6 NTD-affected pregnancies in the trace element supplemented group, 
consistent with a 70% protective effect of supplementation with the multivitamin.  
Despite the use of a multivitamin supplement, it was concluded that the 800 µg of 
folic acid was responsible for the preventative effect observed in this study, based on 
the findings from the MRC trial. Additionally, it has been demonstrated that folate 
status can predict NTD risk (13), and that folic acid supplementation can prevent 
NTDs even in the absence of maternal folate deficiency (14), suggesting a genetic 
underpinning to NTD risk.  
The results of these trials inspired a series of public health efforts to promote 
the use of folic acid-containing supplements among women of child-bearing age.  In 
1992, the U.S. Public Health Services and Institute of Medicine (IOM) issued the 
recommendation that all women of childbearing age consume a vitamin supplement 
containing 400 µg of folic acid daily, and that women with a previous NTD-affected 
birth who were planning another pregnancy should consume 4 mg/day folic acid to 
prevent NTDs.  These recommendations were not effective; only 29% of women were 
found to be compliant with the recommendation (15).  These data were not surprising 
considering that most pregnancies in the United States are unplanned.  Furthermore, 
any public health intervention must be pre-emptive because supplementation after 
pregnancy is not effective as neural tube closure occurs around the fourth week of 
gestation, before most women are aware of their pregnancy.  Therefore, in the late 
1990’s, public efforts to endorse supplement use were deemed inadequate, and the 
decision was made by the Food and Drug Administration to mandate fortification of 
enriched grain products in the US with folic acid to enable individuals to achieve an 
intake of 100 µg of folic acid /day (16).  This fortification initiative has prevented 30% 
of NTDs in the general United States population  (17), providing additional support 
for the preventative effect of folic acid supplementation on NTD occurrence.   
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The folate fortification policy in the United States was unique from previous 
fortification initiatives in that it did not seek to remedy a nutrient deficiency in the 
general population.  Rather, it sought to target a distinct group, (i.e. women of 
childbearing years with genetic susceptibility to bear a child with a NTD) to achieve a 
health outcome (i.e. prevention of a birth defect).  Despite the accumulation of 
decades of research and changes in public health policy, we are still mostly unaware of 
the mechanism(s) by which alterations in folate status and/or metabolism affect neural 
tube closure.  It is most often assumed that supplementation with folic acid is acting 
either directly to correct a nutritional deficiency or indirectly to overcome metabolic 
impairment whose etiology is genetic and/or environmental.  However, evidence that 
folate supplementation affords protection against NTDs even in the absence of overt 
maternal folate deficiency or impaired folate status suggests the possibility that folate 
supplementation may be exerting a protective effect via other unknown mechanisms, 
perhaps independent of metabolism.  
 Although there are no established adverse consequences associated with 
elevated intakes of folate in humans, the current upper limit (UL) for synthetic folic 
acid intake is 1 mg/day (18).  This UL was established as a result of concerns that 
elevated folate intakes may mask the hematological diagnosis of vitamin B12 
deficiency, which occurs in as many as 15% of the population 65 years and older.  
There was also concern that elevated folate intakes may accelerate neuropathology 
associated with vitamin B12 deficiency (19). In addition, although folate fortification 
has been a highly effective public health measure in reducing NTDs, the lack of 
mechanism-based understanding of this prevention leads to general concerns regarding 
unintended consequences resulting from the supplementation policy.  Such concerns 
include cancer risk (20), and more recently, the adverse effects of unmetabolized folic 
acid accumulating in human blood (21).   Further, recent advances in our 
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understanding of epigenetic programming and the influence of folate metabolism on 
epigenetic outcomes (22-24)  have raised concerns regarding the possible 
consequences of over-supplying folate during embryonic development. Without a 
clear understanding of an “upper limit” for folate nutriture or knowledge regarding the 
lowest efficacious dose for prevention, there exists the possibility that some 
population subgroups may not benefit and potentially accrue risk from the fortification 
initiative.   Identifying the mechanism(s) by which folate status affects NTD outcomes 
may help establish more efficacious and better targeted preventative measures that 
minimize unintended consequences for the entire population.   
 
Folate-mediated One-Carbon Metabolism 
Function of Folate.  Tetrahydrofolates (THF), the biologically active form of 
folate in the body, serve as cofactors that chemically activate and carry one-carbon 
units. Activated one-carbon units carried on either N5 or N10 of THF can be 
enzymatically interconverted to different oxidation states ranging from formyl to 
methyl (25-27).  Furthermore, folates differ by the length of their popyglutamate 
peptide.  Serum folates contain a single glutamate residue, whereas intracellular 
folates contain a polyglutamate chain consisting of 5-8 glutamate peptides linked by 
an unusual γ-linked peptide bond (28,29).   Within the cell, folate polyglutamates 
function as coenzymes for the reversible transfer of one-carbon units in a set of 
reactions collectively known as one-carbon metabolism (25,30).  
Folate Absorption and Accumulation.  Most dietary folates are polyglutamated 
and therefore must be deconjugated to monoglutamates prior to absorption and 
transport (31). Deconjugation is catalyzed in the intestine by the enzyme folylpoly-γ-
glutamate carboxypeptidase II, encoded by the gene glutamate carboxypeptidase II 
(GCPII). Folate monoglutamates are then absorbed from the intestine into the 
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bloodstream via the reduced folate carrier (RFC) and/or a novel intestinal folate 
transporter (32); RFC is a facilitative anion exchanger expressed primarily in the small 
intestine, liver, lung, and placenta (33).   Most folates in the blood are present as 5-
methylTHF monoglutamate; cellular uptake of 5-methylTHF can be accomplished by 
the folate receptor alpha, a membrane-anchored receptor with a 
glycosylphosphatidylinositol moiety that mediates folate transport via an endocytic 
process (34,35).  Although folate receptor alpha also has a high affinity for 
monoglutamic 5-methylTHF, it has even higher high affinity for folic acid (36,37).  
Once inside the cell, the addition of a polyglutamate tail to the folate derivative is 
catalyzed by folylpoly-gamma-glutamate synthetase; the polyglutamate moiety serves 
to sequester folates within the cell, as well as to increase the affinity of the THF 
cofactor for enzymes catalyzing one-carbon transfer reactions (25).  Folic acid, which 
refers to the oxidized and synthetic form of folate found in fortified foods and dietary 
supplements, is more bioavailable than natural food folates and contains a single 
glutamate residue.  Once transported into cells, it is enzymatically reduced to THF and 
is chemically identical to natural food folate.  
Folate Mediated One-Carbon Metabolism.  Folate mediated one-carbon 
metabolism (OCM) is compartmentalized in the cell, occurring primarily within the 
cytoplasm and the mitochondria (Figure 1.2). In the mitochondria, the primary role of  
one-carbon metabolism is to produce formate and glycine from serine (27,30).  
Formate traverses into the cytoplasm where it serves as a major source of one-carbon 
units for cytoplasmic one-carbon metabolism.  In the cytoplasm, formate condenses 
with THF to form the cofactor 10-formylTHF in an ATP-dependent reaction catalyzed 
by the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/ 
methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase, 
commonly known as C
1-THF synthase, which is transcribed from the MTHFD1 gene.  
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Figure 1.2.  Folate-mediated one-carbon metabolism. Tetrahydrofolate (THF)-
mediated one-carbon metabolism is required for the synthesis of purines, 
thymidylate and the remethylation of homocysteine to methionine. The 
hydroxymethyl group of serine is the major source of one-carbon units which are 
generated in the mitochondria in the form of formate, or in the cytoplasm through 
the activity of cytoplasmic serine hydroxymethyltransferase.  Mitochondrial-
derived formate can enter the cytoplasm and function as a one-carbon unit for 
folate metabolism.  cSHMT also serves a role in inhibiting homocysteine 
remethylation by sequestering 5-methyl-THF in the cytoplasm. The one-carbon is 
labeled in “bold”.  The “inset” shows the thymidylate synthesis pathway which 
involves three enzymes, cSHMT, TS and DHFR.  AdoMet, S-
adenosylmethionine; AdoHcy, S-adenosylhomocysteine; BHMT, betaine-
homocystiene methyltransferase; CBS, cystathionine- β synthase; cSHMT, 
cytoplasmic serine hydroxymethyltransferase;  DHFR, dihydrofolate reductase; 
dUMP, deoxyuridine monophosphate; MTHFD1, methylenetetrahydrofolate 
dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate 
synthetase; MTHFR, methylenetetrahydrofolate reductase; MS, methionine 
synthase; TS, thymidylate synthase; 
 10 
10-formylTHF serves as a one-carbon donor for the de novo biosynthesis of purines by 
supplying the #2 and #8 carbons to the purine ring.  Alternatively, the one-carbon 
moiety of 10-formylTHF can be reduced in a NADPH-dependent reduction by C
1-
THF synthase to form the cofactor 5,10-methyleneTHF, which is utilized by the  
enzyme thymidylate synthase (TS) as a cofactor in the methylation of dUMP to form 
thymidylate (dTMP).  5,10-methyleneTHF can also be produced from the 
condensation of serine and THF in a reaction catalyzed by the enzyme cytoplasmic 
serine hydroxymethyltransferase (cSHMT)  that preferentially directs one-carbon units 
towards thymidylate biosynthesis (38).  The one-carbon moiety of 5,10-
methyleneTHF can be further reduced to 5-methylTHF, in a reaction catalyzed by the 
enzyme methyleneTHF reductase (MTHFR) that irreversibly commits one-carbon 
units to the methionine/homocysteine remethylation cycle.  5-methylTHF donates a 
one-carbon to the remethylation of homocysteine to form methionine, which is 
catalyzed by the B-12 (cob(I)alamin)-dependent enzyme methionine synthase (MS). 
During the reaction catalyzed by methionine synthase, cob(I)alamin can be oxidized to 
cob(II)alamin, which results in inactivation of the MS-cobalamin complex.  The 
activity of another gene, methionine synthase reductase, encoded by the gene MTRR, 
catalyzes the reductive methylation of cob(II)alamin, thereby restoring MS activity.  
Methionine can be adenylated to form S-adenosylmethionine (AdoMet) which serves 
as the universal methyl donor for numerous cellular methylation reactions 
(25,27,28,39) including the methylation of lipids, histones, DNA, RNA, and 
neurotransmitters, among other molecules.  The product of AdoMet-dependent 
methylation reactions is S-adenosylhomocysteine (AdoHcy) which is consequently 
hydrolyzed to homocysteine.  Thus, cytoplasmic one-carbon metabolism is essential 
for 1) the synthesis of purines and thymidylate, 2) the remethylation of homocysteine,  
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and 3) and the synthesis of AdoMet, which is required for cellular methylation 
(25,27,28,39). 
  Homocysteine is a non-essential amino acid that is toxic when it accumulates 
within the cell.  There are several cellular mechanisms to prevent its accumulation 
(Figure 1.2).  In addition to remethylation via the folate-dependent pathway, 
homocysteine can also be remethylated to methionine via the transfer of a methyl 
group from betaine, a reaction catalyzed by the enzyme betaine-homocysteine 
methyltransferase (BHMT).  The reaction catalyzed by BHMT occurs mainly in the 
liver and kidney (40).  In some cell types and tissues, homocysteine can also be 
degraded by the transulfuration pathway, through which homocysteine irreversibly 
condenses with serine to form cystathionine.  Transulfuration is catalyzed by the 
vitamin B6-dependent enzyme cystathionine β-synthase (CBS).  The transulfuration 
pathway degrades homocysteine and thereby effectively removes a source of cellular 
methionine for protein synthesis and cellular methylation.    
  Stringent regulation of cellular homocysteine levels is not only important in 
preventing cytotoxicity, but is also critical for maintenance of cellular methylation 
potential and protein synthesis. The relative AdoMet:AdoHcy ratio has been suggested 
to be an indicator of cellular methylation potential. Accumulation of homocysteine 
drives the reaction catalyzed by S-adenosylhomocysteine hydrolase (SAHH), which 
normally favors the hydrolysis of S-adenosylhomocysteine (AdoHcy) to 
homocysteine, in the direction of AdoHcy synthesis (41-43). AdoHcy is a potent 
inhibitor of certain AdoMet-dependent methylation reactions (43). In addition, 
accumulation of AdoMet inhibits the enzyme MTHFR (44,45), preventing the 
accumulation of 5-methylTHF when cellular levels of methionine are sufficient to 
meet methylation demands.  AdoMet also inactivates BHMT and activates CBS-
mediated transulfuration (46).  Thus, flux of the methionine cycle is tightly regulated 
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in order to preserve methionine and AdoMet synthesis and to prevent unnecessary 
accumulation of intermediate metabolites.  Regulation of the flux of folate-derived 
one-carbon units into the methionine cycle through MTHFR also has implications for 
other folate-dependent reactions. Because the reduction of 5,10-methyleneTHF  to 5-
methylTHF catalyzed by MTHFR is irreversible, disruptions in the methionine cycle 
result in accumulation of 5-methylTHF at the expense of all other folate derivatives, a 
phenomenon referred to as the folate “methyl-trap”.  Direct causes of methyl trap 
include B12 deficiency, which is the cofactor for methionine synthesis, or genetic 
disruption in enzymes that mediate methionine synthesis.  The methyl trap impairs 
nucleotide biosynthesis due to folate substrate depletion.  Conversely, disruption of 
the MTHFR-mediated reduction of 5,10-methyleneTHF results in more one-carbon 
units available for thymidylate biosynthesis at the expense of the methionine cycle.  
The efficiency of folate-mediated one-carbon metabolism also depends on the 
availability of THF cofactors.  It has been estimated that most cellular folates are 
protein-bound and further, cellular folate binding capacity exceeds the intracellular 
concentration of folates (47).  Thus, the amount of free or unbound folate cofactors in 
the cell is negligible, and as such, under conditions of limited availability of free folate 
cofactors, folate-dependent pathways compete for available cofactors (47,48). 
Competition for folate cofactors is greatest for the cofactor 5,10-methyleneTHF, 
which is utilized by three biosynthetic reactions: 1) the methylation of dUMP to form 
thymidylate, catalyzed by TS, 2) the synthesis of serine, catalyzed by serine 
hydroxymethyltransferase, and 3) the synthesis of 5-methylTHF catalyzed by 
MTHFR, which irreversibly commits one-carbon units to the methylation cycle. The 
cofactor 5,10- methyleneTHF thus represents a significant junction in the pathway, at 
which point one-carbons can either be utilized for thymidylate biosynthesis or 
committed to the methylation cycle for the remethylation of homocysteine and 
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AdoMet biosynthesis.  This indicates that genome synthesis competes for a limiting 
pool of folate-activated one-carbons with chromatin methylation reactions that affect 
genome stability and gene expression.  Experimental evidence and theoretical 
modeling suggest that when folate cofactors are limiting, the synthesis of 5-
methylTHF for cellular methylation is favored at the expense of thymidylate 
biosynthesis (48,49). The exception to this preference occurs in cells which express 
cSHMT.  Recent evidence indicates that when cSHMT is expressed, flux of one-
carbon units is shifted towards thymidylate synthesis at the expense of AdoMet 
synthesis and cellular methylation reactions.  Regulation of these pathways by cSHMT 
is accomplished via two mechanisms: 1) the synthesis of a separate pool of 5,10 
methyleneTHF that is preferentially shuttled to thymidylate synthesis and 2) tight 
binding of the cofactor 5-methylTHF by cSHMT, which prohibits entry of one-carbon 
units to the methylation cycle thereby inhibiting methionine and AdoMet 
biosyntheses.   
 
Impairments in Folate-mediated One-Carbon Metabolism – Association with Neural 
Tube Closure 
  Impairments in folate-mediated one-carbon metabolism can result from 
diminished folate status, single nucleotide polymorphisms (SNPs) in genes that affect 
folate metabolism, and/or secondary micronutrient deficiencies of nutrients that alter 
folate status, such as iron and other B vitamins (19,50,51).  Common biomarkers of 
impaired folate status include elevated plasma homocysteine and increased uracil 
content in DNA (52). Cellular accumulation of homocysteine has been shown to elicit 
oxidative stress responses (53-55) and may be cytotoxic (56).  In addition, 
homocysteine negatively regulates cellular methylation.  Hypomethylation of DNA 
resulting from impaired folate metabolism can alter the expression of the 30% of 
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genes that are regulated by CpG methylation (57), whereas inability to methylate 
proteins, including histones, can affect chromatin structure and many cellular 
functions, including but not limited to neurotransmitter and myelin synthesis (58-61). 
Increased uracil content in DNA results from a lack of available thymidylate for DNA 
replication and repair.  A shortage of one-carbon units for de novo purine or 
thymidylate synthesis will slow replication thereby decreasing mitotic rates as well as 
affecting DNA repair, reducing the proliferative capacity of the cell and promoting 
genomic instability (62,63).    
Completion of neural tube closure requires the precise coordination of cell 
proliferation, survival, differentiation and migration events; any one of these events 
could feasibly be disrupted by impairments in folate metabolism (Figure 1.1). 
Although there are a number of possible mechanisms by which impairments in folate 
metabolism might affect neural tube closure, there is currently no direct evidence 
linking a specific metabolic impairment in folate metabolism with a specific cellular 
event that results in the failure of the neural tube to close.   
 
Potential Mechanisms of Perturbation of Neural Tube Closure 
Homocysteine Accumulation.  Elevated maternal homocysteine levels have been 
linked to NTD-affected pregnancies (64,65) suggesting that cellular homocysteine 
accumulation may contribute to NTD pathogenesis.  In vitro experiments have 
documented cytoxicity of homocysteine at supraphysiological doses (66,67). 
Homocysteine toxicity may be mediated by overactivation of NMDA receptors, 
resulting in glutamate excitotoxicity (56,68,69). A role for oxidative stress in the 
etiology of NTDs has been suggested by gene expression profiling experiments in a 
mouse model of diabetes that is susceptible to NTDs (70,71).  Oxidative stress 
resulting from elevated homocysteine could potentially disrupt neural tube closure.  
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However, mice with deficient CBS activity exhibit hyperhomocysteinemia but do not 
develop NTDs (72).  
 
Cellular Methylation.  Impairments in AdoMet biosynthesis affect genomic 
methylation, which can alter expression of 30% of the genome regulated by CpG 
methylation (73).  Alterations in chromatin methylation may affect embryonic 
development via effects on cellular differentiation (74-76) and/or cellular migration 
processes (77,78).   DNA methylation has been implicated in cell differentiation based 
on several findings demonstrating the disruptive effects of the demethylating agent 5-
deazacytosine on normal differentiation in a variety of cell lines and tissues 
(74,75,79). Loss of DNA methylation is presumed to affect cell differentiation via 
alterations in CpG methylation-regulated gene expression, consistent with findings 
that cell differentiation requires mediators of transcriptional repression of CpG-
methylated genes, including methyl binding proteins and histone deacetylases (80-82) 
.  More specifically, it has recently been posited that de novo methylation and 
associated gene silencing is required for differentiation during development (83).   
This is supported by data from studies in which targeted loss of the de novo 
methyltransferase enzymes Dnmt3a and Dnmt3b altered differentiation capacity in ES 
cells (84).  Further, Dnmt3b -/- embryos display NTDs, confirming the requirement 
for timely cell differentiation in neural tube closure. Targeted deletion of genes that 
mediate methylation-mediated suppression of gene expression also result in failure of 
neural tube closure (85).   Epigenetic regulation of cell migration could also be critical 
for proper neural tube closure, as appropriate migration of neural crest cells adjacent 
to the neuroepithelium may be required for neural tube closure (86,87).   Together, 
these data imply that regulation of cellular differentiation and migration by genome 
methylation is crucial for proper neural tube closure. 
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Nucleotide Biosynthesis.  Impairments in nucleotide biosynthesis for DNA replication 
and repair can decrease mitotic rates during critical morphogenetic windows and/or 
increase mutation rates, both of which can result in failure of neural tube closure (88).  
Rapid growth of the neuroepithelium during neural tube closure requires an increased 
dependency on de novo nucleotide biosynthesis to sustain rate of cell division. 
Genomic instability resulting from uracil misincorporation may also affect neural tube 
closure, as other instances of genomic instability, including centromeric and telomeric 
instability have been reported to cause NTDs (89-91). Although it is widely believed 
that folate functions to provide adequate nucleotide pools during development, the 
extent to which this particular deficiency might contribute to NTDs is unclear.  
Further, the specific effect of uracil misincorporation on genomic instability and 
neural tube closure has not been investigated.  
   
Genetics of Folate Metabolism and NTDs 
Family history of NTD-affected pregnancy is one of the strongest risk factors 
for these birth defects.  Risk of NTD is elevated 3-8% in siblings of affected 
individuals, and there is even some evidence that risk is elevated in second and third 
degree relatives (92).  In addition, NTDs are more common among different ethnic 
groups (92).  Collectively, these data indicate a genetic component to NTD etiology.  
The realization that NTDs could be prevented by maternal folate supplementation 
even in the absence of pre-existing maternal folate deficiency further suggested that 
inherent errors in folate metabolism could contribute to folate deficiency despite 
proper dietary intake (14).  This led to the discovery of single nucleotide 
polymorphisms (SNPs) in folate-related genes that impair folate status and/or 
metabolism without frank folate deficiency.   Since then, many studies have examined 
the effects of SNPs in a number of folate-related genes on NTD risk, providing 
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evidence both for a genetic contribution to the etiology of neural tube defects and 
further support for a direct role of folate-mediated one-carbon metabolism in the 
development of NTDs.  
Beyond identifying genetic risk factors for NTDs, understanding the influence 
of specific SNPs on folate mediated one-carbon metabolism and NTD risk may be 
used to provide some insight into the mechanism(s) underlying folate-NTD 
associations.  The following genetic data and associated biochemical processes are 
described below as follows: 1) Genes within folate transport, 2) Genes contributing to 
nucleotide biosynthesis, and 3) Genes within the methionine/homocysteine cycle.  A 
more thorough review of SNP data for each gene within the folate and 
methionine/homocysteine cycles can be found in a recent review by van der Linden et 
al (93).    
 
Genes within Folate Transport.  Genes involved in folate transport and accumulation 
that have been investigated in relation to NTDs include the reduced folate carrier 
(RFC), and folate receptors (FR) alpha and beta.  Folate receptors are expressed 
throughout the developing neural tube and early in embryonic development (94); RFC 
is strongly expressed in the placenta, as well in the developing neural tube (33).  No 
common genetic variants have been identified in the coding region of the folate 
receptor genes, and SNPs within non-coding regions of these genes do not show 
association with NTDs  (95-98).  A common SNP in RFC1 has been identified, A80G, 
that may modulate plasma folate levels (99).   Investigations of NTD risk associated 
with this SNP have yielded mixed results, with some failing to detect an association 
(100,101) and others detecting an increased risk associated with case and maternal GG 
genotype  (102).  Interestingly, several of these studies have identified an increased 
risk of NTD-affected pregnancy among mothers carrying two G alleles that is either 
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only present under (103-105) or exaggerated by (105) conditions of low folate status.  
The responsiveness of this mutation to dietary folate provides support for a role of 
RFC in mediating folate-responsive NTDs.  This is further suggested by investigation 
of the RFC gene knock-out (KO) mouse model, in which early embryonic lethality is 
rescued by folic acid supplementation (106). However, homozygous RFC KO mice 
die in utero prior to neural tube closure; that folic acid supplementation rescues this 
lethality suggests that RFC-mediated folate transport is critical for other aspects of 
embryonic development beyond neural tube closure.  In contrast, investigation of 
folate receptor α KO mouse has demonstrated unequivocally that embryonic folate 
transport is essential for neural tube closure.  Targeted deletion of the folate receptor 
gene, Folbp1, results in NTDs that can be rescued by maternal supplementation with 
pharmacological doses of folic acid (107).  These are the first experimental data to 
indicate a direct role of embryonic folate utilization in neural tube closure.  It is clear 
from both the human and animal data that both RFC and the high affinity folate 
receptor alpha are critical for embryonic development, most likely due to a high 
embryonic demand for folate cofactors.  However, the present data do not provide 
additional information regarding specific metabolic mechanisms, nor is it clear how 
more subtle modulation of folate status might affect neural tube closure.   
 
Genes Within the Methionine/Homocysteine Metabolic Cycle.  Genes within the 
methionine/homocysteine remethylation cycle have been attractive candidates for 
genetic analysis in relation to NTDs, based on the associations between NTD risk and 
both elevated maternal homocysteine (64,65)  and low B12 status (108). The C677T 
SNP in the MTHFR gene was the first genetic defect in folate metabolism to be 
investigated in relation to NTDs, and remains the most studied.  The alanine-to-valine 
substitution produces a thermolabile enzyme variant associated with a 50-60% 
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reduction of enzymatic activity in homozygous individuals (109-111).  Loss of 
MTHFR activity causes a reduction in 5-methylTHF that is available for 
homocysteine remethylation.  Numerous studies have investigated the association 
between the MTHFR C677T SNP and NTD risk (112-120)   Metanalyses of these 
studies have confirmed an elevated risk for both maternal (50-70% increase) and fetal 
(80-90% increase) TT genotypes (121-123), as well as mildly elevated risk associated 
with the heterozygous 677CT genotype in mothers (10% increase) and offspring (30% 
increase) (123) . Still, several studies have failed to identify a significant association of 
the MTHFR C677T SNP with NTD risk (101,115,124-127).    Notwithstanding these 
discrepancies, the MTHFR C677T SNP continues to be investigated in relation to 
NTDs.  Elevated homocysteine has been observed in individuals homozygous for the 
SNP (119,128,129), although more recently it has been suggested that 
hyperhomocysteinemia occurs primarily under conditions of mild to moderate folate 
deficiency in this genetic sub-group (130,131).  Further, elevated homocysteine in 
individuals homozygous for the MTHFR C677T polymorphism is responsive to 
supplementation with folic acid (132). Because elevated homocysteine is a risk factor 
for NTD-affected pregnancy, it has been proposed that folate supplementation might 
prevent NTDs by stabilizing enzymatic activity thereby normalizing homocysteine 
levels.  Indeed, several studies have suggested that the MTHFR C677T SNP interacts 
with folate status in elevating NTDs risk (114,117).  Still, the frequency of the T allele 
in most populations cannot account fully for either 1) the 70% reduction in NTDs 
observed with folate supplementation, or 2) impaired folate status observed in mothers 
of affected offspring (133). 
  More recently, a second SNP within the MTHFR coding region has been 
investigated in relation to NTDs.  The MTHFR 1298A>C transition also results in 
reduced enzymatic activity, although there is no demonstrated effect on homocysteine 
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levels.  In parallel with the negligible effects on biomarkers of folate status, a limited 
number of studies have been unable to identify a unique contribution of the MTHFR 
A1298C polymorphism to NTD risk (100,101).  Some preliminary investigation of the 
two SNPs in MTFHR in tandem suggests that possession of both polymorphisms 
confers elevated risk greater than that of either polymorphism alone (101,121,134).  
More recently, however, it has been determined that these two SNPs are almost in 
complete linkage disequilibrium (115,135,136); homozygosity for both SNPs is 
undetected at the same loci. Thus, conclusions regarding the effect of the MTHFR 
1298A>C transition on NTD risk are limited.   
Rozen and colleagues have created a mouse model in which the MTHFR gene 
has been deleted (137). Although homozygous MTHFR knock-out (KO) mice die 
soon after birth, live births of all three genotypes occur at expected frequencies.  
Further, investigation of embryonic development of these mice has failed to identify 
an NTD associated with loss of MTHFR, even under folate-deficient conditions (138) 
and despite a 10-fold elevation in homocysteine levels (137). Thus, this model cannot 
be used to further understand the role of MTHFR in regulating folate metabolism 
during neural tube closure.  Further, the discrepancy in NTD phenotype between the 
MTHFR KO mouse and the C677T SNP suggests that the biochemical effect of the 
C677T SNP may modify folate metabolism and consequently NTD risk in a manner 
that has yet to be determined.  
The tenuous association between elevated NTD risk and polymorphisms in the 
MTHFR gene is illustrative of current limitations in our understanding of the 
mechanism(s) by which impairments in folate metabolism alter neural tube closure.  
Although elevated homocysteine has been implicated in mediating the effect of this 
polymorphism on NTD risk, recent evidence also indicates that MTHFR C677T 
affects folate-dependent anabolic reactions beyond homocysteine accumulation.  In 
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particular, homozygous individuals  also show reduced methylation potential and 
some evidence for increased de novo thymidylate biosynthesis  (139-142).  Thus, 
reduced MTHFR activity may affect neural tube closure by altering the partitioning of 
one-carbon units between thymidylate and methionine synthesis in a way that is not 
fully understood.  Regulation of the flux of one-carbon units has important 
implications for folate-related pathologies.  For example, the MTHFR C677T is 
associated with an increased risk of NTDs but a decreased risk of colon cancer (143).  
The opposing influence of this polymorphism on these two pathologies highlights the 
importance of balancing the one-carbon flux between the thymidylate and methionine 
biosynthetic pathways and indicates that it may be the alteration in balance of one-
carbon metabolism, and not one particular anabolic pathway, that increases risk for 
pathology.     
  Other candidate genes within the methionine/homocysteine remethylation 
pathway include methionine synthase (MS, gene name MTR) and methionine synthase 
reductase (MTRR), which cooperate to remethylate homocysteine to methionine via 
the folate-dependent pathway, and BHMT and CBS, which modulate homocysteine 
levels independent of the folate cycle (Figure 1.2).  Examination of the evidence for an 
association between SNPs in MTR/MTRR and NTD risk has yielded inconsistent 
findings. A limited number of studies have investigated the MTR A2756G SNP in 
relation to NTD risk.   The majority of these studies have found no association with 
NTD risk, either in case-control studies  (102,144,145) or with the more robust 
transmission disequilibrium test (TDT) (146).   Two studies (147,148)  identified a 
significant risk associated with this polymorphism in NTD cases; however, in both 
study populations there is a very high frequency of the MTHFR TT allele (149) which 
may interact with the MTR A2765G polymorphism in increasing NTD risk (100,150).  
Interestingly, both of these studies also identified significantly elevated NTD risk 
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associated with homozygosity for a 66A>G polymorphism in the related gene, MTRR, 
in both the mothers and cases.  The positive association between the MTRR A66G 
polymorphism and NTD risk is supported by findings from a handful of smaller, case-
control studies (150,151).  Recently, however, O’Leary and colleagues (152) 
conducted an exhaustive investigation of several MTRR polymorphisms, including 
A66G, in relation to NTD risk and found no association between NTDs and any 
genetic variation in MTRR.  The large sample population and robust statistical 
methods, including case/control comparison, log-linear analysis, and TDT, provide a 
strong argument against an increased NTD risk associated with polymorphisms in 
MTRR.   The lack of a strong association with NTD risk concurs with biochemical 
data indicating that MTRR SNPs have a limited or even lowering effect on 
homocysteine levels (153,154).  In fact, Christenson et al (117) demonstrated a mild 
protective effect of the GG genotype, which may be consistent with a homocysteine-
lowering effect.  In light of the findings that neither MTR nor MTRR SNPs 
significantly affect homocysteine levels, it is possible that these SNPs do not have 
functional consequences.  Thus, based on the human literature, a role of MTR/MTRR 
variants in neural tube closure defects has not been established.     
  To date, evidence from mouse models of MTR and MTRR deficiency has not 
provided additional insight into the influence of these genes on neural tube closure. A 
methionine synthase KO mouse model was created by a homologous recombination 
event in which a PGK cassette was inserted into the coding region of the MTR gene, 
resulting in a null allele (155).  Nullizygous MTR KO embryos did not survive to 
birth, and examination of genotype distributions at different stages during embryonic 
development revealed that nullizygous embryos were being resorbed prior to neural 
tube closure in the mouse, preventing examination of the effect of MS deletion on 
neural tube closure.  Maternal treatment with pharmacological doses of folic acid 
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failed to rescue early embryonic lethality. Further, no developmental anomalies have 
been observed in heterozygous MTR KO mice, suggesting that partial loss of 
methionine synthase is not a risk factor for NTDs in mice.  To avoid early embryonic 
lethality associated with total loss of MS activity, Elmore and colleagues recently 
generated a mouse model with reduced MTRR activity, created by the insertion of a 
gene trap vector within the MTRR gene (156).  Since MTRR activity is required to 
maintain MS activity, hypomorphic expression of MTRR gene results in reduced MS 
activity.  Homozygous MTRR
gt/gt mice survive to birth and display a very mild 
postnatal phenotype, despite a robust metabolic phenotype that includes highly 
elevated plasma homocysteine, reduced plasma methionine, and tissue-specific 
alterations in AdoMet/AdoHcy ratio.  Although no NTD has been observed in these 
mice, examination of embryonic development under conditions of folate deficiency 
may provide better insight into the role of folate-dependent methionine synthesis in 
NTD etiology.   
  Evidence relating genetic alterations in BHMT and CBS do not provide 
support for a role of homocysteine accumulation in NTD pathology.  One common 
variant in the BHMT gene, A742G, has been identified; however, two independent 
studies failed to detect a significant association with NTD risk (157,158). The BHMT 
A742G SNP has not shown a strong relationship with homocysteine levels (159,160) 
indicating that it may not have functional relevance.  One other recent study 
investigated a novel intronic SNP in BHMT that was associated with an increased risk 
of NTDs in mothers taking periconceptional folate supplements (98).  However, the 
biochemical effect of this particular SNP has not been elucidated, precluding any 
insight into a metabolic mechanism.  No mouse model of BHMT deletion has been 
described to date, and therefore little information exists regarding its role in embryonic 
development.  BHMT is not expressed in the developing embryo until after 
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neurulation (161), suggesting that the BHMT-dependent homocysteine remethylation 
may not play a role in embryonic homocysteine metabolism during neural tube 
closure. 
  The severe clinical manifestation of CBS deficiency (162) in humans indicates 
that CBS is essential for normal embryonic development; however, such severe 
deficiencies have not been investigated in relation to NTDs.  CBS is expressed early in 
mammalian development and throughout the developing neural tube (163,164), 
suggesting that it may be a factor in neural tube closure.  Two common 
polymorphisms have been assessed in relation to NTDs; an insertional allele in exon 8, 
844ins68, and a transition mutation T833C, both of which tend to segregate together 
in cis (165). No studies to date have identified an association between either mutation 
and NTDs (126,134,166,167), consistent with the lack of effect of these 
polymorphisms on homocysteine levels (131,168).  More recently, another 
polymorphism in a non-coding region of CBS, a 31 bp variable-number tandem repeat 
(VNTR)  has been identified which has been shown to modulate homocysteine levels 
(169,170); however, one study to date has failed to detect an association with NTDs 
(171).  Further investigation of this polymorphism is warranted.  A mouse knock-out 
model for CBS was generated (72); however, homozygous CBS KO mice survived to 
birth and exhibited early postnatal lethality despite extremely elevated homocysteine 
levels.  The absence of NTDs in the CBS KO mouse suggests that the homocysteine 
transulfuration pathway mediated by the CBS may not be directly involved in the 
pathogenesis of NTDs.     
  Collectively, the lack of evidence from both human SNP association studies 
and knock-out animal models of genes that metabolize homocysteine do not support 
an independent role for homocysteine remethylation and/or homocysteine 
accumulation in neural tube closure defects.  Alternatively, the lack of an association 
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between SNPs in genes that regulate homocysteine methylation and NTDs may reflect 
the lack of penetrance with respect to alterations in homocysteine levels.   Further, the 
minimal effects of these SNPs on homocysteine levels suggest the possibility that 
genetic mutations that produce a greater impairment in homocysteine metabolism may 
be incompatible with embryonic survival.  This notion is supported by studies of 
methionine synthase, in which homozygous deletion of this gene in the mouse is 
embryonic lethal.  Survival of CBS homozygous KO mice, however, suggests that 
homocysteine transulfuration may be expendable during embryonic development.  
 
Genes Contributing To Nucleotide Biosynthesis.  Impairments in de novo nucleotide 
biosynthesis represent one of the earliest proposed mechanisms to account for the 
associations between folate metabolism and neural tube closure defects.  The 
embryonic neural tube is the sight of rapid and widespread cell division, and thus there 
is an increased demand for de novo nucleotide synthesis.  Of the genes involved in 
one-carbon metabolism, MTHFD1, which encodes the trifunctional enzyme C
1-THF 
synthase, provides the most direct contribution to nucleotide biosynthesis by 
catalyzing the synthesis of 10-formylTHF and 5,10-methyleneTHF, the cofactors for 
de novo purine and thymidylate biosynthesis, respectively.  Brody et al (172) 
identified a SNP in the coding region of MTHFD1, R653Q, that is strongly associated 
with maternal risk for NTDs.  The association between homozygosity for the Q allele 
and maternal, but not infant, risk was recently confirmed in a separate cohort (173).  
Analysis of the same SNP in an Italian population identified homozygosity for the 
polymorphism in cases as a risk for NTDs (174).  The lack of observed association 
between fetal genotype and NTDs in the Irish population may be due to transmission 
of the Q allele from homozygous mothers to fetuses resulting in a synergistic 
phenotype that causes early lethality (173).  Indeed, there were fewer QQ cases 
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observed in the population than expected.  It is still unclear how the R563Q 
polymorphism is altering metabolic outcomes, since neither plasma folate, red blood 
cell folate nor homocysteine levels are altered in QQ mothers.  The metabolic effect of 
the polymorphism on cases has not been investigated.  However, the strength of the 
association between the polymorphism and NTDs in the absence of effects on folate 
and homocysteine levels suggests that this polymorphism is affecting neural tube 
closure via alterations in a folate-dependent anabolic pathway other than the 
methylation cycle.  De novo nucleotide biosynthesis is the most likely candidate 
pathway, but this remains to be established. 
  Genes that have been investigated in relation to thymidylate biosynthesis 
specifically include cSHMT and TS.  Limited examination of a common variant allele 
in cSHMT, C1420T, has not yielded an association with NTD risk in two studies, 
although limited power may have precluded the detection of an association (100,175).  
Another study by Relton and colleagues (101) identified a protective effect associated 
with the T allele in case mothers, which may be consistent with mildly elevated 
homocysteine levels observed in CC mothers (175); however, this finding remains to 
be confirmed.  In contrast to many other SNPs that have been examined in relation to 
NTDs, the biochemical effect of the C1420T polymorphism on cSHMT function has 
been partially elucidated.  Recently, Woeller et al (176) demonstrated that cSHMT can 
be imported to the nucleus via SUMOylation, where it may function to directly shuttle 
5,10 methyleneTHF into the nuclear thymidylate biosynthesis pathway.  The authors 
further demonstrated that the C1420T polymorphism inhibits SUMOylation of 
cSHMT in vitro.  Prevention of cSHMT nuclear import may have implications for de 
novo thymidylate biosynthesis and/or flux of one-carbon units, since cSHMT has been 
previously shown to regulate the flux between thymidylate biosynthesis and cellular 
methylation (38).  Thus, further investigation of the role of this enzyme in NTD 
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pathogenesis is warranted.  Recently, a mouse model in which exon 8 of the cSHMT 
gene was replaced with a β-geo cassette has been generated that results in total loss of 
cSHMT protein in homozygous mutants (MacFarlane et al; unpublished).  
Homozygous mutants are viable; thus, the examination of the role of cSHMT in 
embryonic development and neural tube closure can be examined.   
  Only two studies have examined polymorphisms in TS in relation to NTDs.  
Volcik et al (177) examined two polymorphisms outside of the coding region of TS -- 
a 28-bp tandem repeat in the promoter enhancer region (termed TSER) and a 6-bp 
deletion in the 3’ UTR – in relation to spina bifida in a large, ethnically heterogenous 
population.  Homozygosity for the double-repeat allele (TSER 2/2) was not 
significantly associated with risk of spina bifida when examined in the entire study 
population; however, when the population was segregated by ethnicity, the risk for 
spina bifida in non-hispanic whites was increased 4-fold in the presence of the TSER 
2/2 genotype. Further, risk for NTD was even greater in this ethnic group when the 6-
bp deletion in the 3’ UTR was absent.  In contrast, Wilding et al (178) found no 
association between the TSER polymorphism and NTD risk in a white population in 
the UK.  The likelihood of detecting associations across different ethnic populations in 
these studies was likely influenced by differences in the frequency of the various 
repeat alleles in the control populations (178).  TS expression is lower in the presence 
of the 2X repeat as compared to the 3X repeat allele (179,180), but its effects on folate 
and homocysteine levels are uncertain.  Trihn and colleagues (181) observed reduced 
plasma folate and mildly elevated homocysteine under low folate conditions 
associated with TSER 3/3 genotype in a Singapore Chinese population, whereas 
Brown et al (182) observed no effect of the TSER polymorphism on either serum 
folate or homocysteine levels in young Irish adults.  Thus, clearer delineation of the 
effect of the TSER polymorphism on folate and homocysteine levels among different 
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populations may help clarify population differences in NTD risk. 
  The role of dihydrofolate reductase (DHFR) in neural tube closure has recently 
been investigated, following the discovery of a novel 19-bp deletion polymorphism in 
intron1 of the DHFR gene (183).  Johnson et al (2004) first investigated the 
relationship between this polymorphism and risk of spina bifida in a mostly Caucasian 
population in the United States.  Maternal homozygosity for the 19-bp deletion allele 
was associated with an increased risk for spina bifida in the offspring, although there 
was no risk associated with spina bifida cases.  Two more recent studies examining the 
19-bp deletion allele in relation to NTD risk failed to replicate this finding.  Van der 
Linden and colleagues found no association between the deletion allele and risk for 
spina bifida, either in mothers or cases (184).  The authors also investigated DHFR 
expression levels in lymphoblast cell lines derived from spina bifida cases, as well as 
plasma folate and homocysteine in all subjects.  No differences in DHFR expression 
were found in response to the 19-bp deletion and further no differences in plasma 
folate or homocysteine were observed, even when examined in combination with the 
MTHFR C677T genotype.  In sharp contrast, Parle-McDermott et al conducted very 
similar analyses in an Irish population, and found a protective effect of the 19-bp 
deletion allele in case mothers, consistent with a 1.6-fold increase in DHFR expression 
associated with the polymorphism in generic lymphoblast cell lines (185).  The reason 
for the discrepancy between these two studies remains to be determined; indeed, 
further investigation of the biochemical effect of the DHFR polymorphism as well as 
the association with NTD risk is warranted.  Incidentally, the study by Parle-
McDermott et al investigated the entire DHFR gene for additional polymorphisms, 
and failed to detect any within the coding region.  Together, these findings do not 
provide support for a specific role of DHFR in mediating neural tube closure. 
  Limited examination of the role of genes contributing to nucleotide 
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biosynthesis suggests that nucleotide biosynthesis, either in the mother or the fetus, 
may be a determinant of proper neural tube closure.  This is particularly evident in the 
case of MTHFD1, in which the R653Q polymorphism is strongly associated with 
maternal risk for NTD-affected pregnancy.  Investigation of the specific effect of this 
SNP on MTHFD1 function and folate-mediated one-carbon metabolism will shed 
more light on the metabolic mechanism(s) underlying elevated maternal risk.  Further 
examination of polymorphisms in cSHMT, TS, and DHFR in larger and more diverse 
populations will provide more information regarding the role of these genes in neural 
tube closure.  Thus far, limited power to detect associations between SNPs in these 
genes and NTD risk, as well as inadequate understanding regarding the biochemical 
effects of these SNPs on enzymatic function, restrict our ability to draw further 
conclusions.   
 
Summary.  Presently, SNPs in several genes associated with various aspects of folate-
mediated one-carbon metabolism have been explored in relation to NTDs.  Although 
the precise contribution of these genetic variants to NTD risk in the population 
remains undetermined, it is clear that genetic variation in genes regulating folate-
mediated one-carbon metabolism underlies failure of neural tube closure.  Further 
investigation of the interactions of these SNPs with folate status, as well as the 
identification of specific metabolic and/or genomic impairments caused by SNPs in 
different folate-related genes, will provide more information as to the underlying 
mechanisms of folate-responsive NTDs.  In addition, further examination of the 
unique contributions of maternal and fetal genotype, using both more robust TDT 
analysis and animal models, will aid in determining how folate supplementation 
affords protection against NTDs.  Lastly, continuing investigation of gene-gene 
interactions in relation to NTD risk will help to identify populations at the greatest 
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risks for NTDs and provide important information regarding the interactions among 
different folate-dependent anabolic pathways in NTD pathogenesis. 
 
Linking Metabolism and NTDs: Can We Deduce a Mechanism from Animal 
Models? 
  To date, evidence from analysis of human SNPs and mutant mouse models 
within the folate and methionine/homocysteine pathways has not provided sufficient 
information to establish the metabolic and/or genomic mechanism(s) underlying 
human folate-responsive neural tube closure defects.  Additional research is required 
in the area of gene-nutrient and gene-gene interactions within these models to 
establish causal risk factors and the associated mechanisms.  In general, conclusions 
drawn from human genetic studies of folate and NTDs are limited by the numerous 
confounding environmental and genetic influences within a given population.  In 
addition, the metabolic and genomic outcomes that can be investigated in humans are 
restricted.  Animal models are more suitable for investigating links between specific 
biochemical/metabolic impairments, cellular responses, and pathological outcomes.  
Further, the use of animal models allows for more complete assessment of pathology, 
especially related to fetal outcomes.  Unfortunately, since the majority of mouse 
models in which folate-related genes have been disrupted do not exhibit NTDs, their 
utility in exploring metabolic mechanism(s) underlying NTDs is limited.  Here we 
review data in which folate and/or homocysteine status has been experimentally 
manipulated in wild-type mice or in mouse models with genetic mutations that cause 
NTDs in order to better understand the role of folate metabolism in neural tube 
closure.  
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Models of Folate Deficiency and NTDs.  Investigators have long sought a mouse 
model of maternal dietary folate deficiency to investigate mechanism underlying 
neurodevelopmental anomalies.  Surprisingly, folate deficiency alone does not 
produce NTDs in mice (186,187).  Heid et al (186) assessed implantations, 
resorptions, and NTDs in litters at gestational day 12  from dams fed folate-deficient 
diets ranging from 45-2255 nm/kg folic acid. Doses below 181 nmol/kg were 
incompatible with implantation; doses between 221 and 453 nmol/kg resulted in 100% 
resorption rate.  Doses within a range that produced about 75% resorptions did not 
produce NTDs in viable embryos.  In 2002, Burgoon et al (187) fed dams a modified 
diet without folic acid that also contained succinyl sulfathiazole (SS), an antibiotic that 
reduces gut flora capable of generating folates, in an effort to completely eliminate 
sources of folate.  Although some implantations survived past gestational day 11-12, 
there was still no evidence for NTDs in this model.  Thus, is appears that folate 
deficiency in mice is insufficient for generating NTDs, likely due to the ability of mice 
to resorb fetuses that are not viable. 
 
Models of Hyperhomocysteinemia and NTDs.  In light of the failure of folate 
deficiency to induce NTDs in a mouse model, direct supplementation with 
homocysteine, either via maternal diet or embryo culture, has been investigated as a 
direct cause of NTDs in mice.  There is a body of evidence from studies in chick 
embryos indicating that homocysteine may be a teratogen at high levels (for review 
see (188).   Besides a number of developmental defects outside of the nervous system, 
homocysteine has also been shown to induce NTDS in cultured chick embryos, an 
effect that is also folate-responsive (189,190).  Potential cellular mechanisms 
underlying NTDs in this model have been investigated; homocysteine has been shown 
to inhibit neural crest outgrowth in vivo (191) and neural crest differentiation in vitro 
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(192).  It is important to note that the majority of these studies have administered very 
high doses of homocysteine, far above those that have been associated with NTD risk 
in human pregnancy.   In contrast to findings in chick embryos, several recent studies 
have provided evidence against a direct role of homocysteine in neural tube closure 
defects in mice, either in cultured embryos (193,194) or via maternal administration 
with homocysteine (195).  The most recent study by Bennett and colleagues assessed 
NTDs in response to varying doses of homocysteine in several different mouse strains 
susceptible to teratogen-induced NTDs, providing a persuasive argument against a 
direct role of homocysteine in NTD pathogenesis.  Furthermore, in the study by 
Burgoon et al (187) in which pregnant mice were fed a folate-deficient diet with SS, 
elevation of plasma homocysteine within a range comparable to levels observed in 
humans also failed to induce NTDs.  Collectively, these data do not support a direct 
role of homocysteine in NTD pathogenesis, at least in a mammalian model, and the 
absence of phenotype prevents further study of the mechanism(s) by which alterations 
in homocysteine/folate metabolism affect neural tube closure.   
 
Alteration in Methylation Cycle and NTDs.  Although evidence is weak for a direct 
influence of homocysteine on neural tube closure defects, it is possible that 
homocysteine accumulation may alter neural tube closure via perturbation of the 
methionine cycle.  Recent examination of this hypothesis by Dunlevy and colleagues 
has provided preliminary support for a direct role of methionine and methionine-
dependent cellular methylation in neural tube closure.  In two separate studies, the 
authors demonstrated that culture of neurulation-stage mouse embryos with excess 
methionine or inhibitors of methionine adenosyl transferase (MAT) resulted in an 
exencephalic phenotype at high frequency (196,197).  Supplementation of culture 
media with 5mM methionine or the Adomet inhibitors ethionine or cycloleucine 
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reduced the AdoMet/AdoHcy ratio, suggesting that the NTD phenotype might be 
linked to reduction in cellular methylation, in particular DNA hypomethylation.  
Possible cellular mechanisms underlying failure of neural tube closure in this model 
was also examined via morphological investigation of affected embryos.  Reduced 
cranial mesenchymal density was observed in embryos cultured with methionine or 
ethionine, although the direct relevance to the NTD phenotype was not immediately 
apparent.  Although culture with cycloleucine did affect neuroepithelial density, the 
absence of the same effect in methionine- and ethionine-treated embryos raises doubt 
as to the ultimate cause of this morphological defect.  Furthermore, no differences in 
cell proliferation or survival were detected in any affected embryos. The lack of an 
obvious defect in neuroepithelial integrity suggests that the NTD phenotype observed 
in this study may be due to another as yet unidentified mechanism.  In addition, the 
supraphysiological doses of methionine utilized poses questions regarding the 
relevance of these effects to human-responsive NTDs.  Nonetheless, these data are one 
of the few to link a specific metabolic impairment (e.g. altered cellular methylation 
potential) with failure of neural tube closure, and justify further investigation into this 
potential mechanism.   
 
Alterations in Folate Metabolism in Mouse Models of NTDs 
Numerous genetic mutations outside the folate/methionine pathways have been 
identified that cause NTDs in mice.  The majority of these mutations fall within well-
defined developmental pathways.  Impairments in folate metabolism and/or 
responsiveness to dietary manipulation of folate or methionine have been examined in 
a handful of these mutants (for review see (198).  The present review will focus on 
those mouse models that have demonstrated responsiveness to folate or methionine, 
since these bear the most relevance to human-responsive NTDs.  Additionally, these 
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models make strong candidates for studying metabolic impairments underlying folate-
responsive human NTDs because like human NTDs they show dose-dependent 
responsiveness to folic acid in the absence of frank maternal folate deficiency. By 
addressing mechanisms associated with folate supplementation and/or deficiency in 
mouse models with genetic mutations outside the folate pathways we hope to gain 
insight into 1) metabolic/cellular outcomes associated with folate supplementation on 
a folate-replete background, and 2) interaction of folate metabolism with key 
developmental pathways.     
 
Pax3 (Splotch).  Rescue of NTD phenotype by folate supplementation has been 
demonstrated in the splotch mutant both in cultured embryos (199) and with maternal 
folate supplementation (199,200).  The splotch mutant carries a deletion allele in the 
gene encoding the transcription factor Pax3; homozygous splotch mutants display a 
spina bifida phenotype that is 100% penetrant with occasional exencephaly, whereas 
heterozygote splotch mutants are identified by white belly splotch indicative of neural 
crest migration defects in the absence of neural tube closure defects.  Fleming and 
Copp (1998) investigated alterations in folate metabolism in splotch mutants; using 
the deoxyuridine (dU) suppression assay, they determined that splotch mutant 
embryos were impaired in their ability to generate thymidine de novo.  Further, 
supplementation of the culture media with either thymidine or folic acid ameliorated 
impairments in thymidylate biosynthesis while simultaneously preventing NTDs in 
homozygous splotch embryos. NTD rescue was also demonstrated with embryonic 
supplementation of the same compounds in utero.  Interestingly, supplementation of 
culture media with methionine produced NTDs in almost 50% of splotch 
heterozygotes and exacerbated the impairment in de novo thymidine biosynthesis.  
Rescue of NTD phenotype by folic acid and exacerbation with methionine were 
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replicated in utero in the study by Wlodarczyk and colleagues; however, thymidine 
supplementation was not protective against NTDs in this study.   Exploration of folate 
metabolism and folate responsiveness in the splotch mutant to date yields several 
insights.  First, rescue of cultured embryos with folic acid or thymidylate provides 
additional support for a direct role of embryonic folate utilization in neural tube 
closure.  Second, the data from Fleming and Copp provide the first line of evidence 
directly linking a specific metabolic impairment (e.g. impaired thymidylate 
biosynthesis) within the folate pathway with NTDs. That this impairment was also 
responsive to supplementation with folic acid strengthens its significance in relation to 
folate-responsive human NTDs.  Recently, impaired de novo thymidylate synthesis 
was also confirmed in human embryos with NTDs (201) further strengthening the 
evidence for a causal relationship between impaired thymidylate biosynthesis and 
NTDs.   Third, the opposing influences of methionine and thymidine supplementation 
on NTD outcomes in this model again suggests that maintaining the proper balance 
between methionine synthesis and nucleotide biosynthesis is critical for proper neural 
tube closure. Lastly, Wlodarczyk and colleagues note that the supplementation method 
that exerted the greatest protective effect on NTD risk   (i.e. 200mg/kg dietary 
supplementation) also resulted in 6-fold increase in the number of resorptions. These 
findings emphasize potential negative outcomes associated with elevated folate intake 
in the absence of genetic and/or other risk factors.  
 
Cited2.  Mutation of Cited2, a member of family of nuclear transcriptional activators, 
causes exencephaly in 80% of homozygous embryos.  Barbera et al (202) 
demonstrated that maternal periconceptional supplementation with moderate doses of 
folic acid could prevent 75% of NTDs in homozygotes.  Impaired de novo thymidylate 
biosynthesis was investigated in cultured embryos using the dU suppression test; 
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however, despite responsiveness to folic acid supplementation, Cited2 mutants did not 
display impaired thymidylate biosynthesis.  No other metabolic outcomes were 
evaluated in this study. Characterization of the cellular defect underlying exencephaly 
in the Cited2 mutant implicated massive cell death in the rostral neuroepithelium.  
Interestingly, cell death was not rescued by folic acid supplementation, indicating that 
folic acid was preventing NTDs by some other unidentified mechanism.  In the 
absence of an impairment in folate-dependent thymidylate synthesis, these data 
suggest the possibility that folate may be exert a protective effect independent of one-
carbon metabolism.  At a cellular level, the authors suggest that folic acid may be 
acting to stimulate cell proliferation in an effort to compensate for massive cell death.   
 
Crooked Tail (Cd).  The crooked tail (Cd) mutant was identified as a spontaneous 
mutation that produced a kinked tail in heterozygous progeny and exencephaly in 
homozygotes.  Folate-responsiveness was investigated in the Cd mutant (203) using a 
series of folic acid doses within a range comparable to those recommended for 
prevention of NTDs in humans.  Exencephaly in Cd homozygotes showed a dose-
dependent response to maternal supplementation with folic acid, with a 59% 
protective effect akin to that observed with human NTDs. Recently, Carter and 
colleagues mapped the location of the Cd mutation to the gene LRP6, encoding a co-
receptor within the Wnt signaling pathway (204). The Cd mutation has been 
characterized as a single nucleotide missense mutation that alters regulation of Wnt 
signaling.  This is the first evidence indicating that an essential developmental 
signaling pathway interacts with folate status.   It remains to be determined 1) whether 
the Cd mutation is directly associated with impairments in folate-mediated on carbon 
metabolism, and 2) whether folate supplementation rescues NTD phenotype by 
rescuing metabolic impairments.  Recent investigation of folate and homocysteine 
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levels in adult Cd mice did not reveal obvious metabolic impairments, although the 
similarity in metabolic profile of Cd homozygous mice as compared to wild-type and 
heterozygous littermates on folate-deficient diets suggests a defect in intracellular 
folate utilization (205).  Further investigation of the interaction between the Cd 
mutation and folate status should provide novel insights into a potential role of folate 
metabolism in developmental signaling and/or the effects of altered developmental 
signaling on folate-mediated one-carbon metabolism.   
Cart1 and Axd.  Two other mutants have demonstrated responsiveness to 
supplementation within the folate/methionine cycles, although there has been little 
examination of the basis for responsiveness in these models.  Mice mutant for the 
Cart1 gene, which encodes cartiledge homeoprotein 1, develop exencephaly associated 
with loss of forebrain mesenchyme.  Intraperitoneal injection of pregnant females with 
folic acid around the time of neural tube closure prevented about 80% of NTDs in a 
small sample of homozygous embryos, although neither the cellular or metabolic 
bases for this robust effect were explored (206).  Further, the dependence of the 
phenotype on mesenchymal integrity, not neuroepithelial integrity, and the absence of 
Cart1 expression in the neuroepithelium makes this model less appealing for studying 
the role of folate-mediated one-carbon metabolism in neural tube closure.   
  Another NTD mutant, the Axd mutant, demonstrates responsiveness to 
supraphysiological doses of methionine, but not to supraphysiological doses of folic 
acid and vitamin B12 (207).  Variable NTD phenotypes ranging from spina bifida to 
curly tail in embryos from heterozygous Axd mating were prevented by almost 50% in 
dams supplementated with i.p. injections of 180mg/kg methionine during the period of 
neurulation.   Due to the extremely high doses used in these studies, relevance to 
human supplementation is limited. Still, the responsiveness of the NTD phenotype in 
Axd mutants to methionine supplementation, but not to folate supplementation, 
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provides additional support for the requirement of balancing flux of one-carbon units 
between the thymidylate and methionine biosynthetic pathways. 
 
Conclusions 
  In summary, despite decades of research exploring the relationship between 
folate nutriture, genetic variation, and NTDs, we are still mostly unaware of the 
metabolic and/or genomic mechanism(s) by which alterations in folate metabolism 
affect neural tube closure.  Data from genetic studies and studies of animal models 
thus far indicate that disruption in both nucleotide biosynthesis and cellular 
methylation may underlie NTD pathogenesis, although concrete evidence regarding 
the specific metabolic and/or genomic defects is lacking.  In addition, we know 
relatively little concerning how metabolic/genomic outcomes influence cellular 
processes during neural tube closure.  Because folate-dependent anabolic reactions 
compete for folate-derived one-carbon units, it may be that under conditions of low-
folate status, a sensitive regulation of flux is required to achieve normal neurulation.  
Further exploration of human SNPs in a context of gene-nutrient and gene-gene 
interactions may provide greater insight into how genetic alterations in folate-related 
genes affect flux of one-carbon metabolism and thereby contribute to NTD risk.  In 
addition, continued investigation of folate metabolism and folate responsiveness in 
mouse models will yield more information regarding metabolic derangement 
underlying failure of neural tube closure.  Although several of the mouse models in 
which folate-related genes have been mutated exhibit early pre-neurulation lethality, 
exploration of heterozygous KO mice under conditions of low folate status may 
provide a better model of human genetic variation and deficiency.  Lastly, 
manipulation of genes known to regulate flux of folate-mediated one-carbon  
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metabolism, i.e. cSHMT, may provide more opportunity for determining the metabolic 
and/or genomic underpinning of folate-responsive NTDs. 
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CHAPTER 2 
INSIGHTS INTO METABOLIC MECHANISMS UNDERLYING FOLATE- 
RESPONSIVE NEURAL TUBE DEFECTS: A MINI-REVIEW 
 
Abstract 
Neural tube closure defects (NTDs), including anencephaly and spina bifida, arise 
from the failure of neurulation during early embryonic development.  NTDs are 
common birth defects with a heterogenous and multifactorial etiology with interacting 
genetic and environmental risk factors.  Although the mechanisms resulting in failure 
of neural tube closure are unknown, up to 70% of NTDs can be prevented by maternal 
folic acid supplementation.  However, the metabolic mechanisms underlying the 
association between folic acid and NTD pathogenesis have not been identified.  This 
review summarizes our current understanding of the mechanism(s) by which 
impairments in folate metabolism might ultimately lead to failure of neural tube 
closure, with an emphasis on untangling the relative contributions of nutritional 
deficiency and genetic risk factors to NTD pathogenesis. 
 
Introduction 
  Failure of the neural tube to fuse in its entirety during early embryogenesis 
results in a cluster of common developmental anomalies known as neural tube closure 
defects (NTDs).   NTDs usually present with herniation and exposure of nervous 
tissue in the cranial region (termed anencephaly) or the spinal region (termed spina 
bifida).  These malformations are severe, irreversible and debilitating; anencephaly is 
incompatible with postnatal survival whereas spina bifida results in a life-long 
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disability and often necessitates multiple surgical interventions.  Although the 
morphogenic processes underlying both normal neurulation and its failure continue to 
be an area of active investigation, the ultimate causes and the associated biological 
mechanisms of neural tube closure defects in mammals remain unknown.   Over the 
past two decades, numerous genetic and environmental risk factors have been 
identified; however, the strongest association to date is that between the B-vitamin 
folate and NTD risk.  Early clinical observations in the 1960’s led to an understanding 
that reduced maternal folate status was associated with elevated NTD risk (1-3).  
Subsequent studies identified elevated maternal homocysteine, which is a biomarker 
of impaired folate status and/or metabolism, as a risk factor for NTDs (4,5).  Later, 
randomized control trials and population-wide fortification initiatives (6-8) verified 
the efficacy of folic acid supplementation in reducing both NTD occurrence (9) and 
recurrence (10)  by up to 70%.  Despite several decades of epidemiological research 
indicating that folate is intimately linked to NTD risk, the metabolic mechanisms 
underlying the pathogenesis of folate-responsive NTDs have yet to be identified.  
   Although maternal folate status is linked to NTD risk, certain individuals 
within populations are at greater risk than others independent of folate status, 
indicating that folate deficiency alone is not sufficient to cause an NTD-affected 
pregnancy.  A genetic component to NTDs has been long recognized; family history is 
one of the strongest risk factors for NTDs (11). In addition,  NTDs are more common 
among certain ethnic groups and in individuals with a previous NTD-affected 
pregnancy (12).   Because folate status contributes to NTD risk, investigation of 
genetic risk factors in humans has focused primarily on genetic variation within genes 
that encode proteins that bind, transport, process and/or metabolize folate, with the 
assumption that genetically-induced alterations in folate status and/or metabolism are 
likely to contribute to NTD pathogenesis.   Although polymorphisms have been 
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identified in folate-related genes that contribute to risk for an NTD-affected 
pregnancy, the total genetic variation identified to date that contributes to NTD risk 
does not account for the overall genetic contribution to NTD incidence observed in 
human populations.  Commonly, epidemiological studies focus on synergistic gene-
diet interactions, and the identification of polymorphisms within folate-related genes 
that interact with low folate status to confer risk for developmental anomalies 
including NTDs.    
The profile of NTD pathogenesis is emerging as an interaction between 
predisposing genetic factors with primary or secondary nutrient deficiencies (Figure 
2.1).  Although it was originally hypothesized that maternal folate supplementation 
lowered risk for NTDs by correcting a primary folate deficiency, it has become 
apparent that this explanation may not account for many cases of NTD prevention.    
Furthermore, folic acid supplementation may prevent NTDs even in the absence of 
overt maternal folate deficiency, because most women with an NTD-affected 
pregnancy are not folate deficient (13-15). Increased folate intake, in the form of folic 
acid supplements or fortified food, may compensate for genetically-linked 
impairments in folate utilization and/or secondary nutrient deficiencies, not correct 
folate deficiency per say.   Thus, investigations into gene-nutrient interactions that 
result in NTD pathogenesis now distinguish among: 1) single gene variants that affect 
folate status alone, 2) single gene variants that affect folate utilization and/or 
metabolism, and 3) single gene variants that affect both folate status and 
metabolism/utilization.  Impairments in folate status can be the result of dietary folate 
deficiency, but can also result from genetic variation that impacts cellular folate 
accumulation including its absorption, cellular transport, 
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Impaired Folate Status  Impaired Folate Utilization 
 
-  Primary Nutrient Deficiency 
o  folate, folic acid 
-  Genetic Variation 
o  folate transport 
o  folate accumulation 
 
 
-  Secondary Nutrient Deficiency 
o  Vitamin B12, vitamin B2 
-  Genetic Variation 
o  folate metabolism 
  purines 
  thymidylate 
  methionine (AdoMet) 
  glycine 
 
 
NTD Risk 
Figure 2.1.  Gene nutrient interactions in neural tube closure defects.  
Low folate status interacts with impairments in one-carbon metabolism 
(folate utilization) to create risk for NTDs.  Both folate status and folate 
utilization are compromised by interactions among genetic and environmental 
(nutritional) factors.  
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processing, retention and degradation (16).  Likewise, impairments in folate 
utilization/metabolism can result from genetic variation that affects the activity and/or 
stability of folate-dependent metabolic enzymes, but can also result from secondary 
deficiencies of nutrients intimately linked to folate metabolism, such as vitamin B12 
and choline.  Thus, both genetic risk factors and nutrient deficiencies contribute to 
impairments in folate status and/or impairments in folate utilization (Figure 2.1).  
Untangling the relative contributions of the genetic and nutritional components of 
NTD risk will be required to identify the specific biological pathways that lead to 
NTD pathogenesis, which will enable the design of better targeted and efficacious 
interventions for NTD prevention.  In this review, our current understanding of the 
mechanisms underlying NTD pathogenesis in the context of folate-mediated one-
carbon metabolism is summarized. 
Folate-mediated One Carbon Metabolism 
In the cell, folates function as a family of metabolic cofactors that carry and 
chemically activate single carbons, referred to as one-carbon units,  for a variety of 
anabolic and catabolic reactions collectively known as folate-mediated one-carbon 
metabolism (OCM) (Figure 2.2).  Folate-activated one-carbons are carried by 
tetrahydrofolate (THF), the metabolically active form of folates.  THF carries one-
carbons at three different oxidation states ranging from formaldehyde to methanol, and 
the one-carbon forms of folate can be interconverted enzymatically (17-19).   Cellular 
folate cofactors also contain a poly-γ-glutamate peptide that varies in length in cells 
from 3 to 9 glutamate residues.  In the gut, the poly-γ-glutamate peptide is hydrolyzed 
leaving monoglutamated folate derivatives that are transported across the intestinal 
mucosa.  Folate monoglutamates, predominately in the form of 5-methylTHF, are 
present in serum and transported into cells.  Both retention of folate in the cell, and 
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Figure 2.2:  Compartmentation of folate-mediated one-carbon 
metabolism in the cytoplasm and mitochondria.  One-carbon metabolism in 
the cytoplasm is required for the de novo synthesis of purines and thymidylate, 
and for the remethylation of homocysteine to methionine.    One-carbon 
metabolism in mitochondria is required to generate formate for one-carbon 
metabolism in the cytoplasm, to generate the amino acid glycine, and to 
synthesize formylmethionyl-tRNA for protein synthesis in mitochondria. 
FTHFS, 10-Formyltetrahydrofolate Synthetase; MTHFC, 
Methenyltetrahydrofolate Cyclohydrolase; MTHFD, 
Methylenetetrahydrofolate Dehydrogenase; MTHFR, 
Methylenetetrahydrofolate Reductase; GARFT, Phosphoribosylglycinamide 
Formyltransferase; AICARFT, Phosphoribosylaminoimidazolecarboxamide 
formyltransferase; FTCT, Glycine Formiminotransferase/ 
Formimidoyltetrahydrofolate Cyclodeaminase & Glutamate 
Formiminotransferase/ Formimidoyltetrahydrofolate Cyclodeaminase; 
cSHMT, Cytoplasmic Serine Hydroxymethyltransferase; TS, Thymidylate 
Synthase; DHFR, Dihydrofolate Reductase; MS, Methionine Synthase, 
mSHMT, Mitochondrial Serine Hydroxymethyltransferase; GSC, Glycine 
Cleavage System;  SD,  Sarcosine Dehydrogenase; DMGD, Dimethylglycine 
Dehydrogense; mMTHFD, Mitochondrial Methylenetetrahydrofolate 
Dehydrogenase; mMTHFC, Mitochondrial Methenyltetrahydrofolate 
Cyclohydrolase; M-tRNA-FT,  Methionyl-tRNA Formyltransferase; 
mFTHFS, Mitochondrial Formyltetrahydrofolate Synthetase. 
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their conversion to functional cofactors, requires the reestablishment of the poly- γ -
glutamate peptide (20,21).   
Folate-mediated one-carbon metabolism is a metabolic network of 
interdependent pathways that is compartmentalized in the mitochondria, the 
cytoplasm, and the nucleus.  Folate metabolism in mitochondria is required for the 
production of formate, glycine and 
fmettRNA  from the catabolism of choline, serine 
and glycine (18,22).   Once formed, formate traverses from the mitochondria to the 
cytoplasm where it is serves as a primary source of one-carbon units for cytoplasmic 
OCM.  Folate-mediated one-carbon metabolism in the cytoplasm is essential for:  1) 
de novo purine biosynthesis, 2) de novo thymidylate biosynthesis, and 3) the 
remethylation of homocysteine to form methionine.  Methionine is required for the 
biosynthesis of S-adenosylmethionine (AdoMet), which is a cofactor that serves as the 
universal one-carbon donor for cellular methylation reactions including methylation of 
chromatin, proteins, and lipids, and other small molecules (19,20).  During S-phase, 
the enzymes that constitute the de novo thymidylate biosynthesis cycle, serine 
hydroxymethyltransferase, thymidylate synthase and dihydrofolate reductase, are 
modified by the small ubiquitin-related modifier (SUMO) and transported to the 
nucleus for nuclear thymidylate biosynthesis (23,24).  Impairments in folate-mediated 
OCM can result from diminished folate status, single nucleotide polymorphisms in 
genes that encode folate-metabolizing enzymes, or secondary micronutrient 
deficiencies that alter folate status, including other B vitamins (25-27).  Biomarkers of 
impaired one-carbon metabolism include diminished capacity to synthesize 
thymidylate de novo leading to increased uracil content into DNA (28), elevated serum 
homocysteine (29), and DNA hypomethylation (30,31) .   
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Folate Transport 
  Sources of dietary folates include food folates, which contain a polyglutamate 
peptide, and folic acid, a synthetic dietary supplement and fortificant.   Folic acid is a 
monoglutamic and oxidized form of folate that, unlike natural reduced folates, is 
chemically stable.  Most folic acid is readily absorbed and converted to THF within 
the enterocytes where it becomes chemically  indistinguishable from natural food 
folates (32).  Polyglutamated  food folate derivatives must first be converted to 
monoglutamate derivatives by the enzyme folylpoly-γ-glutamate carboxypeptidase II 
(FGCP; gene name, GCPII) in the gut prior to absorption through the intestine (33), 
which is accomplished through a recently identified intestinal folate receptor (PCFT) 
(34).   Serum folates are present in the form of monoglutamated 5-methyl THF, which 
is taken up at the cell surface either by the reduced folate carrier (RFC), a facilitative 
anion-exchange carrier, or by an endocytotic process mediated by one of two folate 
receptors, FRα and FRβ (35).  The folate receptor is a membrane-anchored receptor 
with a GPI-moiety that has a high affinity for 5-methyl THF (35). Once inside the cell, 
polyglutamation of folate cofactors is catalyzed by the enzyme folylpoly-γ-glutamate 
synthetase (FPGS), resulting in the sequestration of folates within the cell.  The 
polyglutamate peptide also increases the affinity of THF cofactors for folate-
dependent enzymes (17,19). Within the cell, 5-methylTHF is the most abundant folate 
derivative. 
Studies to date have not provided conclusive evidence that common 
polymorphisms within genes that encode proteins that mediate folate transport and 
absorption affect folate status.  There have not been any variants identified within the 
coding regions of the folate receptor genes, and investigations of polymorphisms in 
non-coding regions of FRα and FRβ have not yielded an association with NTD risk 
(36-39)..  Coding variants within genes that impair folate transport and accumulation 
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may not be compatible with life and result in embryonic lethality.  Nonetheless, 
genetic variation within the folate receptor genes does not confer risk for NTDs in 
humans.  A common single nucleotide polymorphism (SNP) in the RFC1 gene has 
shown a moderate association with NTD risk under conditions of folate deficiency 
(40-42), although with low penetrance.  With regard to genes encoding proteins that 
mediate folate processing, no polymorphisms have been identified within the gene 
encoding FPGS that confer risk for NTDs in human populations.  Similarly, a single 
variant identified in GCPII does not affect NTD risk in humans (43).  Thus, there is 
little evidence that genetic variation disrupts folate transport, absorption, processing 
and retention to a degree that independently contributes to NTD risk in human 
populations.  However, given that NTDs are complex traits, genetic alterations of 
these processes might exacerbate nutritional deficiencies or metabolic impairments, 
and thereby sensitize population subgroups with genetically-induced impairments in 
one-carbon metabolism.    
A definitive and causal role of embryonic folate deficiency in NTD 
pathogenesis has been demonstrated by the observation that genetic deletion of the 
gene encoding FRα, Folr1, results in NTDs (44).   However, investigation of one-
carbon metabolism in this mouse model has not provided mechanistic information on 
the identity of the one-carbon pathway component that underlies NTD pathogenesis.  
There are no differences observed in homocysteine levels in FolR1
+/- dams maintained 
on a normal diet (44), nor are there any differences in DNA methylation in FolR1
+/- 
embryos or FolR1
-/- embryos rescued to GD15.5 with folinic acid (45).   Furthermore, 
that NTDs in nullizygous FolR1 KO embryos can be rescued by maternal 
supplementation with folic acid  (44) provides further support for the concept that 
genetic disruption of folate transport affects folate status in the absence of alterations 
in folate utilization, because reductions in transport capacity can be overcome by 
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maternal vitamin supplementation.  A similar finding has been observed with deletion 
of the gene encoding RFC in mice.  Deletion of RFC results in early embryonic 
lethality; however, embryonic survival can be rescued up until GD12 by maternal folic 
acid supplementation (46).  Collectively, these data suggest that adequate folate status 
mediated by cellular folate uptake is required for embryonic development and neural 
tube closure.  However, in the absence of an association between human genes 
involved in folate uptakes and NTD risk, these models do not provide further insight 
into specific causes that underlie human folate-responsive NTDs. 
Folate Metabolism in the Mitochondria 
  The primary roles of folate metabolism in mitochondria is to generate formate 
and glycine from the enzymatic cleavage of serine; in certain tissues glycine can also 
be catabolized to generate formate through mitochondrial folate metabolism (47).  
This pathway is initiated by the mitochondrial isoform of serine 
hydoxymethyltransferase (mSHMT; gene name Shmt2), which catalyzes the 
conversion of serine and THF to form glycine and methylene-THF.   Methylene-THF 
can also be synthesized from glycine by the glycine cleavage system (GCS) (48), as 
well as from of the catabolism of sarcosine and dimethylglycine (49).   Methylene-
THF is oxidized to produce methenyl-THF in a reaction catalyzed by 
methylenetetrahydrofolate dehydrogenase (MTHFD), which is subsequently 
hydrolyzed to 10-Formyl THF by the enzyme methenyltetrahydrofolate 
cyclohydrolase (MTHFC).  The formyl group of 10-formyl-THF is hydrolyzed to 
generate free formate and THF to complete the cycle, in a reaction catalyzed by 
formyltetrahydrofolate synthetase (FTHFS) (50).   Formate then traverses into the 
cytoplasm and serves as a major source of one-carbon units for cytoplasmic OCM.  
Some of the genes encoding the enzymes that catalyze the generation of formate from 
5,10-methylene THF in the mitochondria have yet to be identified (47).   
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  To date, there have been few reports and little investigation into the role of 
mitochondrial folate metabolism in NTD pathogenesis, this includes investigations of 
human genetic susceptibility and genetically manipulated mouse models.  One 
limitation is the paucity of knowledge regarding the identity of the genes and enzymes 
that regulate OCM in the mitochondria, and the degree to which the capacity of 
mitochondrial OCM, including formate production, affects cytoplasmic OCM.  
Furthermore, mitochondrial OCM plays different metabolic roles in different tissues 
and cell types.  Whereas it has been shown in certain cell types that mitochondrial 
OCM is an essential source of glycine (47), it remains to be established definitively 
that formate derived from mitochondrial OCM is essential for cytoplasmic OCM.  
Recently, a mouse KO model of the gene encoding the cytoplasmic SHMT isoform 
(cSHMT; Shmt1) was generated and was shown to be both viable and fertile (51).  The 
viability of this mouse model indicates that one-carbon units generated in the 
cytoplasm by cSHMT, through the expression of Shmt1, are not essential for growth 
and survival.  This mouse models emphasizes the importance of mitochondrial OCM 
in the production of one-carbon units for folate-dependent anabolic reactions in the 
cytoplasm.  Further investigation into the role of mitochondrial OCM in regulating 
folate-dependent anabolic pathways in the cytoplasm is warranted.  In addition, 
exploration of human SNPs in mitochondrial folate-dependent enzymes and the 
creation of mouse models with disruptions in genes encoding the mitochondrial folate 
pathway will shed light on the potential contribution of mitochondrial folate 
metabolism to NTD pathogenesis. 
 
Folate Metabolism in the Cytoplasm  
Cytoplasmic OCM is essential for the de novo biosynthesis of nucleotides as 
well as AdoMet-dependent cellular methylation reactions (Figure 2.2).  The purine 
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biosynthesis pathway utilizes the cofactor 10-formylTHF as the one-carbon donor for 
the #2 and #8 carbons in the purine ring.  De novo thymidylate biosynthesis utilizes 
methylene-THF as a cofactor for the methylation of dUMP to form dTMP, in a 
reaction catalyzed by the enzyme thymidylate synthase (TS).   The one-carbons 
carried by 10-formyl-THF and methylene-THF can be generated in the cytoplasm 
from formate via the action of the ATP- and NADPH-dependent trifunctional enzyme 
which contains FTHFS/MTHFC/MTHFD activities encoded by the MTHFD1 gene.  
Methylene-THF can also be synthesized from the PLP-dependent enzymatic 
conversion of serine and THF, catalyzed by the enzyme cytoplasmic SHMT (cSHMT, 
gene name Shmt1), a reaction that also generates glycine (Figure 2.2).   Methylene-
THF can be irreversibly reduced by the enzyme methylene-THF reductase (MTHFR) 
to yield 5- methylTHF, which serves as the cofactor for the B-12 dependent 
remethylation of homocysteine to form methionine, catalyzed by methionine synthase 
(MS; gene name MTR).  Methionine can be adenosylated to form S-
adenosylmethionine (AdoMet), which is the one carbon donor for cellular methylation 
reactions.  The transfer of the one-carbon from AdoMet yields the intermediate S-
adenosylhomocysteine (AdoHcy), which is hydrolyzed to homocysteine and adenosine 
by the enzyme S-adenosylhomocysteine hydrolase (SAHH).   
  Although much is known about OCM and its anabolic pathways in the 
cytoplasm, deciphering the causal metabolic pathway associated with NTD risk has 
been challenging.  Within the cell, the concentration of folate-binding proteins and 
enzymes far exceeds the concentration  of folate cofactors, and thus all cellular folate 
is protein bound (16).  This indicates that folate-dependent anabolic reactions in the 
cytoplasm compete for a limiting pool of folate-derived one-carbon units and folate 
cofactors (16,52).  This competition is greatest for the two anabolic reactions that 
utilize 5,10-methyleneTHF, thymidylate biosynthesis and homocysteine remethylation 
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(leading to AdoMet biosynthesis).  These two pathways are sensitive to folate 
deficiency, and therefore it is challenging to determine independently the impact of 
either thymidylate synthesis or homocysteine remethylation (and cellular methylation 
reactions) on NTD risk.    It has been suggested by mathematical modeling (53) and 
experimental data (52) that under normal cellular conditions, the biosynthesis of 5-
methylTHF is favored over the biosynthesis of thymidylate.  
 
Purine Biosynthesis 
Rapid cell proliferation is essential for neural tube closure, thereby requiring 
increased rates and dependence on de novo nucleotide biosynthesis.  However, 
although the thymidylate biosynthesis and homocysteine remethylation pathways are 
highly sensitive to folate status, the purine biosynthetic pathway appears to be less 
sensitive to conditions of folate deficiency (54).  The “higher priority” conferred to 
purine biosynthesis within the OCM network may be due to the dependency of most 
organisms on maintenance of de novo purine biosynthesis for development and 
survival.  The purine biosynthetic machinery utilizes exclusively 10-formyl-THF as 
the folate cofactor for the biosynthesis of the purine ring.  In addition to 10-
formylTHF, there are two other folate derivatives found in cells at the level of 
oxidation of formate: 5-formyl-THF and 5,10-methenyl-THF.  These folate derivatives 
participate in a futile cycle that involves the SHMT-catalyzed synthesis of 5-formyl-
THF from methenyl-THF, and the ATP-dependent conversion of 5-formyl-THF back 
to methenyl-THF by the enzyme methenyl-THF synthetase (MTHFS) (55,56).    
Although neither of these folate derivatives serve as substrates for folate-dependent 
anabolic reactions, recent evidence indicates that regulation of MTHFS and 5-formyl 
levels may impact cellular folate accumulation and regulate purine biosynthesis.  
Anguera et al (57) demonstrated that increased MTHFS expression depleted cellular 
 67 
folate concentration, and Field et al (54) showed that MTHFS expression enhanced 
purine biosynthesis through the sequestration and potential shunting of 10-formyl-
THF into the purine biosynthetic pathway. Furthermore, the binding of 10-formylTHF 
to MTHFS inhibits 5-formyl-THF metabolism, enabling its accumulation.  In this 
regard, 5-formylTHF may function as a storage form of folate in the cell that can be 
quickly mobilized for purine biosynthesis (54).  Thus, ongoing investigations of de 
novo purine biosynthesis and its regulation are elucidating mechanisms by which 
purine biosynthesis is protected within the OCM network even during periods of folate 
deficiency.  Disruptions in synthesis, utilization or distribution of the formyl folate 
cofactors by MTHFD1 and MTHFS could therefore potentially alter purine 
biosynthesis and/or folate status. 
  Information regarding the potential contribution of folate-dependent enzymes 
that regulate or provide substrates for purine biosynthesis to NTD risk is very limited 
because very few variants within these enzymes have been investigated in relation to 
NTDs in humans.  There have been no SNPs identified within the gene encoding 
MTHFS that have been investigated in relation to NTDs, although the data described 
above warrant such investigation.  The most studied variant associated with purine 
biosynthesis is the R653Q transition in MTHFD1.  A strong association has been 
found between MTHFD1 R653Q and an increased maternal risk for NTDs (58-60), 
although negative results have also been reported (61,62).  Despite this strong 
association, the metabolic basis for increased risk associated with the SNP has not 
been elucidated.   The R653Q SNP does not appear to affect total folate levels (58), 
arguing against an effect mediated by changes in folate status.  Furthermore, the SNP 
has not been found to be associated with elevated plasma homocysteine (58,63), 
suggesting that metabolic disruption is likely located at the level of purine and/or 
thymidylate biosynthesis.  Further investigation of the biochemical effect of the SNP 
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on enzyme function and cellular folate utilization may provide insight into the 
mechanism by which this SNP confers NTD risk.  In addition, the use of animal 
models to elucidate the effects of MTHFD1 deficiency on folate status and utilization 
will be useful in ascertaining the role of this potential genetic component in NTD 
pathogenesis. 
 
Thymidylate Biosynthesis 
Thymidylate synthase (TS) catalyzes the transfer of a one-carbon moiety from 
5,10-methylene-THF to uridylate (dUMP) to form thymidylate (dTMP) de novo.  In 
this reaction, folate serves both as a source of an activated one-carbon, but also as a 
source of reducing equivalents.  The substrate 5,10-methylene-THF is synthesized 
both from the MTHFD-catalyzed reduction of methenyl-THF, and by the PLP-
dependent conversion of serine and THF to form glycine and methyleneTHF, 
catalyzed by cSHMT (Figure 2.2).  The transfer of the one-carbon from methylene-
THF to dUMP also involves the oxidation of THF to dihydrofolate, which is recycled 
back into folate pools by the enzyme dihydrofolate reductase (DHFR).  Decreased 
capacity to synthesize thymidylate de novo  due to folate deficiency is associated with 
increased rates of uracil misincorporation into DNA (28).  Uracil misincorporation can 
result in increased genomic instability (64,65).  Other instances of genomic instability, 
including telomeric and centromeric instability, have been reported to cause NTDs in 
mice (66-68).  In addition, impairments in de novo thymidylate biosynthesis affect 
DNA replication, reducing proliferative capacity essential for neurulation.   
  Recent evidence suggests that the partitioning of one-carbon units towards de 
novo thymidylate biosynthesis represents a point of sensitive regulation within 
cytoplasmic OCM.  The thymidylate biosynthesis machinery, including cSHMT, TS 
and DHFR, was shown to translocate to the nucleus at S-phase following modification 
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of the enzymes with the small ubiquitin-like modifier (SUMO) (23,24).  
Compartmentation of de novo thymidylate biosynthesis in the nucleus enables the 
preferential shunting of cSHMT-derived one carbon units into the thymidylate 
biosynthesis pathway.   Other studies have demonstrated that cSHMT activity is rate 
limiting for de novo thymidylate biosynthesis (69).  In addition to stimulating 
thymidylate biosynthesis, cSHMT also regulates 5-methyl-THF utilization in the 
cytoplasm (69).  5-MethylTHF is bound tightly by cSHMT, preventing its use for the 
remethylation of homocysteine to methionine, which impairs AdoMet biosynthesis 
and ultimately cellular methylation reactions (Figure 2.2).  Therefore, cSHMT 
mediates the competition between thymidylate biosynthesis and homocysteine 
remethylation for folate-activated one-carbons.  In cells that do not express cSHMT, 
data indicate that the partitioning of one-carbon units in the form of methylene-THF is 
favored in the direction of the generation of 5-methylTHF at the expense of 
thymidylate biosynthesis (52,53).  However, increased cSHMT expression favors one-
carbon flux in the direction of thymidylate biosynthesis at the expense of cellular 
methylation.  Recently, our lab generated a mouse model with a null cSHMT allele 
that confirms the metabolic role of cSHMT (51).  Loss of cSHMT expression does not 
affect folate status, but does result in an enhanced methylation potential (as indicated 
by the hepatic AdoMet/AdoHcy ratio) and increased uracil levels in nuclear DNA. 
Together, these data indicate that cSHMT regulates folate utilization by balancing the 
partitioning of one-carbon units between thymidylate biosynthesis and cellular 
methylation, in the absence of effects on folate status. 
  Investigation of the thymidylate biosynthesis pathway as a genetic risk factor 
for NTDs in humans has been inconclusive.  The only human SNPs in the TS gene 
that have been investigated in relation to human NTD risk are present in non-coding 
regions, and the only two studies have yielded conflicting findings (70,71).  The effect 
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of a common SNP in the promoter/enhancer region of the TS gene has yet to be 
clearly delineated, and the effect of altered TS expression on OCM and folate status 
have yet to be investigated in a mouse model.  As with genes involved in purine 
biosynthesis, it is likely that mutations within the TS gene that markedly affect 
function are associated with gestational lethality.  Recently, a non-coding deletion 
allele in the gene encoding DHFR was investigated in relation to NTDs; however, 
results from three studies have been inconclusive in determining a role for DHFR in 
mediating NTD risk (72-74).  A handful of studies have investigated the effect of the 
common L474F polymorphism within the gene encoding cSHMT in relation to NTD 
risk.  However, the scope and size of the studies thus far has been inadequate to fully 
determine a potential association with NTD risk (75-77).  Interestingly, the 
biochemical effect of the L474F cSHMT variant has recently been determined.  The 
L474F variant is impaired in its ability to undergo SUMO modification and SUMO-
dependent nuclear localization (23).  These data suggest that the SNP may interfere 
with the ability of cSHMT to preferentially partition one-carbon units to thymidylate 
biosynthesis, ultimately modifying the utilization of folate cofactors in the cytoplasm.  
Further investigation of the SNP in relation to NTDs in humans should shed light on 
the importance of cSHMT-mediated regulation of folate utilization in human NTD 
risk.   
  Although the incidence of NTDs in response to genetic deletion of folate-
related genes mediating de novo thymidylate biosynthesis in mice has not yet been 
explored, there is some evidence from other folate-responsive mouse models to 
suggest that impairments in de novo thymidylate biosynthesis might underlie NTD 
pathogenesis.  Fleming and Copp (78) investigated metabolic alterations and folate 
responsiveness in the splotch mouse model of NTDs.  Homozygous splotch embryos, 
which display a completely penetrant NTD phenotype, exhibited impairments in de 
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novo thymidylate biosynthesis as evidenced by a reduction in dU suppression values.  
Supplementation of culture media with either folic acid or thymidine prevented NTDs 
in homozygous splotch embryos, directly implicating impairments in thymidylate 
biosynthesis in NTD pathogenesis in this folate-responsive mouse model.  
Surprisingly, supplementation of cultured splotch embryos with methionine 
exacerbated impairments in dU suppression and caused NTDs in heterozygous splotch 
embryos, which do not otherwise develop NTDs.  Rescue of NTDs in homozygous 
splotch embryos by folic acid supplementation and exacerbation by methionine 
supplementation was also observed in another study in vivo (79).  More recently, 
impaired de novo thymidylate biosynthesis was also observed in human embryos with 
NTDs (80).  Collectively, these data provide preliminary evidence that de novo 
thymidylate biosynthesis is crucial for proper neural tube closure.  In addition, 
maintaining a balance of utilization between various folate-dependent anabolic 
pathways in the cytoplasm (e.g. methionine biosynthesis and thymidylate 
biosynthesis) may influence neural tube closure via direct effects on the thymidylate 
biosynthesis pathway.   
 
Homocysteine remethylation/methylation cycle 
  Much of the focus on identifying a metabolic basis for folate-responsive NTDs 
has centered on the role of homocysteine and the methylation cycle, consistent with 
the results from human epidemiological studies that have linked moderately elevated 
maternal homocysteine with NTD risk.  Supplementation with folic acid alleviates 
hyperhomocysteinemia, leading to the hypothesis that impairments in the 
homocysteine remethylation cycle were causal in NTD pathogenesis.  In addition to 
being a biomarker for impaired folate status and reduced methylation potential (the 
AdoMet/AdoHcy ratio), homocysteine at elevated levels is cytotoxic (81,82), and also 
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negatively affects cellular methylation through the accumulation of AdoHcy, which is 
an inhibitor of cellular methylation reactions (83-85).  Altered gene expression 
resulting from chromatin hypomethylation has been proposed as a mechanism 
underlying many folate-related pathologies, including NTDs (86).  Likewise, the direct 
modification of proteins by homocysteine has also been implicated in these 
developmental anomalies (87).  The regulation of homocysteine remethylation and 
AdoMet biosynthesis is complex, and includes feedback mechanisms that  prevent 
both the accumulation of homocysteine and maintenance of both AdoMet and AdoHcy 
concentrations for cellular methylation reactions (84).  For example,  AdoMet is an 
allosteric, feedback inhibitor of MTHFR (88,89), and its accumulation inhibits 
MTHFR activity, thereby preventing the synthesis of 5-methylTHF from the 
methylene-THF cofactor when AdoMet levels are adequate for cellular methylation 
reactions.   
In addition to the folate-dependent remethylation of homocysteine to 
methionine, two other folate-independent pathways exist that function to prevent the 
accumulation of homocysteine in certain tissues and cell types:  homocysteine can be 
remethylated to methionine by the transfer of a one-carbon moiety from betaine, 
catalyzed by the enzyme betaine homocysteinemethyltransferase (BHMT), and 
homocysteine can be eliminated via the transulfuration pathway, in which 
cystathionine β-synthase (CBS) catalyzes the condensation of serine and 
homocysteine to form cystathionine.  Transulfuration simultaneously degrades 
homocysteine while removing a source for methionine biosynthesis in the cell.  It is 
important to note that BHMT and CBS are not expressed in all tissues (84,90,91), 
whereas folate-dependent methionine synthase expression is more ubiquitous (91).  
The activities of the BHMT-mediated methylation pathway and the transsulfuration 
pathway are also regulated via feedback mechanisms associated with the cellular 
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methylation cycle; accumulation of AdoMet inhibits BHMT-mediated methionine 
biosynthesis while stimulating CBS-mediated transulfuration (92).   
Because of the strong association between elevated homocysteine and NTD 
risk, genes involved in homocysteine metabolism and the methylation cycle have been 
at the center of the search for candidate genes involved in NTD pathogenesis.  The 
most prominent of these is MTHFR, for which two human SNPs have been identified 
that are associated with NTD risk, MTFHR C677T and MTHFR A1298C.  The 
MTHFR C677T SNP has been well-characterized and codes for a thermolabile 
enzyme with a 50-60% reduction in enzymatic activity in individuals homozygous for 
the T allele (93-95).  To date, the C677T SNP has been widely considered the most 
attractive genetic candidate underlying folate-responsive NTDs based on three 
findings: 1) it has consistently demonstrated a strong association with NTD occurrence 
in the human epidemiological literature, with both maternal and fetal alleles 
contributing to risk (96-98), 2) it is associated with elevated homocysteine, a predictor 
of NTD risk (99-101), and 3) it interacts with folate status in determining both 
impairments in metabolism and NTD risk (102-107). Furthermore, the strength of the 
association between the MTHFR C677T SNP and NTD risk has reciprocally bolstered 
the hypothesis that metabolic disruptions in homocysteine homeostasis underlie NTD 
pathogenesis.   
 Despite MTHFR having the strongest association in the literature with NTD 
risk, the penetrance of the SNP cannot account for NTD incidence in the population; 
the frequency of the T allele in the general population does not account for the level of 
reduction of NTD risk observed in response to folic acid supplementation (108).  
Furthermore, there is no direct evidence that the association between the MTHFR 
C677T SNP and NTD risk is related to metabolic perturbations of the homocysteine 
remethylation cycle.  Deletion of the MTHFR gene in the mouse germ line is 
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associated with both elevated homocysteine as well as alterations in cellular 
methylation potential and global DNA hypomethylation (109) , yet does not result in 
NTDs in vivo, even in response to maternal folate deficiency (110).  Therefore, there is 
no causal evidence that reduced MTHFR activity induces NTD risk by impairing the 
homocysteine remethylation cycle.  However, in addition to its inhibitory effects on 
homocysteine remethylation, the MTHFR SNP also impairs folate status.  Data from 
several studies have revealed that the T allele is associated with reductions in serum 
and red blood cell folate levels (111-114).  The observed reduction of total folates in 
individuals with reduced MTHFR activity may result from the accumulation of the 
less stable formylated derivatives of folate at the expense of 5-methylTHF, resulting in 
increased folate turnover (115,116).  Therefore, the C677T SNP may influence NTD 
risk by impairing folate status, as opposed to impairing folate metabolism via the 
methylation cycle. This suggestion has been corroborated by the finding that MTHFR 
KO mice also display reduced plasma folate levels, in addition to an alteration in 
percentage of methylated folate derivatives (117) .  Because folate deficiency alone 
does not induce NTDs in mice (118,119), data from studies of the MTHFR KO mouse 
model support the notion that alterations in MTHFR activity in humans may influence 
neurulation indirectly via alterations in folate status and/or the distribution of folate 
cofactors that ultimately impinge upon other folate-dependent anabolic pathways 
beyond the methylation cycle.  
 Other studies support the conclusion that the accumulation of homocysteine is 
not an underlying cause of NTDs.  Examination of SNPs in other genes regulating 
cellular homocysteine accumulation, including MS, CBS, and BHMT, has not 
provided convincing evidence that these genes are associated with NTD risk in 
humans (120-126).  Similarly, mouse models with deletions of genes that regulate 
homocysteine accumulation fail to support the hypothesis that homocysteine 
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accumulation underlies NTD pathogenesis.  Genetic deletion of CBS in mice produces 
highly elevated homocysteine levels but these mice do not exhibit NTDs (127).   
Another mouse model with reduced expression of the gene MTRR, which regulates 
methionine synthase activity, also produces a robust metabolic phenotype, including 
elevated plasma homocysteine, reduced plasma methionine, and tissue-specific 
alterations in methylation potential, but do not exhibit a developmental phenotype 
(128).  Lastly, hyperhomocysteinemia induced in culture or in vivo by nutritional 
manipulation does not affect neural tube closure in mice (129-131).  Together, these 
data do not provide support for a direct role of homocysteine in NTD pathogenesis, 
and instead indicate that elevated homocysteine is merely a biomarker for impairments 
in folate status which disrupt the function of the entire folate-dependent OCM 
network.  
  Notwithstanding the lack of evidence for a role of homocysteine in NTD 
pathogenesis,  vitamin B12 status has been found to be moderately associated with 
NTD risk (132-134).  Many of these studies have been limited by the failure or 
inability to statistically account for maternal folate status, which is often closely linked 
to maternal B12 status.  Recently, the association between vitamin B12 status and 
NTD risk was examined in a folic acid fortified population.  Vitamin B12 levels in the 
lowest quartile were associated with a tripling of NTD risk (133).   Severe vitamin 
B12 deficiency impairs the activity of MS, and leads to both impairment of the 
homocysteine remethylation cycle as well as impaired nucleotide biosynthesis.  The 
impairment in nucleotide biosynthesis is indirect; lack of MS activity can result in the 
accumulation of cellular folate as 5-methylTHF at the expense of other folate 
cofactors, a condition referred to as a methyl trap.  The methyl trap occurs because the 
reduction of methylene-THF to 5-methyl-THF catalyzed by MTHFR is irreversible, 
and MS is the only folate-dependent enzyme to use 5-methylTHF as a cofactor (Figure 
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2.2).  Vitamin B12 deficiency also diminishes AdoMet levels, resulting in the 
activation of MTHFR activity thereby enhancing the methyl trap.  Therefore, vitamin 
B12 deficiency may influence NTD risk by altering the distribution of folate cofactors 
thereby affecting the entire OCM network. Future investigation of the association 
between vitamin B12 deficiency, cellular folate utilization, and NTD risk is required 
to determine the precise metabolic perturbation underlying NTD pathogenesis. 
 
Conclusions 
  Although maternal folic acid supplementation/fortification is effective for the 
prevention of NTDs, the mechanisms underlying folate-responsive NTDs remain 
unknown.  Continued investigation of gene-gene interactions and gene-nutrient 
interactions in humans will provide greater insight into the influence of genetic 
perturbations on both folate status and folate utilization in NTD pathogenesis. 
This examination of potential genetic risk factors is currently limited by gaps in 
knowledge of the enzymes and associated genes involved in OCM, especially in 
mitochondria, and the metabolic sequelae associated with specific gene-nutrient 
interactions. Furthermore, there is still much knowledge to be gained concerning the 
regulation of cellular folate status, metabolism/utilization and the impact of alterations 
in the flux of folates through the metabolic network on all metabolic, genomic, and 
cellular outcomes.   As an example, it is still unclear if the C677T polymorphism in 
MTHFR increases human NTD risk by influencing homocysteine levels, distribution 
of folate cofactors in the cell, and/or depressing cellular folate status.  In addition, the 
generation and detailed metabolic characterization of genetically altered mice that 
model impairments in specific folate-dependent anabolic pathways and their 
regulation is necessary to provide greater insight into the effects of altered folate 
metabolism on genomic, cellular and developmental outcomes and ultimately result in 
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the establishment of the underlying mechanisms of developmental anomalies. 
Determining the precise metabolic impairments that result in NTDs will enable the 
design of improved nutritional interventions that target both susceptible subgroups of 
the population and the metabolic pathway that causes neural tube closure defects.    
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CHAPTER 3 
SHMT1 AND THE METABOLIC ORIGIN OF FOLATE-RESPONSIVE 
NEURAL TUBE DEFECTS 
 
 
Abstract 
The specific metabolic disruption that causes human folate-responsive neural tube 
closure defects (NTDs) is unknown.  In this study, disruption of the gene encoding 
cytoplasmic serine hydroxymethyltransferase (Shmt1) in mice is shown to induce 
NTDs.  SHMT1 regulates folate metabolism by providing folate-activated one-carbons 
for de novo thymidylate biosynthesis in the nucleus.  Shmt1 is expressed in the 
embryonic neuroepithelium and neural crest during neural tube closure in mice and 
Shmt1
-/- embryos exhibited exencephaly.  Maternal and fetal genotype and maternal 
diet contributed to NTD incidence, mimicking gene-nutrient interactions contributing 
to folate-responsive human NTDs.  Shmt1 disruption on the Pax3
sp/+ background 
exacerbated NTD frequency and severity.  Pax3 deficiency impaired de novo 
thymidylate and purine biosynthesis, and altered levels of Shmt1 and thymidylate 
synthase protein.  Shmt1 is the only gene encoding a folate-metabolizing enzyme that 
affects neural tube closure in mice.  These results provide evidence that repression of 
Shmt1 expression causes NTDs by impairing thymidylate biosynthesis.   
 
Introduction 
During embryogenesis, the neuroepithelium bends, fuses and cavitates to form 
the embryonic neural tube through the process of neurulation, which ultimately gives 
rise to the central nervous system.  Failure of neurulation results in a spectrum of 
common developmental anomalies collectively referred to as neural tube closure 
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defects (NTDs).  The most common and severe NTDs include spina bifida, a condition 
caused by defective caudal neurulation resulting in herniation and exposure of spinal 
tissue, and anencephaly, a failure of rostral neurulation with consequent deterioration 
of brain tissue due to in utero exposure.  Worldwide prevalence of human NTDs 
ranges from <1 to 9 per 1000 births (1).    
NTDs are complex traits that result from deleterious gene-nutrient interactions.  
One of the strongest environmental determinants of NTD risk is maternal folate status,   
but the majority of NTD-affected pregnancies are not associated with overt maternal 
folate deficiency (2-4).  Rather, nutritional folate deficiency interacts with genetic 
variants that compromise folate metabolism to confer increased NTD risk (5-8).  
Maternal folic acid supplementation reduces both NTD occurrence and recurrence 
(9,10).  Currently, over 20 countries have taken measures to fortify their food supply 
with folic acid to reduce the incidence of NTDs, which has resulted in a 20-80% 
reduction in NTD prevalence (11-13).   
The specific metabolic pathway(s) within folate-mediated one-carbon 
metabolism that affect neural tube closure are unknown.   Folates function as a family 
of enzyme cofactors that carry and activate one-carbons to support a network of 
anabolic reactions collectively known as one carbon metabolism (OCM, Figure 3.1).  
Folate-mediated OCM is essential for the de novo biosynthesis of purines and 
thymidylate (dTMP), and for the remethylation of homocysteine to form methionine.  
Methionine can be adenosylated to form S-adenosylmethionine (AdoMet), the 
universal methyl donor for numerous cellular methylation reactions, including 
chromatin methylation (Figure 3.1).  Impairments in OCM can be caused by low 
folate status resulting either from dietary folate deficiency or genetic variations that 
disrupt cellular folate accumulation or uptake.  OCM can also be impaired by genetic 
variations or secondary nutrient deficiencies that affect the activity and/or stability of  
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Figure 3.1.  Compartmentation of folate-mediated one-carbon metabolism in 
the cytoplasm, and nucleus.  One-carbon metabolism in the cytoplasm is 
required for the de novo synthesis of purines and thymidylate, and for the 
remethylation of homocysteine to methionine.  One-carbon metabolism in the 
nucleus synthesizes dTMP from dUMP and serine.  MTHFD1, 
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folate-dependent metabolic enzymes thereby disrupting cellular folate utilization.  
Because the anabolic pathways within the one-carbon network are tightly coupled and 
compete for a limiting pool of folate cofactors (14,15), impairments in OCM often 
disrupt simultaneously de novo nucleotide biosynthesis and cellular methylation 
potential, resulting in reduced proliferative capacity, increased DNA uracil content, 
elevated plasma homocysteine, reduced cellular methylation capacity (as indicated by 
the ratio of AdoMet/AdoHcy) and chromatin hypomethylation (16).   
Most studies to date have focused on the role of homocysteine remethylation 
and cellular methylation in the etiology of NTD pathogenesis.  Association studies 
have identified elevated homocysteine (17,18), vitamin B12 deficiency (19-21) and 
gene variants that encode enzymes in the homocysteine remethylation pathway (22-
24) as risk factors for an NTD-affected pregnancy.   Most notably, the 677CÆT 
polymorphism in the gene encoding the enzyme methylenetetrahydrofolate reductase 
(MTHFR) is associated with elevated homocysteine (25,26), impaired folate 
accumulation (27,28), and NTD risk, with both maternal and fetal genotype 
contributing to risk (22,29).   However, disruption of genes that encode enzymes 
which are required for homocysteine remethylation, including MTHFR and 
methionine synthase (Figure 3.1), have not yielded NTDs in mice (30-32).  
Over 150 genes have been identified that influence neural tube closure in mice, 
including genes associated with apoptosis, cell-cell communication, gene 
transcription, and major developmental signaling pathways (33). Only a subset of 
these NTD mouse models are responsive to maternal folate  (34-37).  Of these, only 
the splotch mutant (Pax3
sp), which carries a point mutation in the gene encoding the 
nuclear transcription factor Pax3, has demonstrated impairments in OCM.  
Homozygous splotch embryos exhibit fully penetrant spina bifida and impaired de 
novo thymidylate biosynthesis, although the mechanisms are unknown.  NTDs in the 
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splotch mutant can be rescued with supplemental dietary folic acid or thymidine, but 
are exacerbated by methionine supplementation (34,35).  Amelioration of impaired 
thymidylate biosynthesis and NTD occurence with either folic acid or thymidine 
supplementation suggests that folic acid may prevent NTDs in the splotch mutant by 
rescuing de novo thymidylate synthesis.  However, Pax3 has not been linked to human 
NTD pathogenesis (38-40). 
The thymidylate biosynthesis pathway is comprised of three enzymes which 
function in the cytoplasm and the nucleus: serine hydroxymethyltransferase, 
thymidylate synthase and dihydrofolate reductase (41) (Figure 3.1).  The enzyme 
serine hydroxymethyltransferase (SHMT1) provides folate-activated one-carbon 
moieties for thymidylate synthesis by catalyzing the transfer of the hydroxymethyl 
group of serine to tetrahydrofolate (THF) to form glycine and the cofactor 5,10- 
methyleneTHF (42).  During S phase, these cytoplasmic enzymes undergo SUMO-
dependent translocation into the nucleus to provide dTTP for DNA replication (41,43) 
(Figure 3.1) .  In the cytoplasm, methyleneTHF required for thymidylate biosynthesis 
can be derived either from SHMT1- or MTHFD1-catalyzed reactions.  Shmt1 is not 
essential in mice, but its expression enhances the efficiency of de novo thymidylate 
biosynthesis (44,45).  To determine directly if impaired de novo thymidylate 
biosynthesis increases risk for NTDs, the contribution of Shmt1 to NTDs was 
investigated in mice. 
 
Results 
Shmt1 is expressed in the developing neural tube and paraxial structures  
Shmt1 transcription was examined by monitoring β-galactosidase activity 
generated from the endogenous Shmt1 promoter in Shmt1
flox/flox embryos across the 
period from gastrulation through neuropore closure and early organogenesis (day 
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E12).  Early expression is most robust in splanchnopleure, especially in the yolk sac 
and allantois (Figure 3.2A,B), within the neural plate and cardiac loop myocardium. 
Craniofacial neural crest mesenchymal populations are also labeled (Figure 3.2B).   
Within the neuroepithelium, expression is initially diffuse and uniform along the 
length of the body and also along the medio-lateral (future ventro-dorsal, basal-alar) 
axis of the forming brain and spinal cord.  Non-neural surface ectoderm is not labeled.  
Widespread expression in the neuroepithelium decreases rapidly in a rostro-
caudal sequence following neural tube closure, with expression remaining primarily in 
the more caudal, continually forming parts of the neural tube, including but not limited 
to the region of the caudal neuropore.  The exceptions to this loss of Shmt1 expression 
occur at the midbrain-hindbrain boundary and within rhombomeres 3 and 5 (Figure 
3.2B, D), where elevated levels persist to E10.25 (rhombomere 3) and E11 
(rhombomere 5).   
Beginning at E10.5, neural tube Shmt1 expression is reinitiated selectively 
along the central nervous system and becomes robust by E12-13.  Within the brain,  
this is strongest in the alar and basal regions of the telencephalon (Figure 3.3), but 
seen also in the future thalamic regions of the diencephalon, cortical regions of the 
mesencephalon, and subventricular columns along the ventral hindbrain.  The rhombic 
lip also shows elevated expression.   
Also beginning at day E10.5, expression of Shmt1 becomes elevated along the 
full length of the spinal cord.  This is most pronounced in a longitudinal band located 
dorsal to the sulcus limitans and excluding the dorsal neural plate (Figure 3.2G, H).  
Expression is greatest at the region of the cervical flexure (Figure 3.3A).  This wave of 
expression is transient, and is largely gone by E13. 
Olfactory, and otic epithelia, both derived from surface ectoderm, lack Shmt1 
expression during their initial stages of invagination and differentiation, though the 
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Figure 3.2. Shmt1 expression in embryos from E8-E13.  
(A) lateral view of an E8 (5 somite) embryo, showing diffuse labeling throughout 
the forming neural tube and also in the yolk sac (YS), allantoic stalk (Al), and heart 
(H).   
 (B) By E9.5, expression in the brain is restricted to the midbrain-hindbrain 
boundary (MHB) region, and rhombomeres 3 and 5 (Rh3, Rh5), but is still present 
in the spinal cord.   Expression is present in craniofacial neural crest populations, 
best seen in the mandibular (Md) and maxillary (Mx) prominences.   
(C) is a coronal section through the caudal flexure of an E10, 20-somite embryo, 
showing diffuse labeling in the spinal cord (SC), somites, and limb mesoderm.   
(D) is a coronal section through the hindbrain of a E9.25 embryo, showing Shmt1 
expression restricted to rhombomeres 3 and 5.   
(E-G)  An E10.5 embryo, with (F) and (G) sections at the levels indicated.  Diffuse 
labeling in the telencephalic lobes (Tel), midbrain (Mes) and rostral hindbrain 
(metencephalon, Met) are evident, as is Shmt1 expression in the lateral and medial 
nasal processes (LNP, MNP) derived from craniofacial neural crest.  
(H) The restriction of spinal cord expression to a longitudinal band located dorsal to 
the sulcus limitans is shown in a caudal coronal section from an E11.5 embryo. 
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S Figure 3.3.  Whole embryo views of  hmt1 expression in (A) E12 and (B) E13 
embryos. 
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chondrogenic mesenchymal tissues surrounding these are well labeled.  In contrast, the 
brain-derived optic vesicle epithelium is initially diffusely labeled.  As the optic cup 
forms, expression becomes restricted to the anterior (limbic) and optic stalk regions. 
Paraxial mesoderm, which underlies most of the neural plate and later 
surrounds the brain (excluding prosencephalon) and spinal cord, lacks prominent 
Shmt1 expression until after neural tube closure.  With the separation of distinct 
somitic compartments, both the pre-chondrogenic sclerotome and pre-myogenic 
myotome regions express Shmt1.  Early limb bud mesoderm is uniformly positive, but 
this quickly falls in the core, skeletogenic regions of developing limbs (Figure 3.2C). 
Expression of Shmt1 is evident in craniofacial neural crest populations as they 
emerge from neural fold epithelium, and remains high during the formation of 
pharyngeal (branchial) arches and frontonasal prominences through days E9-10.5 
(Figure 3.2B).  Expression levels then fall off except in skeletogenic and odontogenic 
mesenchymal populations.  
 
Shmt1 deficiency sensitizes embryos to exencephaly 
  The effect of Shmt1 disruption on neural tube closure was determined in litters 
derived from crosses of Shmt1
+/- males to Shmt1
+/+, Shmt1
+/-, or Shmt1
-/- female mice 
maintained on either congenic 129SvEv or C57Bl/6 backgrounds. Dams were fed 
either a modified AIN93G diet lacking folate and choline (FCD) or control AIN93G 
diet from weaning through gestation.  Litters were harvested at E11.5, when neural 
tube closure was completed, and individual embryos were examined for the presence 
of NTDs (Tables 3.1-3.4).  Incidence of NTDs on the 129SvEv background is 
described below; however, NTDs were also observed albeit at a lower frequency on 
the C57Bl/6 background (Tables 3.3, 3.4). A low frequency of exencephaly was  
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Table 3.1  Frequency of NTDs observed in E11.5 embryos isolated from crosses of 
Shmt1-deficient mice on a 129/SvEv background as a function of maternal Shmt1 
genotype and diet.  Main effects of maternal Shmt1 genotype and maternal diet were 
determined by analysis of variance.  Both maternal Shmt1 genotype (p < 0.05) and 
maternal diet (p < 0.01) significantly influenced NTD occurrence. 
 
Diet  Maternal 
Genotype  No. litters  No. embryos  No. NTDs (%) 
Shmt1
+/+ 8 44  0 
Shmt1
+/- 27 149  1  (<1%)  Control 
Shmt1
-/- 8 39  0 
Shmt1
+/+ 19 101  1  (1%) 
Shmt1
+/- 36 180  7  (3.9%)  FCD 
Shmt1
-/- 16 85 11  (13%) 
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  Embryonic Shmt1 Genotype 
Maternal 
Shmt1 
genotype 
  Shmt1
+/+ Shmt1
+/- Shmt1
-/-
No. NTDs 
(%)  0 1  (1.8%) - 
Shmt1
+/+
No. 
Embryos  46 55  - 
No. NTDs 
(%)  0  3 (3.4%)  4 (8.2%) 
Shmt1
+/-
No. 
Embryos  43 88 49 
No. NTDs 
(%)  -  2 (4.8%)  9 (21%) 
Shmt1
-/-
No. 
Embryos  - 42  43 
Table 3.2.  Frequency of NTDs observed in E11.5 embryos isolated from crosses 
of Shmt1-deficient dams on a 129/SvEv background maintained on the FCD diet, 
as a function of maternal and embryonic Shmt1 genotype. 
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Diet  Maternal 
Genotype  No. litters  No. embryos  No. NTDs (%) 
Shmt1
+/+ 4 27  0 
Shmt1
+/- 28 209  0  Control 
Shmt1
-/- 10 78  0 
Shmt1
+/+ 32 239  0 
Shmt1
+/- 38 195  2  (1%)  FCD 
Shmt1
-/- 25 184  6  (3.4%) 
Table 3.3.  Frequency of NTDs observed in E11.5 embryos isolated from crosses of 
Shmt1-deficient dams on a C57Bl/6 background as a function of maternal Shmt1 
genotype and diet.   
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  Embryonic Shmt1 Genotype 
Maternal 
Shmt1 
genotype 
  Shmt1
+/+ Shmt1
+/- Shmt1
-/-
No. NTDs 
(%)  0 0 - 
Shmt1
+/+
No. 
Embryos  122 117  - 
No. NTDs 
(%)  0  1 (1%)  1 (2%) 
Shmt1
+/-
No. 
Embryos  45 103 47 
No. NTDs 
(%)  -  2 (1.7%)  4 (5.7%) 
Shmt1
-/-
No. 
Embryos  - 114  70 
Table 3.4.  Frequency of NTDs observed in E11.5 embryos isolated from crosses of 
Shmt1-deficient mice on a C57Bl/6 background maintain on the FCD diet, as a 
function of maternal and embryonic Shmt1 genotype. 
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observed in embryos harvested from crosses of Shmt1
+/- mice fed the FCD diet (Figure 
3.4A-D, Tables 3.1, 3.2).  Exencephaly was primarily observed in litters from dams 
maintained on the FCD diet, as supported by a significant main effect of maternal diet 
(p < 0.01), although a single Shmt1
-/- embryo with exencephaly was uncovered from a 
dam maintained on the control diet.   In all cases, exencephalic embryos were either 
Shmt1
+/- or Shmt1
-/-, whereas no NTDs were observed in Shmt1
+/+ littermates from 
any litters examined.  The frequency of exencephaly was higher for Shmt1
-/- 
littermates (8.1%, 4 of 49 embryos) as compared to Shmt1
+/- embryos (3.4%, 3 of 88 
embryos) in litters isolated from Shmt1
+/- dams fed the FCD diet, indicating that 
complete loss of Shmt1 in the developing embryo was associated with a greater risk of 
exencephaly as compared to partial loss (p =0.09, Table 3.2).  Loss of Shmt1 
expression in the dam also resulted in an increased frequency of exencephaly, as 
evidenced by a significant main effect of maternal genotype (p < 0.05).  Only 1 
Shmt1
+/- embryo with exencephaly (1%; 1 of 101 embryos) was uncovered from 
crosses involving Shmt1
+/+ dams fed the FCD diet.  Approximately 10% (7/70) of 
embryos recovered from crosses of Shmt1
-/- dams fed the FCD diet exhibited 
exencephaly as compared to 4% (7/180) observed in crosses of Shmt1
+/- dams fed the 
FCD diet.  The increased frequency of exencephaly observed in litters from Shmt1
-/- 
dams was due to a greater proportion of Shmt1
-/- embryos developing exencephaly 
(18.4%, 9 of 43).   
The number of observed Shmt1
+/+, Shmt1
+/-, and Shmt1
-/- embryos at E11.5 did 
not deviate from expected values for any of the crosses examined (data not shown).  
Maternal diet (F = 21.5, p < 0.0001) and embryonic Shmt1 deficiency (F= 4.45, p = 
0.01) significantly affected embryonic length as measured at E11.5 (Figure 3.5A,B).  
Embryos isolated from dams fed the FCD diet had significantly shorter crown-rump 
lengths, as did Shmt1
-/- embryos isolated from dams fed either diet.  Analyses of log- 
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Figure 3.4. Neural tube defects in Shmt1-deficient embryos.
(A and B). At E11.5, Shmt1
+/- embryos from dams fed the FCD diet exhibit failure of 
rostral neural tube closure at the midbrain/hindbrain boundary (B). All wild-type 
littermates (A) are unaffected.  Arrows indicate extent of lesions.   
(C and D). At E14.5, affected Shmt1
+/- embryos (D) exhibit prominent exencephaly. 
(E and F). H&E stained transverse sections of the hindbrain region in E10.5 embryos 
reveal complete failure of closure in the hindbrain region in E11.5 Shmt1
+/- embryos 
(E). 
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Figure 3.5.  Crown-rump length of embryos derived from crosses of Shmt1-
deficient mice.   
(A) Crown-rump length as a function of embryonic Shmt1 genotype. *, p = 0.003; **, 
p = 0.03. 
(B)Crown-rump length as a function of maternal diet.  *, p = < 0.0001.  
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transformed resorption rates indicated a significant effect of maternal diet (F = 7.52, p 
< 0.01), with significantly higher resorption rates associated with the FCD diet as 
compared to the control diet (24% vs 8% resorptions, respectively).  In addition, there 
was also a trend toward an effect of maternal genotype (F = 3.15, p = 0.054) on 
resorption rates.  Shmt1
+/- females had significantly higher resorption rates than 
Shmt1
+/+ females (20% vs 12% , p = 0.03), but the comparison between Shmt1
-/- 
females and Shmt1
+/+ females (23% vs 12%) did not reach significance.  Neither 
maternal Shmt1 genotype nor maternal diet significantly affected the weight of female 
mice at onset of gestation (p > 0.05, data not shown).   
Maternal Shmt1 deficiency does not influence markers of folate status 
Shmt1 genotype did not influence red blood cell (RBC) folate levels in 
pregnant dams (p > 0.05, data not shown), whereas the FCD diet resulted in a 
significant reduction in RBC folate levels (F = 2637.18, p < 0.0001, Figure 3.6). RBC 
folate levels were reduced approximately 80% in female mice maintained on the FCD 
diet as compared to the control diet.  Similarly, maternal Shmt1 genotype did not 
influence plasma homocysteine levels or the levels of several metabolites associated 
with homocysteine remethylation and metabolism (Table 3.5).  The FCD diet resulted 
in plasma homocysteine levels that were elevated more than three-fold relative to 
levels on the control diet (49 vs 15 µM).  The FCD diet also significantly affected 
levels of all metabolites associated with homocysteine remethylation (Table 3.5). 
Shmt1 and Pax3 interact in neural tube closure  
 Shmt1 expression was examined in splotch embryos, a NTD model with 
impaired de novo thymidylate biosynthesis.  There was a gene-dosage dependent 
increase in SHMT1 protein levels in E10.5 embryo extracts from Pax3
sp/+ crosses 
(Figure 3.7A).  To determine whether Shmt1 was misexpressed in splotch embryos, 
Pax3
sp/+, Shmt1
flox/flox mice were intercrossed and embryos were stained for the  
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Table 3.5.  Plasma metabolites in Shmt1-deficient dams. Differences between genotype and diet and genotype x diet 
interactions were analyzed by two-way analysis of variance procedure in SAS.  Data represent mean ± SEM. a, Shmt1+/- on 
the FCD diet is significantly different from all other groups. 
 
Diet p  value 
Control FCD  Metabolite 
Shmt1
+/+ Shmt1
+/- Shmt1
-
/- Shmt1
+/+ Shmt1
+/- Shmt1
-/-
Diet 
effect 
Genotype 
effect 
Diet X 
genotype 
effect 
Homocysteine 
(μM) 
19.8 ± 
5.3 
15.2 ± 
4.1 
10.5 ± 
1.1 
44.1 ± 
5.5 
49.8 ±  
7.8 
54.6 ± 
7.9  < 0.0001  NS  NS 
Cysteine (μM) 
200 ± 
6  208 ± 4  211 ± 7  180 ± 7  184 ± 5  184 ± 4  < 0.0001  NS  NS 
Cystathionine 
(μM) 
1282 ± 
225 
1100 ± 
176 
1034 ± 
66 
2090 ± 
223 
2608 ± 
283 
2826 ± 
355  < 0.0001  NS  NS 
α - 
Aminobutyric 
Acid (μM) 
11.3 ± 
1.0 
9.5 ± 
1.0 
11.3 ± 
1.4  8.3 ± 0.5  8.7 ± 0.7  7.9 ± 
0.4  0.003 NS  NS 
Methionine 
(μM) 
45.8 ± 
2.7 
47.3 ± 
3.3 
50.5 ± 
1.7 
51.4 ± 
5.2  60 ± 6  58 ± 3.7  0.0148  NS  NS 
Glycine (μM) 
63.5 ± 
7.0 
53.1 ± 
2.7 
53.1 ± 
4.1 
61.1 ± 
6.7 
77.6 ± 
10.5 
74.1 ± 
18.3  0.067 NS  NS 
Serine (μM) 
108 ± 
8  109.± 7  117 ± 7  132 ± 9  153 ± 13  158 ± 
12  < 0.0001  NS  NS 
Dimethylglycine 
(μM) 
5.8 ± 
0.5 
6.4 ± 
0.5 
6.7 ± 
0.6  3.9 ± 0.3  3.0 ± 0.4  3.3 ± 
0.3  < 0.0001  NS  NS 
Methylglycine 
(μM) 
0.42 ± 
0.03 
0.33 ± 
0.01 
0.40 ± 
0.04 
0.41 ± 
0.03 
0.61 ± 
0.08 
0.45 ± 
0.06  0.006 NS  0.009
a 
 
 
 
 
 
 
 
 
 
 
S Figure 3.7.  Interaction of  hmt1 and Pax3.
(A and B) Protein extracts from E10.5 embryos isolated from splotch crosses were 
analyzed by western blot with a polyclonal anti-SHMT1 antibody (A) and a 
monoclonal anti-TYMS antibody (B).  GAPDH was probed with a polyclonal antibody 
to verify equal loading in both experiments.    Both SHMT1 and TYMS protein levels 
are responsive to the splotch mutation. 
(C and D) Protein extracts from E10.5 embryos isolated from crosses of Shmt1
+/- dams 
on the FCD diet were analyzed by western blot using a polyclonal antibody to Pax3 
(C) and TYMS (D). GAPDH and actin were probed as to verify equal loading. Both 
Pax3 and TYMS protein levels are responsive to Shmt1 deficiency. 
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Figure 3.8.  Shmt1 is not misexpressed in Pax3
sp/sp embryos.
Blue stain indicates the presence of β-galactosidase staining in Pax3
+/+, Shmt1
flox/flox 
(A) and Pax3
sp/sp, Shmt1
flox/flox embryos (B).  
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presence of β-galactosidase.  Comparison of Pax3
+/+ and Pax3
sp/sp littermates did not 
indicate alterations in of Shmt1expression patterns, indicating that the elevated 
SHMT1 protein in splotch embryos was not associated with altered domains of 
expression (Figure 3.8).  Thymidylate synthase (TYMS) was also examined in splotch 
embryos by western blot in the same embryo extracts.  TYMS protein levels were 
reduced in a gene-dosage dependent manner in response to the splotch mutation 
(Figure 3.7B).  Examination of Shmt1 and TYMS message levels by real-time PCR did 
not reveal any genotype differences (data not shown), indicating that the splotch 
mutation affects SHMT1 and TYMS protein levels post-transcriptionally. 
  Alterations in Pax3 and TYMS protein levels were examined in Shmt1-
deficient embryos.  A gene-dosage dependent increase in Pax3 protein levels was 
observed in response to Shmt1 deficiency (Figure 3.7C).  Disruption of Shmt1also 
resulted in reduced TYMS protein levels in Shmt1
-/- embryos (Figure 3.7D).   
Shmt1 deficiency exacerbates the NTD phenotype in splotch embryos 
  The effect of Shmt1 deficiency on NTDs in splotch embryos was examined in 
compound Pax3, Shmt1 mutant embryos generated from crosses of Pax3
sp/+, Shmt1
+/- 
and Pax3
sp/+, Shmt1
-/- female mice maintained on a standard rodent diet.  Previous 
studies have shown that Pax3
sp/sp embryos display a spina bifida phenotype that is 
100% penetrant with occasional exencephaly, whereas Pax3
sp/+embryos do not display 
NTDs but do exhibit a white belly splotch indicative of neural crest migration defects 
(46).  Post-neurulation stage embryos (E11.5) were harvested from compound mutant 
crosses and examined for presence and extent of NTDs (cranial, spinal, or combined 
cranial and spinal, Table 3.6).    Maternal Shmt1 deficiency and embryonic sex 
significantly influenced the incidence of combined cranial and spinal lesions in 
Pax3
sp/spembryos (Figure 3.9A). Embryos isolated from crosses of Pax3
sp/+, Shmt1
-/- 
dams fed the standard rodent diet had a significantly higher incidence of combined  
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Embryonic genotype (Pax3, Shmt1) 
 
+/+  sp/+  sp/sp +/+  sp/+ sp/sp +/+  sp/+ sp/sp  Cross 
+/+ +/+  +/+  +/-  +/-  +/-  -/-  -/-  -/- 
Pax3
sp/+x Pax3
sp/+ 49 84  41  (40)  --  --  --  --  --  -- 
Pax3
sp/+Shmt1
+/- x 
Pax3
sp/+,Shmt1 
+/- 7  33  9 (9)  32(1)  60(4)  23 (22)  12  20  12 (12) 
Pax3
sp/+,Shmt1
-/- x 
Pax3
sp/+,Shmt1 
+/- --  --  --  16(1)  26 (1)  11 (11)  21  28 (2)  17 (17) 
 
Table 3.6.  Frequency of NTDs and genotype distribution in embryos derived from crosses of C57Bl/6J-Pax3
sp/+ dams and
Shmt1- and Pax3- deficient dams. The number of NTDs is indicated in parentheses.  
 
 
 
 
 
 
 
 
Figure 3.9.  Shmt1 deficiency exacerbates NTDs in splotch mutants 
(A) Incidence of spinal and combined cranial + spinal lesions in Pax3
sp/sp embryos 
isolated from compound mutant crosses (Pax3, Shmt1) and C57Bl/6J-Pax3
sp 
crosses maintained on a standard rodent diet.   
(B and C) Spina bifida in Shmt1-deficient Pax3
+/+ (B) and Pax3
sp/+ (C) embryos 
derived from compound mutant crosses maintained on a standard rodent diet. 
(D and E) Exencephaly in Shmt1-deficient Pax3
+/+ (D) and Pax3
sp/+ (E) embryos 
derived from compound mutant crosses maintained on a standard rodent diet. 
(F and G).  Craniorachiscisis in Shmt1-deficient Pax
sp/+ (F) and Pax3
sp/sp (G) 
embryos derived from compound mutant crosses maintained on the FCD diet. 
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 Figure 3.9, continued. 
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lesions as compared to embryos isolated from crosses of Pax3
sp/+, Shmt1
+/- dams fed 
the standard rodent diet (70.5% vs 38%, p < 0.05).  In addition, female embryos were 
significantly more likely to exhibit the combined phenotype (48% vs 21%, p < 0.01), 
as previously described (47,48).  There was not sufficient statistical power to assess 
the contribution of embryonic Shmt1 genotype to the incidence of the combined 
phenotype, due to a limited number of Shmt1
+/+,Pax3
sp/sp embryos for comparison (n = 
9).   However, when combined incidence of cranial and spinal lesions in compound 
mutant embryos was compared to incidence in embryos isolated from crosses of 
C57Bl/6J-Pax3
sp/+ mice,  Pax3
sp/sp, Shmt1
+/- and Pax3
sp/sp, Shmt1
-/- embryos had 
significantly higher incidence of combined spina bifida and exencephaly (46% and 
66%, respectively) as compared to embryos isolated from crosses involving the 
splotch mutation alone (22%; p = 0.04 and p = 0.001, respectively), whereas incidence 
of combined lesions in Pax3
sp/sp, Shmt1
+/+ embryos isolated from compound mutant 
crosses (22%) did not differ significantly from the effects of the splotch mutation 
alone (p > 0.95).   
  In addition to increasing the severity of NTDs observed in Pax3
sp/sp embryos, 
Shmt1 deficiency also resulted in instances of Pax3
sp/+ and Pax3
+/+ littermates with 
spina bifida or exencephaly under folate-replete conditions (Table 3.6, Figure 3.9B-E).  
Pax3
sp/+ and Pax3
+/+ embryos with NTDs were either Shmt1
+/- or Shmt1
-/- in all cases.  
Approximately 3-5% of Pax3
sp/+ and Pax3
+/+ embryos from crosses of Pax3
sp/+, 
Shmt1
+/- and Pax3
sp/+, Shmt1
-/- dams displayed NTDs.  In most cases, the lesion 
observed was exencephaly, but isolated spina bifida was also observed in a few cases 
(Figure 3.9B,C); the severity of these lesions was comparable to that observed in 
Pax3
sp/sp embryos.  Whereas lesions induced by Shmt1 deficiency alone were confined 
to the cranial region, embryonic Shmt1 deficiency resulted in spina bifida in response 
to either embryonic or maternal Pax3 deficiency.  Furthermore, embryonic or maternal 
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Pax3 deficiency was sufficient to induce spina bifida or exencephaly in Shmt1-
deficient embryos in the absence of dietary folate deficiency.  Although a low 
frequency of spontaneous NTDs in Pax3
sp/+ embryos has been previously reported 
(49,50), NTDs were not observed in any Pax3
sp/+ or Pax3
+/+ embryos that were 
Shmt1
+/+.  In addition, there have not been previous reports of spontaneous NTDs in 
Pax3
+/+ littermates isolated from splotch matings.    
  The effect of dietary folate deficiency on NTD extent and frequency in 
compound Pax3, Shmt1 mutants was examined (Table 3.7).  Compound mutant dams 
were placed on the FCD diet from weaning through gestation, and embryos were 
harvested as previously described.  Impaired folate status both exacerbated and 
increased the frequency of lesions observed in response to combined Shmt1 and Pax3 
deficiency.  Notably, there were several instances of craniorachiscisis observed, in  
which the entire length of the neural tube was open.  Craniorachischisis was observed 
in Shmt1-deficient Pax3
sp/+ and Pax3
sp/sp embryos (Figure 3.9F,G) .  To our 
knowledge, craniorachischisis has not been observed previously in response to the 
splotch mutation alone.  Furthermore, the frequency of NTDs observed in Pax3
sp/+ 
littermates rose from 3-5% to 11-14% in response to dietary folate deficiency in 
compound Pax3, Shmt1 mutant crosses (Table 3.7).  The majority of NTDs in Pax
+/+ 
and Pax3
sp/+ littermates were confined to the cranial region.  
Metabolic disruption of folate-mediated OCM in splotch MEFs 
 The  metabolic  phenotype associated with Pax3 deficiency was determined in 
MEF cell lines generated from splotch matings.  Impairments in de novo thymidylate 
biosynthesis were observed in a gene-dosage dependent manner in response to the 
splotch mutation, consistent with a previous report (35) (Figure 3.10A).  Relative 
incorporation of 
14C-uridine as compared to 
3H-thymidine, which reflects the 
efficiency of de novo thymidylate biosynthesis, was significantly reduced in Pax3
sp/sp  
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Table 3.7.  Frequency and types of NTDs in embryos isolated from crosses of Shmt1- and Pax3- deficient dams maintained 
on the FCD diet as a function of embryonic Pax3 genotype.  NTDs in Pax3
+/+ and Pax3
sp/+ embryos were only observed in 
Shmt1-deficient embryos.   
 
Cross  Embryonic 
Pax3 genotype 
No. 
Embryos
No. NTDs 
(%)  Spinal Cranial
 
 
Spinal 
and 
Cranial
Craniorachiscisis
Pax3
+/+ 10 1  (10%) 0  1  0  0 
Pax3
sp/+ 28 4  (14%) 0  3  0  1 
Pax3
sp/+,Shmt1
+/- x 
Pax3
sp/+,Shmt1 
+/-
  
   Pax3
sp/sp 12 12  (100%) 4  1  6  1 
Pax3
+/+ 5 0  0  0  0  0 
Pax3
sp/+ 18 2  (11%) 1  0  0  1  Pax3
sp/+,Shmt1
-/- x 
Pax3
sp/+,Shmt1 
+/-  
   Pax3
sp/sp 7 7  (100%)  1  2  4  0 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.  Metabolic disruption of folate-mediated OCM in splotch MEFs.
(A) Pax3
+/+, Pax3
sp/+, and Pax3
sp/sp MEF cells were cultured to confluency in α- 
minimal essential medium supplemented with 
14C-dUMP and 
3H-thymidine.    
Efficiency of de novo thymidylate biosynthesis was determined by the relative 
enrichment of 
14C-dUMP (10 μM))/ 
3H-thymidine (500 nm) in nuclear DNA.  All 
values represent the average of triplicate measures of three different cell lines per 
genotype.  Results shown are mean ± SD. Genotype differences were determined 
using a one-tailed t-test.   
(B) Pax3
+/+, Pax3
sp/+, and Pax3
sp/sp MEF cells were cultured to confluency in α- 
minimal essential medium supplemented with 
14C-formate and 
3H-hypoxanthine.  
Efficiency of de novo purine biosynthesis was determined by the relative 
enrichment of 
14C-formate (20 μM) / 
3H-hypoxanthine (2 nm) in nuclear DNA.  
All values are the average of triplicate measures of three different cell lines per 
genotype. Results shown are mean ± SD. Genotype differences were determined 
using a one-tailed t-test.   
(C) Relative ratio of AdoMet to AdoHcy in Pax3
+/+, Pax3
sp/+, and Pax3
sp/sp MEF 
lines.  N= 2-3 lines per genotype. Results shown are mean ± SD. Genotype 
differences were determined using a one-tailed t-test.   
* indicates p < 0.05.  ** indicates p < 0.01. 
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Figure 3.10, continued 
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MEF lines, as compared to Pax3
+/+ lines (p = 0.05).  Rates of de novo thymidylate 
biosynthesis in the Pax3
sp/+ MEF cell lines was intermediate between the Pax3
+/+ and 
Pax3
sp/sp MEF cell lines, but the comparison to the Pax3
+/+ lines did not reach 
statistical significance.  Surprisingly, Pax3-deficient MEF lines also exhibited 
statistically significant impairment in de novo purine biosynthesis, as evidenced by a 
decrease in the relative ratio of incorporation of 
14C-formate to 
3H-hypoxanthine 
(Figure 3.10B).  In this case, both Pax3
sp/+ and Pax3
sp/sp lines exhibited reduced rates 
of de novo purine biosynthesis compared to Pax3
+/+ lines ( p = 0.04 and 0.01, 
respectively), but the impairment was greatest for the Pax3
sp/sp lines.  
  The effect of Pax3 deficiency on methionine biosynthesis and cellular 
methylation was determined.  The relative ratio of AdoMet to AdoHcy, which serves  
as an indicator of the cellular methylation potential, was increased in a gene-dosage 
dependent manner in response to the splotch mutation, although only the comparison 
between Pax3
sp/sp lines and Pax3
+/+ lines was statistically significant (p < 0.01, Figure 
3.10C).   
     
Discussion 
This study is the first to demonstrate that changes in the expression of a folate-
dependent enzyme sensitizes mice to folate-responsive NTDs, and the results 
implicate impaired thymidylate synthesis and Shmt1 in the etiology of folate-
responsive NTDs.  In the cytoplasm, SHMT1 regulates the partitioning of one-carbon 
units between thymidylate biosynthesis and homocysteine remethylation (45), whereas 
in the nucleus SHMT1 is the source of folate-activated one-carbons for thymidylate 
synthesis (Figure 1).  Consequently, de novo thymidylate biosynthesis is impaired in 
Shmt1 null fibroblasts (MacFarlane et al, unpublished) and loss of Shmt1 expression 
increases uracil misincorporation into genomic DNA in livers of Shmt1
+/- mice (44).  
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Shmt1 is highly penetrant relative to NTD risk as haploinsufficiency is sufficient to 
induce NTDs in litters of folate- and choline-deficient dams..    
Although Shmt1 is not expressed in all cells (51), it is expressed throughout the 
developing neural plate during folding and closure stages.  This ubiquitous expression 
is transient, and after neural tube closure secondary centers of Shmt1 expression 
appear in both brain and spinal cord regions.  Some of these, e.g. the midbrain-
hindbrain boundary and rhombomeres 3 and 5 are sites at which position-determining 
gene expressions occur (52,53) Other sites, e.g. the alar zone of the spinal cord, are 
more closely associated with neuronal specification. The presence of SHMT1 
throughout neurula-stage neuroepithelium supports its likely contribution to nucleotide 
biosynthesis at sites of rapid proliferation, although later sites of expression appear 
more closely related to differentiation-dependent processes 
Shmt1-deficient mice recapitulated the NTD risk profile observed in humans, 
which involves interactions among embryonic genotype, maternal diet and maternal 
genotype.  Only embryonic Shmt1 deficiency was essential for NTD pathogenesis in 
this study, but NTD penetrance was increased by maternal folate/choline deficiency 
and maternal Shmt1 disruption in both Shmt1-deficient crosses and compound Shmt1, 
Pax3 mutant crosses.  Decreased maternal Shmt1 expression increased the frequency 
of exencephaly in Shmt1-deficient embryos, and induced more extensive lesions in 
compound Pax3, Shmt1 mutant embryos.  NTDs occurred predominantly under 
folate/choline-deficient conditions in Shmt1-deficient embryos, with maternal folate 
deficiency resulting in instances of craniorachischisis and three-fold elevations in 
NTD incidence among Pax3
sp/+ and Pax3
+/+embryos deficient for Shmt1.  The highest 
incidence of NTDs was observed in Shmt1
-/- embryos harvested from Shmt1
-/- dams 
fed the folate/choline deficient diet.  In contrast, only one exencephalic embryo was  
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recovered from a Shmt1
+/+ dam, indicating that maternal Shmt1 expression protects 
against NTDs in Shmt1-deficient embryos.  
  The mouse models investigated in this study do not support a prominent role 
for homocysteine or cellular methylation in the etiology of NTDs.  Shmt1-deficient 
dams did not exhibit elevated plasma homocysteine, and AdoMet/AdoHcy levels were 
previously shown to be unchanged or mildly elevated in Shmt1-deficient mice fed the 
folate/choline deficient diet (44).   Similarly, the homocysteine remethylation pathway 
is not implicated in NTD pathogenesis in the splotch NTD model.  In this study, the 
ratio of AdoMet/AdoHcy was elevated in both Pax3
sp/+ and Pax
sp/sp MEFS in a gene-
dosage dependent manner.  AdoMet and AdoHcy levels were also shown to be similar 
in wild type and splotch embryos in a recent study (54).  Methionine supplementation 
in vivo or in culture is not protective but rather increases the frequency of more 
extensive defects in Pax3
sp/sp embryos and also causes occasional NTDs in Pax3
sp/+ 
embryos (34,35). Lastly, exposure of splotch embryos to excess homocysteine in 
culture does not exacerbate NTD frequency or severity in Pax3
sp/sp embryos or cause 
NTDs in Pax3
sp/+ or Pax3
+/+embryos (54), suggesting that the exacerbating effect of 
methionine is not mediated by elevated homocysteine levels.  Together, these data do 
not support a role for elevated homocysteine or impaired cellular methylation as an 
underlying cause of NTDs in these two folate-responsive NTD models. 
The impairment of de novo thymidylate biosynthesis in the Pax3 model was 
validated and the underlying mechanism(s) extended in this study.  We confirmed 
previous studies that Pax3 deficiency impairs de novo thymidylate biosynthesis in 
splotch MEFs.  Furthermore, we demonstrated that Pax3 deficiency decreased TYMS 
enzyme levels in splotch embryos, indicating that TYMS is a downstream target of 
Pax3.  We also demonstrated that Shmt1 deficiency decreased TYMS enzyme levels.   
The common effects of Pax3 and Shmt1 deficiency on TYMS protein levels and de 
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novo thymidylate biosynthesis support the role of impaired thymidylate biosynthesis 
in the etiology of NTDs, as Shmt1 and Pax3 deficiency interact to increase the 
frequency and severity of NTDs in Pax3
sp/sp embryos, and cause NTDs in Pax
sp/+ and 
Pax3
+/+ embryos in the absence of folate deficiency.  Of interest, Pax3 and SHMT1 
protein levels appear to be mutually regulated and compensatory.   Shmt1 deficiency 
increased Pax3 protein levels and SHMT1 protein levels were similarly elevated in 
response to Pax3 deficiency in splotch embryos.   Because Shmt1 deficiency 
exacerbated NTDs in Pax3-deficient embryos, and both Pax3 and Shmt1 deficiency 
are associated with reduced TYMS levels, the elevation in SHMT1 protein levels 
observed in Pax3-deficient embryos may function to compensate partially for reduced 
TYMS protein levels by increasing the concentration of methyleneTHF, the required 
cofactor and substrate for de novo thymidylate biosynthesis.    Similarly, the increased 
Pax3 levels observed in Shmt1-deficient embryos may function to elevate TYMS 
levels and thereby increase rates of thymidylate biosynthesis.  Although the molecular 
mechanism underlying the interactions between Pax3 and SHMT1 remains to be 
established, the independent associations of Shmt1 and Pax3 with TYMS levels and de 
novo thymidylate biosynthesis indicates that the observed reciprocal regulation 
functions as a compensatory mechanism that normalizes impairments in de novo 
thymidylate biosynthesis, thereby affording some protection against NTDs. When this 
protective mechanism is disrupted in compound Pax3, Shmt1 mutants, the NTD 
phenotype is exacerbated.  Impairments in de novo thymidylate biosynthesis may 
disrupt neural tube closure by reducing proliferative capacity or increasing genomic 
instability via misincorporation of uracil into DNA (55). Both reduced proliferative 
capacity and genomic instability cause NTDs in mice (56-59) 
The influence of maternal Shmt1 genotype on NTD occurrence indicates a role 
for a maternally-derived soluble factor or metabolite in NTD risk.  Maternally-derived 
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thymidine nucleotides or nucleosides have been implicated in NTD pathogenesis 
based on data from previous studies, as maternal thymidylate supplementation was 
shown to prevent NTDs in some but not all studies of Pax3-deficient splotch embryos 
(34,35).  In this study, Pax3 deficiency in MEFs was shown to impair both de novo 
thymidylate and purine biosynthesis, and the magnitude in the impairment in de novo 
purine biosynthesis was greater than that observed for thymidylate biosynthesis.  
Therefore, the conflicting experimental results present in the literature regarding 
maternal thymidylate supplementation on NTD prevention may be accounted for by 
impairments in both purine and thymidylate biosynthesis in splotch mutants.  Unlike 
the splotch model, previous studies have shown that Shmt1 disruption does not impair 
de novo purine biosynthesis (MacFarlane et al, unpublished).   The differential effects 
of Pax3 and Shmt1 on nucleotide biosynthesis may account for the disparity in NTD 
phenotype between these two folate-responsive NTD models; Shmt1 deficiency alone 
is associated only with exencephaly, whereas Pax3 deficiency causes 100% penetrant 
spina bifida and low frequency exencephaly.  Shmt1 deficiency at both maternal and 
embryonic levels increased the frequency of exencephaly in splotch embryos, whereas 
the only instances of spina bifida observed in Shmt1-deficient embryos occurred in 
litters derived from Pax3
sp/+ dams.  These data suggest that impaired purine 
biosynthesis therefore results in spina bifida, whereas impairments in thymidylate 
biosynthesis result in exencephaly.   
      Decreased Mthfr expression in mice does not cause NTDs (30) and Mthfr does 
not interact with Pax3 (49), although MTHFR is recognized as a candidate gene 
underlying human NTD risk.  In addition to disrupting  the homocysteine 
remethylation pathway, the common  MTHFR 677CÆT variant alters the distribution 
of cellular folate derivatives (60-63), and reduces markedly serum and red blood cell 
folate levels (28,64,65) in humans.  Similarly, mice with reduced Mthfr expression 
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exhibit reduced plasma folate levels and altered distribution of methylated folate 
derivatives (66).   The discrepancy between the results from human genetic association 
studies that have identified MTHFR gene variants as NTD risk factors, and the lack of 
NTDs resulting from Mthfr disruption in mice, indicates that MTHFR affects NTD 
risk by modifying folate status, not homocysteine remethylation.  Previous studies 
have shown that reduced folate status is not sufficient to induce NTDs in mice (67,68).  
By impairing folate status, the MTHFR 677CÆT variant may sensitize genetically-
susceptible individuals to NTDs without directly contributing to causal metabolic 
impairments in nucleotide biosynthesis.   
We demonstrate that a 50% decrease in Shmt1 expression is sufficient to 
induce NTDs in mice, and therefore factors that affect Shmt1 expression are candidate 
risk factors for NTDs.  Cellular SHMT1 activity and levels vary over a wide range.  
SHMT1 synthesizes it’s own tightly-binding inhibitor, 5-formylTHF (69), and binds 
5-methylTHF as an inhibitor with high affinity (45).   Shmt1 expression is also 
regulated by zinc (70), retinoic acid (71), heavy chain ferritin (72,73), and c-myc (74).  
Whereas most screens for human NTD candidate genes have focused on the 
identification of gene variants, this study demonstrates that relatively modest changes 
in SHMT1 expression confer increased NTD risk, thereby accounting for the paucity 
of human NTD candidate genes in the folate metabolic network identified to date.   
Experimental Procedures 
Mouse models 
   Shmt1
flox/+ and Shmt1
-/- mice are viable and fertile, and their generation has 
been described previously (44).  Shmt1
flox/+ and Shmt1
+/- lines are maintained as a 
heterozygote breeding colonies on either congenic 129/SvEv or C57Bl/6 backgrounds.  
Heterozygous C57Bl/6J-Pax3
sp mice were obtained from Jackson Laboratories (Bar 
Harbor, ME).  Embryonic Shmt1 expression was examined in embryos derived from 
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crosses of B6;129(P2)-Shmt1
flox/flox mice, which express β-galactosidase from an IRES/ 
β-geo cassette inserted within intron 8 of the Shmt1 gene (44).   NTDs were examined 
in litters harvested from crosses of either 129SvEv-Shmt1(N10+) or C57Bl/6-
Shmt1(N10+) mice.  Shmt1 expression patterns in Pax3-deficient embryos were 
examined in Pax3
sp/+, Shmt1
flox/flox mice generated from crosses between Shmt1
flox/flox 
mice and Pax3
sp/+ mice.  To determine the impact of Shmt1 deficiency on NTDs in the 
splotch mutant, Pax3, Shmt1 compound mutants were obtained by crossing Shmt1
+/- 
mice on a mixed C57Bl6/ 129Sv/EV/ Balb/c background to Pax3
Sp/+ mice.  F1 
compound heterozygotes (Pax3
sp/+, Shmt1
+/-) were then used for colony breeding. 
Pax3
sp/+, Shmt1
+/- or Pax3
sp/+, Shmt1
-/- female mice were then crossed to Pax3
sp/+, 
Shmt1
+/- male mice for timed mating experiments as described below.   
Experimental animals and diets 
  All animal experiments were approved by the Cornell Institutional Animal 
Care and Use Committee according to the guidelines of the Animal Welfare Act and 
all applicable federal and state laws.  Mice were maintained on a 12 hour light/dark 
cycle in a temperature controlled room.  For studies investigating Shmt1 deficiency 
and neural tube closure, female mice were randomly assigned to either an 
experimental AIN93G diet lacking folate and choline  (FCD) or an AIN93G (Control) 
diet (Dyets, Bethlehem, PA) at weaning.  Choline was excluded from the experimental 
diet in addition to folate to increase stress on the homocysteine remethylation cycle.  
Choline synthesis requires methyl groups in the form of S-adenosylmethionine and it 
provides a source of four one-carbons for homocysteine remethylation through its 
catabolism.  Studies investigating the interaction between Shmt1 and Pax3 in Pax3, 
Shmt1 compound mutants were conducted in mice fed either a standard rodent chow 
(Harlan) or the FCD diet.  For all studies, dams were maintained on diet from weaning 
throughout the breeding period and for the duration of gestation, until killed.  For all 
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studies, virgin female mice aged 70-120 days were housed overnight with males.  The 
following morning, females were examined for the presence of a vaginal plug. Nine 
o’clock a.m. the day of the plug was designated as gestational day 0.5 (E0.5).  
Pregnant females were sacrificed between E9.5-E11.5.  Gravid uteri were removed 
and all implants and resorption sites were recorded.  Embryos were dissected free of 
extra embryonic membranes under a dissecting microscope, examined for presence of 
NTDs, and measured for crown-rump length. All yolk sacs were collected for 
subsequent genotyping.  Embryos extracted for later use in biochemical assays or for 
protein extraction were taken at E9.5-10.5 and rapidly frozen in liquid nitrogen 
followed by storage at -80ºC.  Embryos examined for morphological abnormalities 
were derived at E11.5, fixed 24 hours in 10% neutral buffered formalin, dehydrated in 
an ethanol series, and stored in 70% ethanol.  For all metabolic studies, pregnant mice 
were sacrificed at E9.5-10.5 by cervical dislocation and blood was collected by 
cardiac puncture. For morphological analysis, pregnant mice were sacrificed by 
carbon dioxide-induced asphyxiation. 
Genotype analysis 
  DNA was isolated from tail tissue or yolk sacs using the Qiagen DNeasy kit 
protocol for animal tissue (Qiagen).  Genotyping for the splotch mutation and sex was 
performed using established protocols (75,76).  Genotyping for Shmt1
flox and Shmt1
+/- 
alleles was performed using a previously described protocol (44). 
Histology 
  Embryos were processed for histological analysis following gross 
morphological examination.  Tissues were cryoprotected in 30% sucrose in phosphate-
buffered saline, embedded in O.C.T. (Tissue-Tek)) and frozen in isopentane cooled in 
liquid nitrogen. Thirty-micrometer thick cryosections were affixed to plus charged 
slides, and stained with hematoxylin and eosin.  
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Determination of plasma metabolites 
Plasma levels of homocysteine, cystathionine, cysteine, α - aminobutyric acid, 
methionine, glycine, serine, N,N-dimethylglycine and N-methylglycine were 
determined by stable isotope dilution capillary gas chromatography mass spectrometry 
as previously described (77,78) 
Analysis of red blood cell folate levels 
Folate levels in red blood cell samples was quantified using a Lactobacillus 
casei microbiological assay as previously described (79). 
Western blot 
  Western blot analyses were performed in triplicate using 15-30 µg of protein 
extracted from individual embryos as described elsewhere (44).  The primary 
antibodies were diluted in 5% nonfat skim milk in PBS as follows: monoclonal mouse 
anti-mouse thymidylate synthase (TYMS) (Zymed, 1:2000), monoclonal mouse anti-
mouse GAPDH (Novus, 1:40,000), polyclonal goat anti-mouse Pax3 (Santa Cruz, 
1:3000), polyclonal rabbit anti-mouse actin (Abcam. 1:40,000) and polyclonal sheep 
anti-mouse SHMT1 (1:10000,(80).  Relative levels of SHMT1, TYMS, and Pax3 
protein were normalized to GAPDH or actin as a loading control.   
Generation of mouse embryonic fibroblast cell lines 
  Mouse embryonic fibroblast (MEF) cell lines were generated from embryos 
isolated 10-14 days post-coitus from crosses of Pax3
sp/+ mice.  Genotyping of MEF 
lines was completed both at the time of generation using nuclear DNA isolated from 
embryo heads, as well as from cell pellets, using the genotyping protocols described 
above.  MEFs were incubated at 37° C in Defined Minimal Essential Media (Hyclone) 
with 10% fetal bovine serum.  MEFs were grown to confluency and frozen down in 
fetal bovine serum with 10% dimethyl sulfoxide for later use. 
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Nucleotide biosynthesis assays 
MEFs were plated in triplicate in 6-well plates at a density of 1 X10
4 cells per 
well.  A formate suppression assay, which measures the relative efficiency of de novo 
purine nucleotide synthesis relative to synthesis from the purine nucleotide salvage 
pathway,  was performed as previously described (81).   Similarly, a deoxyuridine 
(dU) suppression assay was performed to determine the relative efficiency of de novo 
thymidylate biosynthesis.   The dU surpression assay was a modification of that used 
by Fleming and Copp (35), in which relative rates of de novo thymidine biosynthesis 
were determined by the relative ratio of incorporation of [
3H] thymidine (500 nM) as 
compared to radiolabeled deoxyuridine monophosphate ([
14C] dUMP, 10 μM)) in 
nuclear DNA.  Preparation of media for nucleotide biosynthesis assays has been 
described elsewhere (81).  Cells were grown at 37°C, 5% CO2 in tracer media until 
confluent. Cells were harvested by trypsinization and DNA was isolated from cell 
pellets using the Qiagen DNeasy kit protocol for harvested cells.  Isotope 
incorporation into nuclear DNA was quantified using a Beckman LS6500 scintillation 
counter in dual dpm mode. 
Determination of S-adenosylmethionine (AdoMet) and S-Adenosylhomocysteine 
(AdoHcy) Concentrations 
  Total levels of AdoMet and AdoHcy  were measured in frozen MEF cell pellets by 
an established HPLC procedure (45,82).   
Statistical analyses 
  Analyses of NTD incidence and embryonic crown-rump length were 
conducted using repeated-measured analysis of variance (PROC MIXED or PROC 
GENMOD, SAS, Cary, NC) in which independent variables included maternal Shmt1 
genotype and maternal diet, and litter was considered as a repeated measure. 
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Embryonic Shmt1 genotype was excluded from the model when assumptions of 
variance were violated due to the absence of exencephaly observed in Shmt1
+/+ 
embryos.  Embryonic sex was also included in the model, as gender modifies the 
incidence of exencephaly (33).  Analysis of total litter resorptions and implants was 
analyzed by analysis of variance in which litter was considered as the unit of analysis.  
Independent variables in the model included maternal Shmt1 genotype and diet.  
Resorption rate was calculated as the ratio of resorptions/ total implants per litter and 
log-transformation was applied to normalize the data. Specific comparisons within 
main effects were assessed by comparisons of least-squared means.  Chi-squared 
analyses were used to assess any deviation from expected genotype ratios based on 
Mendelian inheritance.  For cell culture assays, genotype differences were assessed 
using a one-tailed t-test.   
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CHAPTER 4 
MATERNAL MTHFD1 HAPLOINSUFFICIENCY IMPAIRS FERTILITY, 
NEURAL TUBE CLOSURE, AND FETAL GROWTH 
 
Abstract 
  The folate-dependent gene MTHFD1 catalyzes the activation of one-carbons 
required for the synthesis of purines, thymidylate, and methionine.  A common human 
polymorphism in MTHFD1 (A1298C) increases maternal risk for adverse pregnancy 
outcomes including neural tube defects (NTDs), but the mechanism(s) are unknown.  
Here we demonstrate that maternal Mthfd1 disruption caused by a gene-trapped (gt) 
allele caused fetal growth restriction, and gestational supplementation of pregnant 
Mthfd1
gt/+ females with hypoxanthine resulted in rescue of early fetal loss and 
occasional NTDs in Mthfd1
gt/+ embryos. Pregnant Mthfd1
gt/+ females exhibited 
reductions in red blood cell folate and plasma methionine levels. These results suggest 
that Mthfd1 disruption affects fetal growth and neural tube closure by disrupting both 
folate status and cellular folate utilization.  
 
Introduction 
Maternal folate status is a penetrant environmental risk factor for several 
adverse outcomes in pregnancy.  Maternal folic acid supplementation reduces both 
neural tube defect (NTD) occurrence and recurrence (1,2), and has been suggested to 
reduce the risk of other anomalies including orofacial clefts, limb defects, and 
congenital heart defects (3-7).    Currently, over 20 countries worldwide have taken 
measures to fortify their food supply with folic acid for the prevention of NTDs, which 
reduced NTD prevalence by 20-80% (8-10).  However, overt folate deficiency is not 
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present in a majority of women whose pregnancies are affected by NTDs or other 
development anomalies (11-13). Instead, nutritional folate deficiency interacts with 
genetic variants that compromise folate metabolism and confer risk for NTDs and 
other developmental anomalies (14-20). 
Folates function in the cell to provide activated one-carbons (1Cs) for the de 
novo biosynthesis of purines and thymidylate and for the remethylation of 
homocysteine to methionine (Figure 4.1).   Adenosylation of methionine produces S-
adenosylmethionine (AdoMet), which serves as the methyl donor for cellular 
methylation reactions including the methylation of chromatin. Folate deficiency and 
genetic disruption in folate-metabolizing enzymes impair folate-dependent anabolic 
reactions, thereby resulting in reduced proliferative capacity, increased DNA uracil 
levels, elevated homocysteine and chromatin hypomethylation (21).   
Biomarkers of impaired folate status, including reduced serum folate levels and 
elevated plasma homocysteine, have been linked to increased risk for several 
pathological conditions in pregnancy and fetal development, including neural tube, 
cardiac, limb, and jaw defects, pre-eclampsia, placental abruption, low birth weight, 
pre-term delivery, intrauterine growth restriction, and spontaneous abortion  (22-29).  
The mechanism(s) that underlie pathogenesis in these diverse conditions are unknown.  
Whereas a majority of studies have investigated mechanisms underlying the 
association between impaired folate status and NTD risk, less is known about the 
mechanism(s) by which impairments in folate metabolism lead to other adverse 
pregnancy outcomes.  It has been suggested that reduced maternal and/or fetal folate 
status compromises cellular proliferative capacity in the developing fetus and/or 
placenta due to limited nucleotide availability (24).   
Formate is a  primary source of 1Cs for nucleotide biosynthesis , and is 
generated   from serine, glycine or choline catabolism in the mitochondria (30).   
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Figure 4.1.  Folate-mediated one carbon metabolism
One-carbon metabolism in the cytoplasm is required for the de novo synthesis of 
purines and thymidylate, and for the remethylation of homocysteine to methionine.  
Formate is generated by one-carbon metabolism in mitochondria from serine, 
glycine, sarcosine and dimethylglycine.  MTHFD1 catalyzes the ATP-dependent 
synthesis of 10-formylTHF, as well as the NADP-dependent reduction of 10-
formylTHF to methyleneTHF.  Abbreviations: THF, tetrahydrofolate; MTHFD1, 10-
Formyltetrahydrofolate synthetase /Methenyltetrahydrofolate synthetase/ 
Methylenetetrahydrofolate dehydrogenase; MTHFR, Methylenetetrahydrofolate 
reductase; MTR, Methionine synthase; AdoMet, S-adenosylmethionine; AdoHcy, S-
adenosylhomocysteine; SHMT1, Cytoplasmic serine hydroxymethyltransferase; 
TYMS, Thymidylate synthase; DHFR, Dihydrofolate reductase; dUMP, deoxyuracil 
monophosphate; DHF, dihydrofolate. 
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Formate traverses to the cytoplasm and condenses with tetrahydrofolate (THF) to form 
10-formylTHF, the cofactor required for de novo purine biosynthesis.  This ATP-
dependent reaction is catalyzed by the synthetase domain of the trifunctional enzyme, 
MTHFD1, which is encoded by MTHFD1. The NADP-dependent 
cyclohydrase/dehydrogenase domain of  MTHFD1 catalyzes the reduction of 10-
formylTHF to methyleneTHF, which is utilized for synthesis of thymidine, serine, or 
methionine (31) (Figure 4.1).  Association studies of human gene variants that encode 
folate-dependent enzymes have consistently identified MTHFD1 as a candidate gene 
contributing to risk for adverse pregnancy outcomes.  A common variant of MTHFD1, 
1958G>A, results in the substitution of arginine for a glutamine in the active site of 
the synthetase domain.  MTHFD1 G1958A has been linked to increased risk of NTDs 
(32-34), cleft lip and palate (35), congenital heart defects (36), placental abruption 
(37), unexplained second trimester pregnancy loss (38), and intrauterine growth 
restriction (39).  The G1958A  variant encodes a thermolabile enzyme associated with 
a 36% reduction in enzymatic activity and a 22% reduction in the incorporation of 
labeled formate into DNA, indicating disrupted de novo purine biosynthesis (36).  
Interestingly, adequate folate status protected against reduced protein stability 
associated with the G1958A polymorphism.  These data suggest that impairments in 
de novo purine biosynthesis may underlie pathogenesis in response the MTHFD1 
G1958A SNP, but this has not been demonstrated experimentally. 
A Mthfd1-deficient mouse model containing a gene trap vector insertion in the 
synthetase domain of the Mthfd1 gene has recently been generated and characterized 
(40).  Homozygous Mthfd1 
gt/gt mice are not viable, demonstrating the requirement for 
folate-activated formate during embryonic development.   Mthfd1
gt/+ mice are viable, 
exhibit 50% decreased MTHFD1 protein levels and exhibit impaired cellular 
methylation capacity but enhanced de novo thymidylate biosynthesis (40).  In this 
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study we have investigated the effect of Mthfd1 heterozygosity as a model of the 
MTHFD1 G1958A variant on embryonic development and neural tube closure.  We 
demonstrate that maternal Mthfd1 deficiency is a risk factor for adverse pregnancy 
outcomes by impairing folate status, methionine metabolism, and purine biosynthesis. 
 
Results 
Mthfd1
gt/gt mice exhibit early embryonic lethality 
  Mthfd1 is an essential gene in mice (40).  To determine the approximate 
embryonic stage at lethality, litters were harvested from intercrosses of heterozygous 
B6.129(P2)C57Bl/6- Mthfd1
gt/+ (N6) mice fed a standard rodent diet at various 
gestational time points, and the genotype distribution of embryos was determined 
(Table 4.1, and data not shown).  There were no Mthfd1
gt/gt embryos recovered at any 
time point during gestation beginning at embryonic day 9 (E9).  The genotype 
distribution from ten litters harvested at E9 differed significantly from that expected 
by Mendelian inheritance (Table 4.1, Χ
2 analysis, p = 3.8 X 10
-8).  The data indicate 
that embryonic lethality in Mthfd1
gt/gt embryos occurs prior to E9. 
Maternal Mthfd1 disruption and low folate status causes FGR 
        The effect Mthfd1 disruption in Mthfd1
gt/+ embryos on embryonic development 
and neural tube closure in response to compromised maternal folate status was 
examined.  Congenic 129P2Ola- Mthfd1
gt/+ and Mthfd1
+/+ female littermates were 
weaned onto either the AIN93G (control) diet or the folate/choline deficient AIN93G 
(FCD) diets.  At 8 weeks of age, 129P2Ola-Mthfd1
+/+ and Mthfd1
gt/+ females were 
mated to 129P2Ola- Mthfd1
gt/+ or Mthfd1
+/+ males, respectively, in order to discern the 
independent contributions of maternal and embryonic Mthfd1 genotype to embryonic 
development.  Litters were harvested at E11.5 or E14.5 and examined for gross 
morphological abnormalities. Genotype distribution in litters examined at E11.5 and  
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  Observed Genotype 
Distribution 
Expected Genotype 
Distribution 
Genotype Male  Female  Total  Male  Female Total 
Mthfd1
+/+ 11 11  22  7.25  7.25  14.5 
Mthfd1
gt/+ 17 19  36  14.5  14.5  29 
Mthfd1
gt/gt 0 0  0  7.25  7.25  14.5 
Total 28  30  58  29  29 58 
Table 4.1.  Early embryonic lethality in Mthfd1
gt/gt embryos.  Mthfd1
gt/+ mice were 
intercrossed and 10 litters were harvested at E9.5.  The expected genotype distributions 
were calculated based on expected Mendelian inheritance.  Deviation from the expected 
genotype distribution was determined using a Χ
2 statistic.  The observed genotype 
distribution differed significantly from the expected genotype distribution (p = 3.8 x 10
-8) 
 145 
 146
E14.5 did not differ significantly from expected values (Tables 4.2, 4.3; Χ
2 test, p = 
0.5 and p = 0.3, respectively).  No NTDs were observed in any of the litters examined.  
However, a proportion of embryos examined at E11.5 from crosses of Mthfd1
gt/+ 
female mice or Mthfd1
+/+ female mice maintained on the FCD diet were either 
resorbing and/or severely malformed, suggesting severe fetal growth restriction (FGR, 
Table 4.2).  Malformed embryos were characterized by an irregular and convoluted 
neuroepithelium, torqued body symmetry, and severe delay in heart, limb, and jaw 
development (Figure 4.2B-D).  In many cases, affected embryos were in the process of 
resorbing (Figure 4.2C-D). Embryo loss and/or developmental arrest appeared to have 
occurred between E9.5 and E11.5, following neural tube closure.   No NTDs were 
observed, even in embryos that were in the process of resorption.  
The incidence of fetal growth restriction (FGR) in litters derived at E11.5 was 
not influenced by embryonic Mthfd1 genotype (p = 0.85), as approximately equal 
numbers of Mthfd1
gt/+ and Mthfd1
+/+ littermates were affected by FGR (Table 4.2).  
FGR incidence was significantly influenced by both maternal Mthfd1 disruption and 
maternal diet (Χ
2 = 4.42, p = 0.03 and Χ
2 = 5.16, p = 0.02, respectively).  There was 
also a trend towards an effect of embryonic sex on FGR incidence (Χ
2 = 3.31, p = 
0.068), with more males affected than females (14 vs. 8).  There were no FGR-
affected embryos uncovered in 12 litters isolated from crosses of Mthfd1
gt/+ males and 
Mthfd1
+/+ females fed the control diet.  Approximately 10% of embryos isolated either 
from crosses of Mthfd1
+/+ males and Mthfd1
gt/+ females fed the control diet or crosses 
of Mthfd1
gt/+ males and Mthfd1
+/+ females fed the FCD diet exhibited FGR.   The 
highest incidence of FGR occurred in litters derived from Mthfd1
gt/+ females fed the 
FCD diet, with approximately 20% of embryos exhibiting FGR.  The additive effect of   
Table 4.2.  Incidence of FGR in E11.5 embryos harvested from crosses of Mthfd1
gt/+ and Mthfd1
+/+ mice fed either the control or 
FCD diet.  Main effects of diet, maternal Mthfd1 genotype, and embryonic Mthfd1 genotype and sex on FGR incidence were 
analyzed by analysis of variance in SAS.  Differences between observed and expected genotype distribution by genotype and sex 
were analyzed using a chi-squared statistic.  There were no differences between observed and expected genotype distributions (Χ
2 
test, p = 0.5).  Maternal genotype (p = 0.03) and maternal diet (p = 0.02) significantly influenced the number of FGR-affected 
embryos. 
 
 
Maternal 
Genotype 
No. of 
Litters 
Embryonic 
genotype 
Total  
Embryos 
No. 
Female 
No. 
Male 
# Affected 
(sex)  Diet 
Mthfd1
+/+
1
4
7
18 8  10  0  12  Mthfd1
+/+
  Mthfd1
gt/+
22 14  8  0 
Mthfd1
+/+
28  16  12  3 (2M, 1F) 
Control 
  15  Mthfd1
gt/+
  Mthfd1
gt/+
21  10  11  2 (1M, 1F) 
Mthfd1
+/+
30  15  15  4 (3M, 1F)  Mthfd1
+/+ 15 
Mthfd1
gt/+
30 15  15 1  (M) 
Mthfd1
+/+
35  14  21  6 (5M, 1F) 
FCD 
 
Mthfd1
gt/+ 12 
Mthfd1
gt/+
28  14  14  6 (2M, 4F) 
  
Table 4.3.  Incidence of FGR in E14.5 embryos harvested from crosses of Mthfd1
gt/+ and Mthfd1
+/+ mice fed either the control or 
FCD diet.  Main effects of diet, maternal Mthfd1 genotype, and embryonic Mthfd1 genotype and sex on FGR incidence were 
analyzed by analysis of variance in SAS.  Differences between observed and expected genotype distribution by genotype and sex 
were analyzed using a chi-squared statistic.  There were no differences between observed and expected genotype distributions (Χ
2 
test, p = 0.3).  There was a significant interaction between maternal genotype and maternal diet (p = 0.03) that predicted the # of 
FGR-affected embryos. 
 
 
Diet  Maternal 
Genotype 
No. of 
Litters 
Embryonic 
genotype 
Total  
Embryos 
No. 
Female 
No. 
Male 
# Affected 
(sex) 
Mthfd1
+/+ 22 11  11  0 
Mthfd1
+/+ 11 
Mthfd1
gt/+ 24 12  12  0 
Mthfd1
+/+ 22 11  11  0 
Control 
 
Mthfd1
gt/+ 17 
Mthfd1
gt/+ 28  11  17  3 (1F, 2M) 
Mthfd1
+/+ 28  14  14  3 (2F, 1M) 
Mthfd1
+/+ 20 
Mthfd1
gt/+ 18 11  7  3(2F,1M) 
Mthfd1
+/+ 19 10  9  0 
FCD 
 
23  Mthfd1
gt/+ 15  Mthfd1
gt/+
9  14  0 
 
1
4
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Maternal Mthfd1 disruption affects embryonic development. 
 (A, B)  Normal (A) and growth-restricted (B) Mthfd1
+/+ littermates isolated from a 
Mthfd1
gt/+ female fed the FCD diet.   
(C) Wild-type embryo exhibiting growth restriction and in the process of resorption, 
isolated at E11.5 from a Mthfd1
gt/+ female fed the FCD diet.   
(D) Mthfd1
gt/+ embryo exhibiting growth restriction, torqued body symmetry, and 
highly irregular neuroepithelial organization, isolated at E11.5 from a Mthfd1
gt/+ 
female fed the FCD diet. 
(E, F)  Normal Mthfd1
+/+ embryo (E) and Mthfd1
gt/+ littermates with exencephaly 
(F).  Embryos were uncovered in a litter isolated from a Mthfd1
gt/+ females fed the 
FCD diet and supplemented with 500 µM hypoxanthine.  
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compromised maternal folate status and maternal Mthfd1 disruption on FGR incidence 
suggests that these two factors did not interact in FGR pathogenesis. 
Litters examined at E14.5 had significantly fewer FGR-affected embryos as 
compared to litters examined at E11.5 (Χ
2 = 3.65, p = 0.056; Table 4.3).  FGR-affected 
embryos examined at E14.5 were similar in appearance to those examined at E11.5 
except that developmental arrest had occurred slightly later in development.  FGR 
incidence in E14.5 embryos was not affected by embryonic Mthfd1 genotype.  A 
significant interaction was observed between maternal Mthfd1 genotype and maternal 
diet on the number of FGR-affected embryos at E14.5 ( Χ
2 = 4.34, p = 0.037), 
indicating that the incidence of FGR was greatest in litters derived from Mthfd1
gt/+ 
females on the control diet (5%) and in litters from Mthfd1
+/+ females fed the FCD 
diet (11%). No FGR-affected embryos were uncovered at E14.5 from Mthfd1
+/+ 
females fed the control diet or Mthfd1
gt/+ females fed the FCD diet.  The absence of 
FGR-affected embryos at E14.5 in litters derived from Mthfd1
gt/+ females fed the FCD 
diet indicated that affected embryos from these litters did not survive past E11.5 and 
were resorbed.   
Hypoxanthine supplementation in Mthfd1
gt/+ females  
  The effect of maternal hypoxanthine supplementation on fetal outcomes was 
examined in Mthfd1
gt/+ females maintained on the FCD diet.  Pregnant female mice 
were supplemented with 500 µM hypoxanthine in drinking water from the time of 
vaginal plug until sacrifice at E11.5.  Hypoxanthine supplementation did not affect the 
genotype distribution of embryos derived from Mthfd1
gt/+ females on the FCD diet 
(data not shown).  Hypoxanthine supplementation did result in a 50% increase in the 
incidence of FGR-affected embryos as compared to unsupplemented Mthfd1
gt/+  
females fed the FCD diet, although this comparison did not reach significance (28% 
vs. 19%; Χ
2 = 4.32, p = 0.11).  Although FGR was observed in both Mthfd1
+/+ and 
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Mthfd1
gt/+ embryos derived from hypoxanthine-supplemented litters, the increased 
incidence of FGR in these litters could be attributed to a doubling of the incidence of 
FGR in Mthfd1
gt/+ embryos as compared to Mthfd1
+/+  littermates (10 vs. 5 embryos; 
36% vs. 19%; p = 0.08).  In addition, two Mthfd1
gt/+ embryos exhibited exencephaly of 
15 litters derived from Mthfd1
gt/+ females on the FCD diet supplemented with 
hypoxanthine (Figure 4.2E-F).      
Maternal Mthfd1 disruption and impaired folate status influence embryo length at 
E14.5 
  Crown-rump length was measured in individual embryos derived from the 
crosses described above.  Crown-rump lengths of embryos at E11.5 were not 
significantly affected by embryonic Mthfd1 genotype, maternal Mthfd1 genotype or 
maternal diet (data not shown).  Crown-rump lengths of E14.5 embryos were also 
unaffected by embryonic Mthfd1 genotype.  However, there was a trend towards a 
significant interaction of maternal Mthfd1 genotype and diet (F= 2.9, p = 0.09) on 
crown-rump lengths of embryos at E14.5.  Embryos derived from Mthfd1
gt/+ females 
on the FCD diet had decreased crown-rump lengths as compared to embryos derived 
from Mthfd1
+/+ females on the control diet at E14.5 (10.9 mm vs. 11.6mm, p = 0.05,  
Figure 4.3).   
Effect of maternal Mthfd1 disruption and low folate status on fertility  
  Total implants and resorptions were examined in litters isolated at E11.5 and 
E14.5 from Mthfd1
gt/+ and Mthfd1
+/+ females maintained on the control or FCD diets 
(Tables 4.4, 4.5). Analysis of total litter implants included viable embryos, FGR-
affected embryos that were either viable or in the process of being resorbed, and 
complete resorptions.  Analysis of resorptions included complete resorptions only; 
FGR-affected embryos that were in the process of resorbing were excluded from these  
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Figure 4.3 Crown-rump length in embryos isolated at E14.5 as a function 
of maternal Mthfd1 genotype and diet.  Main effects of embryonic genotype, 
maternal genotype, and maternal diet and relevant interactions were analyzed by 
analysis of variance in SAS.  Data represent mean ± SEM. There was a trend 
towards a significant interaction effect of maternal genotype x maternal diet on 
CR-length (p = 0.09).   
* Embryos derived from Mthfd1
gt/+ females on the FCD diet had decreased 
crown-rump lengths as compared to embryos derived from Mthfd1
+/+ females 
on the control diet at E14.5 (p = 0.05). 
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Diet  Maternal 
Genotype 
No. of 
Litters 
Total 
Implants
No. 
implants/ 
litter 
Total 
Resorp. 
No. 
resorp/  
litter 
Mthfd1
+/+ 10 
 
34 
 
3.4 ± 0.6  1 
  0.1 ± 0.1   
Control 
 
Mthfd1
gt/+ 15  56  3.7 ± 0.6 
 
7 
  0.47 ± 0.23  
16 
 
74 
 
4.4 ± 0.5  10 
  0.63 ± 0.24 Mthfd1
+/+
 
FCD 
 
13  Mthfd1
gt/+
  82  6.3 ± 0.7 
 
10 
  0.77 ± 0.28
p value, diet effect    p < 0.005    NS 
p value, genotype effect    NS    NS 
p value, diet X genotype effect    NS    NS 
Table 4.4.  Resorptions and implants in litters derived at E11.5 from Mthfd1
gt/+ and 
Mthfd1
+/+ dams fed the control or FCD diets.  Values represent mean ± SEM.  Main 
effects of Mthfd1 genotype, diet, and the interaction of genotype and diet on 
implantation-rate and log-transformed resorption rates were analyzed by analysis of 
variance in SAS. There was a significant main effect of diet on the total number of 
implants (F = 9.59, p = 0.003). There was also a trend towards a main effect of Mthfd1 
genotype on total implants (F = 2.82, p = 0.099). The interaction between Mthfd1 
genotype and diet was not significant.   
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Diet  Maternal 
Genotype 
No. of 
Litters 
Total 
Implants
No. 
implants/ 
litter 
Total 
Resorp. 
No. resorp/ 
litter 
Mthfd1
+/+ 11 
 
43 
 
3.9 ± 0.6 
 
6 
  0.55 ± 0.25 
Control 
 
Mthfd1
gt/+ 17 
 
3.2 ± 0.3 
 
14 
  0.82 ± 0.18  55 
Mthfd1
+/+ 22 
 
55 
  2.5 ± 0.3  17 
  0.77 ± 0.25 
FCD 
 
Mthfd1
gt/+ 12 
  30  2.5 ± 0.4 
 
11 
  0.91 ± 0.40 
p value, diet effect    NS    NS 
p value, genotype effect    NS    NS 
p value, diet X genotype effect    NS    NS 
 
Table 4.5.  Resorptions and implants in litters derived at E14.5 from Mthfd1
gt/+ and 
Mthfd1
+/+ dams fed the control or FCD diet.  Values represent mean ± standard error.  
Main effects of Mthfd1 genotype, diet, and the interaction of genotype and diet on 
implantation-rate and log-transformed resorption rates were analyzed by analysis of 
variance in SAS. There was a trend towards a main effect of maternal diet on total 
implants (F= 3.06, p = 0.08).  Mthfd1 genotype did not significantly influence any 
outcomes. 
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analyses.  Maternal diet significantly affected the total number of fetal implants in 
litters derived at E11.5; there were significantly more implants in litters derived from 
females maintained on the FCD diet as compared to the control diet (5.4 vs. 3.6; F = 
9.59, p = 0.003).  Total fetal implants were also slightly higher in Mthfd1
gt/+ dams as 
compared to Mthfd1
+/+ dams (5.0 vs. 4.0; F = 2.82, p = 0.099). Total fetal implants in 
litters isolated from Mthfd1
gt/+ females fed the FCD diet and supplemented with 500 
µM hypoxanthine were significantly lower than unsupplemented Mthfd1
gt/+ females on 
the FCD diet (3.8 vs. 6.3, p < 0.01), and were similar to litters of Mthfd1
gt/+ females 
maintained on the control diet (3.8 vs. 3.7 implants).  Litters derived at E14.5 from 
females maintained on the FCD diet had slightly fewer fetal implants as compared to 
litters derived from females fed the control diet (3.3 vs. 4.3; F= 3.06, p = 0.08; Table 
4.5).  There was no independent effect of maternal Mthfd1 genotype on the number of 
fetal implants in litters derived at E14.5. 
Examination of total resorptions in litters derived at E11.5 revealed a trend 
towards a significant effect of maternal diet (F = 2.89, p = 0.087).  More resorptions 
occurred in response to the FCD diet as compared to the control diet (0.7 vs. 0.28 
resorptions/litter).  Maternal Mthfd1 genotype had no effect on total resorptions in 
litters derived at E11.5.  However, only 1 resorption was found in 10 litters derived 
from Mthfd1
+/+ females on the control diet, whereas almost 50% of litters isolated 
from crosses of Mthfd1
gt/+ females on the FCD diet included at least one resorption. 
There was no effect of either maternal Mthfd1 genotype or maternal diet on total 
resorptions in litters derived at E14.5.   Hypoxanthine supplementation in Mthfd1
gt/+ 
females on the FCD diet was associated with a moderate reduction in the number of 
resorptions per litter as compared to unsupplemented Mthfd1
gt/+ females on the FCD 
diet (0.37 vs. 0.77), but this comparison was not statistically significance (p = 0.1, 
one-tailed t-test).  
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Maternal Mthfd1 disruption and low folate status influence markers of folate 
metabolism 
  The FCD diet was associated with a significant decline in maternal RBC folate 
levels measured at E11.5 (Figure 4.4; F = 234, p < 0.0001).  RBC folate levels were 
reduced by approximately 65% on the FCD diet relative to the control diet (8 vs. 23 
fmol/µg protein). Mthfd1 disruption was also associated with a significant reduction in 
RBC folate levels in pregnant dams maintained on both diets (F = 46.7, p < 0.0001). 
However, Mthfd1 genotype influenced RBC folate levels to a greater extent in mice 
maintained on the control diet than on the FCD diet (F = 31.25, p = 0.01).  RBC folate 
levels in Mthfd1
gt/+ females were reduced approximately 35% compared to Mthfd1
+/+ 
females on either diet, but the magnitude of the difference was greater in females 
maintained on the control diet (18.4 vs. 27.9 fmol/µg protein; p < 0.0001) as compared 
to the FCD diet (6.5 vs. 10.3 fmol/µg protein; p = 0.01).   
  The effects of maternal Mthfd1 disruption and maternal folate/choline status on 
plasma metabolites associated with homocysteine remethylation and metabolism were 
determined in plasma samples taken from pregnant female mice at E11.5 (Table 4.6).  
The FCD diet significantly influenced several markers of homocysteine metabolism.  
Plasma homocysteine was elevated approximately three-fold in all dams maintained 
on the FCD diet, regardless of Mthfd1 genotype (5.3 vs. 14.2 µM, p = 0.0008).  The 
FCD diet was also associated with significantly elevated cystathionine and serine 
levels (Table 4.6), and significantly decreased levels of dimethylglycine in all mice.  
Mthfd1 genotype did not affect the levels of any of the metabolites measured.  
However, there was a trend towards a significant interaction effect between maternal 
Mthfd1 genotype and diet on plasma methionine levels (F = 3.24, p = 0.08).  Plasma 
methionine in Mthfd1
gt/+ females on the control diet were decreased relative to  
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Figure 4.4. Red blood cell folate levels in Mthfd1
gt/+ and Mthfd1
+/+ mice.  Both diet 
and Mthfd1 genotype influenced RBC folate levels in dams.  Significant main effects 
of diet, genotype, and diet x genotype interaction were analyzed by analysis of 
variance in SAS (Cary, NC). Data represent mean ± SD.   A significant diet X 
genotype interaction (F = 9.06, p = 0.01) reflected a larger effect of genotype 
associated with the control diet. 
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Diet 
Control FCD  Metabolite 
Mthfd1+/+ Mthfd1gt/+  Mthfd1+/+ Mthfd1gt/+ 
Diet effect  Genotype 
effect 
Diet X 
genotype 
effect 
Homocysteine 
(μM) 
4.9 ± 0.9  5.7 ± 1.3  15.5 ± 3.1  12.8 ± 2.9  p = 0.0008  ns  ns 
Cysteine (μM)  183 ± 15  183 ± 39  192 ± 12  184 ± 17  ns  ns  ns 
Cystathionine 
(μM) 
997 ± 490  694 ± 101  1211 ± 129  1204 ± 214  p = 0.03  ns  ns 
α - 
Aminobutyric 
Acid (μM) 
5.3 ± 0.8  4.9 ± 1.1  5.7 ± 0.5  5.1 ± 1.1  ns  ns  ns 
Methionine 
(μM) 
54.0 ± 8.6  33.5 ± 3.4  51.4 ± 3.6  56.8 ±10.6  ns  ns  p = 0.08
A
Glycine (μM)  93.3 ± 12.1  103 ± 13  91.0 ± 14.0  80.2 ± 11.6  ns  ns  ns 
Serine (μM)  115 ± 9  92 ± 7  130 ± 10  127 ± 17  p = 0.04  ns  ns 
Dimethylglycin
e (μM) 
7.25 ± 0.67  8.11 ± 0.53  4.64 ± 0.51  3.61 ± 0.44  P < 0.0001  ns  ns 
Methylglycine 
(μM) 
0.54 ± 0.05  0.56 ± 0.06  0.50 ± 0.05  0.45 ± 0.03  ns  ns  ns 
/ Table 4.6.  Plasma metabolites in pregnant Mthfd1
gt/+ and Mthfd1
+ + dams. Values represent mean ± SEM.  Independent 
effects of Mthfd1 genotype, diet, and the interaction between Mthfd1 genotype and diet were determined by analysis of 
variance. A, Mthfd1gt/+ fed the control is significantly different than Mthfd1gt/+ fed the FCD diet (p= 0.03).  
Mthfd1
+/+ females fed the control diet (33.5 µM vs. 54.0 µM, p = 0.05) and Mthfd1
+/+ 
females fed the FCD diet (33.5 µM vs. 51.4 µM , p = 0.03).       
  Comparison of plasma metabolite profiles of hypoxanthine-supplemented and 
unsupplemented Mthfd1
gt/+ females fed the FCD diet revealed that hypoxanthine 
supplementation influenced glycine and methylglycine levels (data not shown).  
Glycine levels were significantly higher in hypoxanthine-supplemented females as 
compared to unsupplemented Mthfd1
gt/+ females fed the FCD diet (140 vs. 80 µM; p = 
0.04, 1-tailed T test). Similarly, methylglycine levels were significantly elevated in 
hypoxanthine supplemented females as compared to unsupplemented females (0.63 vs. 
0.45 µM, p = 0.01, 1 tailed t-test).  Both glycine and methylglycine levels in 
hypoxanthine-supplemented females were also elevated in comparison to Mthfd1
gt/+ 
females fed the control diet, although these comparisons did not reach statistical 
significance.   
Folate-mediated OCM is not disrupted in Mthfd1
gt/+ MEFs 
  The effects of Mthfd1 disruption on de novo purine biosynthesis and cellular 
methylation potential was investigated in four independent Mthfd1
gt/+ and Mthfd1
+/+ 
MEF cell lines derived from crosses of C57Bl/6J females and 129.Ola- Mthfd1
gt/+ 
males.  Rates of de novo purine biosynthesis were similar in Mthfd1
gt/+ and Mthfd1
+/+ 
MEF cell lines (Figure 4.5), as measured by the relative ratio of incorporation of [
14C]-
formate to [
3H]-hypoxanthine into nuclear DNA.   Similarly, there was no effect of 
Mthfd1 disruption on the AdoMet/AdoHcy ratio, an index of cellular methylation 
capacity.  Mthfd1
gt/+ MEF cell lines did not exhibit statistically significant differences 
in AdoMet, AdoHcy, or the AdoMet/AdoHcy ratio as compared to Mthfd1
+/+ cell lines 
(Table 4.7). 
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gt/ Figure 4.5. De novo purine biosynthesis is not altered in Mthf
+ MEFs.  
Efficiency of de novo purine biosynthesis was determined by the relative enrichment 
of 
14C-formate (20 μM) / 
3H-hypoxanthine (2 nm) in nuclear DNA.  All values are 
the average of triplicate measures of three different cell lines per genotype. Data 
represent mean ± SEM.   A one-tailed unpaired T-test was used to determine 
genotype differences. 
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Metabolite 
 
Genotype 
  
AdoMet (pmoles/ug 
protein) 
AdoHcy (pmoles/ug 
protein) 
Ratio 
(AdoMet:AdoHcy)
Mthfd1+/+  0.04 ± 0.008   0.11 ± 0.056 0.82 ± 0.43
Mthfd1gt/+  0.04 ±  0.005  0.04 ± 0.005 0.75 ± 0.12
p value  ns  ns  ns 
Table 4.7.  AdoMet and AdoHcy concentrations in Mthfd1-deficient MEFs. 
Concentration of AdoMet and AdoHcy were determined by HLPC analysis.  One-
tailed t-tests were used to determine genotype differences.  
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Discussion 
  Mthfd1
gt/+ mice exhibited a 50% decrease in formylTHF synthetase activity, 
similar to the reduction of activity observed for the human formylTHF synthase 
protein in the MTHFD1  G1958A  variant (40).  In this study, the metabolic disruption 
associated with Mthfd1
gt/+ mice adversely affected fertility and embryonic 
development, and recapitulated reproductive outcomes associated with the human 
G1958A polymorphism including delayed heart and jaw development and pregnancy 
loss.  Maternal Mthfd1 disruption and/or low folate status induced fetal growth 
restriction, whereas embryonic Mthfd1 disruption had no effect on fetal growth.  
Complete loss of Mthfd1 expression resulted in very early fetal loss prior to 
neurulation, consistent with human studies demonstrating that the G1958A SNP is not 
in Hardy-Weinberg equilibrium, with the 1958A genotype being underrepresented 
relative to expectations  (32).  Together, these data confirm that the generation of 1Cs 
in the cytoplasm by C1THF synthase is essential for early embryonic development and 
that partial loss of synthetase activity at the maternal level is sufficient to affect fetal 
growth and development. 
  In the absence of nutrient supplementation, neither maternal nor embryonic 
Mthfd1 disruption caused NTDs.  However, hypoxanthine supplementation of 
Mthfd1
gt/+ pregnant females fed the FCD diet, the group that exhibited the greatest 
degree of impairment in 1C metabolism, resulted in 2 of 28 Mthfd1
gt/+ embryos 
exhibiting exencephaly.  Hypoxanthine supplementation also resulted in an increase in 
the incidence of FGR in the same litters.  The observed increase was due to a two-fold 
increase in the incidence of FGR in Mthfd1
gt/+ embryos.  The increase in FGR-affected 
embryos and incidence of NTDs in litters derived from hypoxanthine-supplemented 
Mthfd1
gt/+ females fed the FCD diet indicates either that hypoxanthine 
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supplementation negatively impacted fetal growth or that hypoxanthine 
supplementation rescued earlier fetal loss in Mthfd1
gt/+ embryos.  The latter 
explanation is supported by the observed moderate decrease in the number of 
resorptions in litters derived from hypoxanthine supplemented Mthfd1
gt/+ females as 
compared to unsupplemented Mthfd1
gt/+ females.  Rescue of early fetal loss by 
hypoxanthine supplementation indicates impaired purine biosynthesis as an underlying 
cause of impaired fertility and fetal development in response to Mthfd1 disruption.  
Furthermore, the occurrence of NTDs in Mthfd1
gt/+ embryos also implicates impaired 
nucleotide biosynthesis in NTD pathogenesis. Although purine biosynthesis was not 
impaired in Mthfd1
gt/+   MEFs in this study, Christensen et al (41) have previously 
demonstrated purine auxotrophy in immortalized MEF lines in which Mthfd1 has been 
inactivated.  Furthermore, the effect of Mthfd1 disruption on adverse fetal outcomes 
was most strongly associated with maternal genotype.  Similarly, the NTD risk 
associated with the human MTHFD1 G1958A polymorphism is strongly linked to 
maternal genotype (32,38). Therefore, maternal de novo purine biosynthesis capacity 
may be more important for fetal development than embryonic de novo purine 
biosynthesis.   
  In a previous study, plasma folate levels were unaffected in Mthfd1
gt/+ male 
mice (40).  In this study, we observed a significant reduction in RBC folate levels in 
pregnant Mthfd1
gt/+   females.  Although AdoMet and AdoHcy levels were unaffected 
in Mthfd1
gt/+  MEFs, Mthfd1
gt/+dams maintained on the control diet exhibited reduced 
plasma methionine levels, suggesting that Mthfd1 disruption also influenced the 
availability of 5-methylTHF for methionine biosynthesis. Similarly, reduced liver 
AdoMet levels were reported previously in Mthfd1
gt/+  male mice maintained on the 
control, but not the FCD diet (40).  Thus, maternal folate deficiency and/or 
impairments in purine and/or methionine biosynthesis may have contributed to poor 
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reproductive outcomes in Mthfd1
gt/+   females. 
  Maternal hypoxanthine supplementation rescued early fetal loss, but did not 
ameliorate fetal growth restriction associated with combined maternal Mthfd1 
disruption and dietary maternal folate and choline deficiency.  Furthermore, maternal 
hypoxanthine supplementation induced NTDs in Mthfd1
gt/+ dams consuming the FCD 
diet.  These data indicate that the underlying cause of FGR in neurulation-stage 
embryos may be distinct from that of earlier fetal loss, or that maternally-derived free 
nucleotides may be more available to the fetus prior to formation of the definitive 
placenta.  The timing of FGR in affected embryos coincided with the development of 
the definitive placenta in mice.  Elevated homocysteine in response to the FCD diet 
may have also contributed to impaired placental function in Mthfd1
+/+  females, as 
homocysteine is an established risk factor for vasculopathy (42-45).   In any event, 
these data indicate that maternal hypoxanthine supplementation increases risk for 
NTDs in folate-deficient Mthfd1
gt/+ dams, potentially by rescuing early fetal loss. 
 
Experimental Procedures 
Experimental animals and diets 
All animal experiments were approved by the Cornell Institutional Animal 
Care and Use Committee according to the guidelines of the Animal Welfare Act and 
all applicable federal and state laws.  Mice were maintained on a 12 hour light/dark 
cycle in a temperature controlled room.  For timed pregnancies, virgin female mice 
aged 70-120 days were housed overnight with males.  The following morning, females 
were examined for the presence of a vaginal plug. Nine o’clock A.M. the day of the 
plug was designated as embryonic day 0.5 (E0.5).   Pregnant females were sacrificed 
by carbon dioxide-induced asphyxiation and blood was collected by cardiac puncture.  
Embryos were harvested at E11.5 or E14.5.  Gravid uteri were removed and all 
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implants and resorptions sites were recorded.  Embryos were dissected free of extra 
embryonic membranes under a dissecting microscope, and examined for presence of 
NTDs.  All yolk sacs were collected for subsequent genotyping.  Embryos were fixed 
for 24 hours in 10% neutral buffered formalin, dehydrated in an ethanol series, and 
stored in 70% ethanol.   
The generation and characterization of mice with a gene trap insertion in the 
Mthfd1 gene (Mthfd1
gt/+) has been previously described (40). To determine the 
developmental stage of embryonic lethality in Mthfd1
gt/gt mice, embryos were 
examined from crosses of heterozygote B6.129P2-Mthfd1
gt mice.  Diet studies were 
conducted using Mthfd1
gt/+and Mthfd1
+/+ mice derived from crosses of 129P2/OlaHsd 
females to heterozygote 129P2/OlaHsd-Mthfd1
gt/+ male mice.  Female mice were 
randomly assigned to either an experimental AIN93G diet lacking folate and choline 
(FCD) or an AIN93G (Control) diet (Dyets, Bethlehem, PA) at weaning.  Choline was 
excluded from the experimental diet in addition to folate to increase stress on the 
homocysteine remethylation cycle.  Choline synthesis requires methyl groups in the 
form of AdoMet and it provides a source of one-carbon units for homocysteine 
remethylation through its catabolism (46).  Females were maintained on diet from 
weaning throughout the breeding period and for the duration of gestation, until killed.  
For studies involving hypoxanthine supplementation, hypoxanthine (Sigma) was 
dissolved in nanopure water at a concentration of 10 mM and diluted with acidified 
drinking water to a final concentration of 500 µM.  The final concentration of 
hypoxanthine in drinking water was verified by uv spectroscopy (ε =10.5 mM at λ= 
250 nm). 
Genotype analysis 
 Genotyping  of  the  Mthfd1
gt allele was performed as recently described (40).  
Embryonic sex was determined using a genotyping protocol described elsewhere (47). 
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Analysis of red blood cell folate levels 
Folate levels in red blood cell samples was quantified using a Lactobacillus casei 
microbiological assay as previously described (48). 
Determination of plasma metabolites 
Plasma levels of homocysteine, cystathionine, cysteine, α - aminobutyric acid, 
methionine, glycine, serine, N,N-dimethylglycine and N-methylglycine were 
determined by stable isotope dilution capillary gas chromatography mass spectrometry 
as previously described (49,50) 
Generation of mouse embryonic fibroblast cell lines 
Mouse embryonic fibroblast (MEF) cell lines were generated from embryos isolated 
10-14 days post-coitus from crosses of C57Bl6/J females and 129P2.OlaHsd- 
Mthfd1
gt/+ males.  Genotyping of MEF lines was completed both at the time of 
generation using nuclear DNA isolated from embryo heads, as well as from cell 
pellets, using the same genotyping protocols described above.  MEFs were incubated 
at 37° C in Defined Minimal Essential Medium, alpha modification (Hyclone, Inc) 
with 10% fetal bovine serum.    
Formate suppression assay 
MEFs were plated in triplicate in 6-well plates at a density of 1 X10
4 cells per well.    
A formate suppression assay, which measures the relative efficiency of de novo purine 
nucleotide synthesis relative to synthesis from the purine nucleotide salvage pathway,  
was performed as previously described (51).    
Determination of AdoMet and AdoHcy concentrations 
  Total levels of AdoMet and AdoHcy  were measured in MEF cell pellets using an 
established HPLC procedure (52,53).   
Statistical Analysis  
Analyses of FGR incidence and embryonic crown-rump length were conducted using 
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repeated-measured analysis of variance (PROC MIXED or PROC GENMOD, SAS, 
Cary, NC) in which independent variables included maternal and embryonic Mthfd1 
genotype, maternal diet ,and embryo sex,  and litter was considered as a repeated 
measure. Relevant interaction terms were included unless assumptions of variance 
were violated.  Analysis of total litter resorptions and implants was analyzed by 
analysis of variance in which litter was considered as the unit of analysis and 
independent variables included maternal Mthfd1 genotype and diet.  Resorption rate 
was calculated as the ratio of resorptions/ total implants per litter and log-
transformation was applied to normalize the data. Analysis of total red blood cell 
folate levels and metabolite levels was accomplished by analysis of variance in which 
maternal Mthfd1 genotype and diet were considered as independent variables.  
Specific comparisons within main effects were assessed by comparisons of least-
squared means.  Χ
2 analyses were used to assess any deviation from expected 
genotype ratios based on Mendelian inheritance.  For cell culture assays, genotype 
differences were assessed using a one-tailed t-test.   
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Scope of Problem  
       Neural tube closure defects (NTDs) arise from complex interactions of genetic 
and environmental risk factors. Low maternal folate status is a strong environmental 
determinant of NTD risk (1).  Furthermore, it has been clearly demonstrated from both 
observational and randomized controlled trials that maternal folic acid 
supplementation substantially reduces both occurrence and recurrence of NTDs in the 
general population (2-6). Unfortunately, promotion of maternal vitamin use for NTD 
prevention has proved largely ineffective as a majority of pregnancies are unplanned 
and the process of neural tube closure occurs within the first three week of human 
gestation, often before most women know they are pregnant.  As such, many countries 
today either fortify or are considering fortification of their food supply with folic acid 
for the prevention of NTDs (7-10). Although the protection against NTDs afforded by 
maternal folic acid supplementation is so convincing as to drive public policy, the 
mechanism(s) by which folic acid supplementation prevents NTDs remain unknown.  
This unusual predicament results in fortification of entire populations for the 
protection of a relatively small subset of the population (e.g. women of childbearing 
age) with very little known regarding potential consequences for other population 
groups (e.g. aging individuals, cancer patients).  Therefore, identifying the direct 
mechanism(s) underlying the association between disrupted folate metabolism and 
NTD risk is critical for better targeting of preventative measures and minimization of 
potential unintended consequences.  
In parallel to identifying the mechanism(s) by which impaired folate 
metabolism affects neural tube closure, the identification of candidate genes that 
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mediate elevated NTD risk in humans is necessary in order to identify and target 
genetically susceptible individuals.  There is a strong genetic component to NTD risk 
(11); although genetic variants have been identified within folate-related genes that 
contribute to elevated NTD risk (12), the penetrance of these variants does not account 
for the prevalence of NTDs in the general population (13).  Furthermore, investigation 
of current folate-related gene candidates has not yielded any further information as to 
underlying mechanism of NTD pathogenesis, and genetic disruption of these same 
candidate genes in mice does not yield NTDs (14), preventing the use of these models 
to further investigate metabolic mechanisms and suggesting that these genes may not 
directly contribute to NTD risk.      
  Folate-mediated one carbon metabolism (OCM) is essential for nucleotide 
biosynthesis, the remethylation of homocysteine to methionine, and S-
adenosylmethionine (AdoMet)-dependent cellular methylation.  OCM can be impaired 
by nutrient deficiency, either of folate or other micronutrients that influence folate 
status, or by variation in genes that accumulate or metabolize folate.  Impairments in 
OCM result in elevated homocysteine, misincorporation of uracil into DNA, reduced 
nucleotide availability, and chromatin hypomethylation (15). All of these metabolic 
sequelae have the potential to disrupt neural tube closure by impinging on the cellular 
proliferation, survival, differentiation or migration processes within the embryonic 
neuroepithelium that are required for neural tube closure.   Although limited evidence 
from human genetic and epidemiological studies has implicated homocysteine 
accumulation and/or impaired cellular methylation in NTD pathogenesis (16-18), 
direct evidence from human or animals studies to support this hypothesis is lacking.   
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Summary:  Deletion of Shmt1 Causes NTDs by Impairing De Novo Thymidylate 
Biosynthesis 
  The data presented herein identify both the mechanism and the candidate gene 
responsible for pathogenesis in folate-responsive NTDs.  These data demonstrate that 
deletion of Shmt1 in mice induces NTDs by impairing de novo thymidylate 
biosynthesis.  This is the first demonstration of an NTD associated with deletion of a 
folate-metabolizing gene in mice and therefore provides a novel model with which to 
address metabolic mechanisms underlying folate-responsive NTDs.   NTDs in 
response to Shmt1 deficiency mimic the profile of human folate-responsive NTDs 
because they are partially penetrant, folate-responsive, and both maternal and fetal 
genotypes contribute to NTD risk  This study also identifies impaired thymidylate 
biosynthesis as an underlying cause of folate-responsive NTDs. Our lab has 
demonstrated previously that Shmt1 regulates the partitioning of folate-mediated OCM 
by prioritizing de novo thymidylate biosynthesis at the expense of the homocysteine 
remethylation cycle.  Deletion of Shmt1 causes NTDs and results in impaired de novo 
thymidylate biosynthesis in fibroblast cell lines and increased DNA uracil content in 
mice, whereas homocysteine levels are unaffected.  Impaired thymidylate biosynthesis 
has been identified previously as a mechanism underlying NTD pathogenesis in 
response to the splotch mutation within the gene encoding Pax3.  In this study we 
confirmed impaired thymidylate biosynthesis in splotch MEF cell lines and 
demonstrated that Shmt1 and Pax3 interacted in NTD pathogenesis, with Shmt1 
deficiency resulting in exacerbated lesions in Pax3
sp/sp embryos and occasional NTDs 
in Pax3
sp/+ and Pax3
+/+ embryos isolated from compound Shmt1, Pax3 mutant crosses.  
The interaction between Pax3 and Shmt1 occurred at both the fetal and maternal 
genotype levels, and was also sensitive to maternal folate status.   Furthermore, Pax3 
and Shmt1 were both shown to influence thymidylate synthase (TYMS) protein levels 
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as well as be mutually regulated. The demonstrated genetic interaction between Shmt1 
and Pax3 further confirms the role of thymidylate biosynthesis in NTD pathogenesis.  
Lastly, these data also indicate that impairments in purine biosynthesis may also 
contribute to NTD pathogenesis. Collectively, these data provide additional evidence 
implicating impaired nucleotide biosynthesis as an underlying cause of NTDs in these 
two folate-responsive NTD models.   
 
Summary: Maternal Mthfd1 Disruption Impairs Fertility, Neural Tube Closure, and 
Fetal Growth 
 A  common  human  polymorphism in MTHFD1 (A1298C) has been identified 
in human genetic screens as a maternal risk factor for NTDs, as well as adverse 
pregnancy outcomes related to fertility and overall embryonic development. 
Disruption of Mthfd1 by insertion of a gene trap vector mimics the loss of formyl 
synthetase activity associated with the MTHFD1 A1298C human polymorphism.  This 
study confirms the maternal effect of Mthfd1 disruption on embryonic development.  
Both low maternal folate status and maternal Mthfd1 disruption resulted in fetal 
growth restriction, with severe delay in heart, limb, and jaw development, similar to 
the anomalies associated with the Mthfd1 polymorphism in humans.  Rescue of very 
early fetal loss with hypoxanthine supplementation revealed occasional NTDs in 
Mthfd1
gt/+ embryos, confirming a role of Mthfd1 in neural tube closure.  Mthfd1 
disruption in pregnant dams was associated with reduced folate status and impaired 
methionine metabolism.  Together, these data indicate that disruption of Mthfd1 
affects embryonic growth and neural tube closure by affecting folate status, 
methionine metabolism, and purine biosynthesis, although different mechanisms my 
contribute uniquely to pathogenesis in different conditions. 
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Implications 
  The data presented herein have major implications for understanding the 
mechanism by which impaired folate metabolism contributes to NTD pathogenesis.  
Previously, appropriate mouse models for addressing metabolic mechanisms 
underlying NTD pathogenesis were inadequate.  Mouse mutants within the OCM 
network did not develop NTDs and therefore provided limited opportunity to study 
mechanism.  Furthermore, the degree to which other folate-responsive NTD mouse 
models (e.g. splotch) informed pathogenesis of human NTDs was questionable 
because the associated genes were not implicated in human genetic screens (e.g. Pax3) 
(19). Here we describe two new models, Shmt1+/- and Mthfd1gt/+ mice, which can be 
used to gain further insight into pathogenesis of folate-responsive NTDs.  Each of 
these mutants closely models NTD pathogenesis in humans; NTDs in these models are 
partially penetrant, folate-responsive, and reflect the relative contributions of 
embryonic and maternal genotype as observed in humans.    These models can now be 
used not only to address metabolic disruption underlying NTD pathogenesis, but to 
link specific impairments with genomic responses and cellular responses that 
ultimately result in failure of neural tube closure.   
  The current aim of research within the field of folate-responsive NTDs is to 
disentangle gene-nutrient interactions in NTD pathogenesis. The data presented here 
provides novel insight into how nutrient status interacts with genetic disruption of 
folate utilization to confer NTD risk. Impaired nucleotide biosynthesis was implicated 
as an underlying cause of NTD pathogenesis in both Shmt1 and Mthfd1 models.  
However, subtle differences between these two models highlight the interaction 
between folate status and folate utilization (Chapter 2).  Deletion of Shmt1 impaired 
thymidylate biosynthesis but did not affect folate status; furthermore, embryonic 
Shmt1 deletion was required for NTD pathogenesis.  In contrast, disruption of Mthfd1 
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affected maternal folate status, which may have contributed to NTD incidence.  
Furthermore, the robust maternal effect of Mthfd1 disruption suggests that maternally-
derived purines may be essential for early embryonic development, suggesting that 
maternal nutrient status might affect some folate-dependent pathways more than 
others.   Thus, NTDs in response to Shmt1 deletion result from impairment of cellular 
folate utilization, whereas Mthfd1 disruption may confer NTD risk by disrupting both 
folate accumulation and folate utilization.  Disentangling the relative contributions of 
maternal and fetal genotype in terms of metabolic impairments will provide further 
insight into the interaction of maternal and fetal genotype in human NTD 
pathogenesis.    
A robust human gene candidate for folate-responsive NTDs has yet to be 
identified.  Although human genetic studies have implicated genes with the 
homocysteine remethylation cycle, these studies have been limited by their inability to 
identify causal mechanisms.  The present data indicate that elevated homocysteine in 
NTD-affected pregnancies is merely a biomarker of low folate status and/or impaired 
folate metabolism, as both Mthfd1 disruption and Shmt1 deficiency resulted in NTDs 
in the absence of changes in homocysteine levels.  Thus, these data provide further 
support for the hypothesis that gene candidates within the homocysteine remethylation 
pathway confer NTD risk by affecting folate status, not by impairing metabolism.  
Moreover, Shmt1 haploinsufficiency and partial disruption of Mthfd1 was sufficient to 
induce NTDs, indicating that relatively small changes in expression of folate-related 
genes contribute to NTD pathogenesis.  These data imply that the failure of human 
genetic screens to identify promising human NTD candidate genes, including Shmt1, 
may have been due to the inability of these screens to identify alterations in expression 
levels, which may represent more penetrant risk factors.  Lastly, these data suggest 
that future studies of human candidate NTD genes should focus on genes regulating 
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nucleotide biosynthesis instead of genes involved in the homocysteine remethylation 
cycle.   
 
Future Directions 
  In addition to providing novel insight into metabolic mechanisms underlying 
folate-responsive developmental anomalies, the present data offer several avenues for 
future research.  To begin, the experimental diet used in these studies was deficient in 
both folate and choline.  Although our goal in using choline deficiency was to increase 
the demand for folate-activated 1Cs and thereby increase the demand for folate, 
human epidemiological studies have recently suggested that disrupted choline 
metabolism may be an independent risk factor for NTDs (20,21).  These data warrant 
investigation of the independent contribution of folate and choline deficiency to NTD 
risk in Shmt1-deficient mice.  If indeed choline deficiency is found to interact with 
Shmt1 deficiency in NTD pathogenesis, then the metabolic mechanism underlying this 
interaction should be explored further.  
  The effects of Mthfd1 disruption on embryonic development were sensitive to 
hypoxanthine supplementation, but impairments in de novo nucleotide biosynthesis 
were not directly demonstrated in this study.  Further investigation of impairments in 
nucleotide biosynthesis including thymidylate biosynthesis, either in vivo or in a cell 
culture model, in response to Mthfd1 disruption is warranted.  In particular, 
investigation of nucleotide biosynthesis in a context of folate deficiency may be more 
informative.  As Mthfd1 disruption may confer NTD risk by both impairing both folate 
utilization and folate status, it is possible that impairments in purine biosynthesis in 
response to partial disruption of Mthfd1 (e.g. in Mthfd1
gt/+ mice) will be more apparent 
under folate-deficient conditions.   
  The finding of impaired de novo purine biosynthesis in the Pax3-deficient 
 179 
splotch mutant is novel and implicates impaired purine biosynthesis in NTD 
pathogenesis.  It has been previously demonstrated that thymidine supplementation 
can prevent NTDs in splotch embryos (22,23).  It would be interesting to determine if 
hypoxanthine supplementation could similarly rescue NTDs in splotch embryos, and if 
spina bifida or exencephaly would be more sensitive to supplementation with 
hypoxanthine, thereby confirming the hypothesis that impairments in purine and 
thymidine biosynthesis contribute to pathogenesis in spina bifida and exencephaly, 
respectively. 
Methionine supplementation exacerbates NTDs in the splotch mutant, which 
exhibit impairments in de novo thymidylate biosynthesis.  This effect is not mediated 
alterations in homocysteine levels or cellular methylation potential (24), which implies 
that methionine influences NTD pathogenesis by affecting thymidylate biosynthesis.   
Exploration of the effects of methionine supplementation on thymidylate biosynthesis 
in a cell culture model would shed light on this hypothesis.  In addition, it would be of 
interest to determine whether methionine supplementation would also exacerbates 
NTDs in Shmt1-deficient mice.   
  Pax3 and Shmt1 were shown to influence TYMS protein levels and interact in 
NTD pathogenesis; however, Shmt1 and TYMS message levels were no altered in 
response to the splotch mutation.  Investigation of the molecular mechanisms 
underlying the interaction of Pax3 and Shmt1 in relation to TYMS and thymidylate 
biosynthesis is warranted.  One potential clue arises from the finding that combined 
Pax3 and Shmt1 deficiency resulted in embryos with craniorachiscisis in response to 
dietary folate deficiency.  This extensive defect has been linked exclusively to 
mutations within the planar cell polarity (PCP) pathway (25,26) (27).  As Pax3 has not 
been previously linked to the planar cell polarity pathway, it is possible that Shmt1 
may fall in this pathway and if so, that Shmt1 may either contribute to neural tube 
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development beyond its metabolic capacity or that thymidylate biosynthesis is 
involved in the PCP pathway.  Indeed, the expression pattern of Shmt11 across 
development suggests that it may play a role in developmental patterning.  To explore 
this possibility, one could utilize the cochlea as a model to study alterations in planar 
cell polarity in Shmt11-deficient mice.  Disruption of the PCP pathway lead to defects 
in the orientation of the stereociliary bundles at the apex of each hair cell within the 
cochlea (28).   Investigation of cochlear organization in Shmt11-deficient mice would 
reveal any disruption in the PCP pathway.  One could then explore alterations in 
expression patterns of PCP-related genes within the neural tube to understand how 
Shmt1 disruption affects the PCP pathway and ultimately results in NTDs.  
The ultimate goal in identifying metabolic mechanisms underlying NTD 
pathogenesis is to understand how these metabolic impairments translate into failure 
of neural tube closure.  To this end, the mouse models described herein should be used 
to investigating underlying genomic and cellular changes that ultimately result in 
NTDs.  Specifically, investigation of uracil misincorporation, genome stability and 
damage, and well as changes in proliferation rates, apoptosis and cell survival, and cell 
differentiation will shed light on the mechanisms by which specific metabolic 
impairments affect neural tube closure.   
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